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Aims
The main aim of these studies was to explore the biology of normal breast tissue. This is 
important in order to contribute to the creation of methods to identify women with high 
risk of breast cancer and early stages of the disease. 
To achieve this overall aim, we decided to focus on three main topics:  
1. The variation in gene expression in normal breast tissue  
2. The biology underlying mammographic density, one of the strongest breast cancer 
risk factors.  
3. The biology associated with high levels of serum estrogen.  
The specific questions addressed to reach these aims were 
1. Can the variation of gene expression patterns in breast tissue from healthy women 
be used to identify subgroups of women with different breast biology? 
2. If so, what are the biological differences between such subgroups?  
3. Which genes have expression levels in normal breast tissue that are associated 
with mammographic density? 
4. Which genes have expression levels in normal breast tissue that are associated 
with high levels of serum estradiol? 
5. Which single nucleotide polymorphisms (SNPs) are associated with 
mammographic density and/or serum estradiol levels? 
6. Which mRNA transcripts mediate the genetic variation identified in pt 5? 
7. Are the genes and SNPs identified in pt 3, 4 and 5 associated with risk for breast 
cancer?
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1. Introduction 
The breast cancer survival rates have improved greatly over the past decades (1969: 65%, 
2008: 88%, (1)). This is partly due to earlier diagnosis and better treatment. Still, this 
disease is a major killer of women worldwide, with an age-standardized mortality-rate of 
13% in Norway. The improvement seen on survival rates is not seen for breast cancer 
prevention. The breast cancer incidence continues to increase in most countries. The main 
reason is the poor understanding of the very first steps of breast carcinogenesis, including 
the complex interactions of the different risk factors for the disease (2). We use 
information about family history and BRCA-mutations to identify high-risk women, but 
most women developing breast cancer are not in the high-risk groups. Better 
identification of high-risk women will enable early diagnosis and possibly even 
prevention of the disease. 
Breast cancer is a disease where early diagnosis improves the prognosis. Mammographic 
screening is used to detect the tumors early, but not all breast cancers are detected at 
screening. Interval cancers are diagnosed between two screening sessions. These are 
more often aggressive cancers with rapid growth (3) and do often occur in areas of 
mammographic density (MD) due to masking (the tumor is radiologically dense and a 
small tumor may not be visible in the dense areas) (4). Blood tests aimed at detecting 
breast cancer are available (5), but there is today no reliable method of detecting the very 
first steps of breast carcinogenesis and there is need for better tools for early detection 
(6).
MD is a strong risk factor for breast cancer and may be used as an intermediate to inform 
about breast cancer risk. The number of factors influencing such an intermediate may be 
fewer, producing more powerful studies (7). 
The anatomy and physiology of the normal, adult breast are well described. The last 
decade there have been some publications focusing on the molecular biology and gene 
expression of the healthy breast, but much is still unknown. A better understanding of the 
molecular biology of the normal breast will make it easier to identify breasts that deviate 
from the normal on the path towards malignancy. Finding molecular subgroups of 
healthy breasts may help us identify high-risk groups and hence understand the molecular 
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mechanism involved in the development of the different breast cancer diseases. 
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2. Development and physiology of the normal breast
2.1 Breast development  
The breast originates in ectodermal tissue forming a ridge on either side of the ventral 
aspect of the body from the groin to the axilla. The ridge regresses after 6 weeks of 
gestation, except for the areas that develop into the breasts. Accessory nipples are 
remnants of this ectodermal ridge that has not regressed fully. From 7 to 32 weeks of 
gestation, the breast develops with invasion of mammary parenchyma in the stroma, 
formation of epithelial buds, branching, acquisition of smooth muscle cells and formation 
of ducts and the nipple. During these first months, estrogen receptor (ER) is not 
detectable and the development occurs independently of estrogen. During the last 
trimester, ER is expressed and the breast tissue is estrogen sensitive (8). In this period, 
the level of pro-lactating hormones is high in maternal and fetal circulation, resulting in 
the secretion of colostrum from the breasts of some newborn infants. The breasts regress 
shortly after birth. Throughout childhood, the breasts remain immature and the growth is 
isometric (9-11).  
During puberty, maturation of the breasts occurs under influence of growth hormone and 
estrogen. The ducts are elongated from the nipple and into the fat pads through the 
terminal end buds which give rise to new branches of ducts. The stroma also contributes 
to branching of the mammary ducts and there is a marked increase of adipose tissue in the 
breast. A type 1 lobule is formed and consists of alveolar buds clustered around a 
terminal duct (Figure 1). This is the most common lobule in nulliparous women. (10,11). 
As number of alveolar buds in each lobule increases, type 2 and 3 lobules will form 
(Figure 1), but only to a limited extent in a nulliparous breast.  
The adult breast goes through cyclic changes during the menstrual cycle. In the luteal 
phase there is high mitotic activity and development of the lobules. In the follicular 
phase, the lobules are small and there is low mitotic activity.  
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Figure 1 The lobular structures of the normal human breast. Type 1 lobules are present from birth 
and are most prominent in the breasts of nulliparous and postmenopausal women. A limited 
number of type 2 lobules forms during puberty. Type 3 lobules are formed during the last 
trimester. Type 4 lobules are milk-secreting. After menopause, most type 3 lobules will regress to 
type 1 and 2 lobules. AB: Alveolar bud. TED: Terminal end bud. A) From 
http://www.abortionbreastcancer.com/maturity.htm B) From Russo and Russo, 2004 (11).  
During pregnancy, further elongation and branching of the ductal system and growth of 
the lobules is driven by female hormones and growth factors (9). As the ductal system 
grows, the ductules mature into acini and type 4 lobules are formed. (11). The joint action 
of estrogen, progesterone and prolactin are necessary for the final differentiation of the 
mammary gland that leads to the reduced risk for breast cancer seen after the first full-
term pregnancy (12). After lactation, involution occurs, where the alveoli stop milk 
production and decrease in number and the ducts collapse. Until menopause, breasts of 
parous women still have more glandular tissue, with type 2 and 3 lobules, compared to 
the breasts of nulliparous women (11).  
The post-lactational involution is further enhanced by menopause when the levels of 
estrogen and progesterone are dramatically reduced (9). During the menopausal 
involution, a large proportion of the type 3 lobules will regress to type 1 and 2 lobules. In 
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postmenopausal women, type 1 lobules are most common, both in parous and nulliparous 
women (11).  
Interestingly, the proliferative activity (measured by Ki67-staining) is significantly higher 
in type 1 than in type 2 and 3 lobules (which are the most common lobules in parous 
women) (11). This is also the type of lobule where most breast cancers are believed to 
arise (13). The difference in activity between the different types of lobules is greater in 
nulliparous women; parity reduces the proliferative activity of the mammary epithelium. 
For both groups of women, breast epithelial proliferation is greatly reduced by 
menopause, but even for postmenopausal women, nulliparous women have a higher 
proliferative rate. This may explain why, in postmenopausal women, nulliparous women 
still have a higher risk of developing breast cancer despite the fact that both groups of 
women have predominantly type 1 lobules (11).  
Mammary stem cell 
The origin of the luminal and myoeptihelial cells has been suggested to be mammary 
stem cells (MaSC) (Figure 2). Stem cells divide asymmetrically and give rise to one cell 
identical to itself (with infinite replicative potential) and to a progenitor differentiating 
into the myoepithlial or luminal lineage in a hierarchical fashion (14). MaSC are able to 
express telomerase (15), and have an infinite replicative potential and remain in the body 
as active, replicating cells from embryogenesis into adult life, and do therefore have a 
higher risk of accumulating oncogenic alterations than other cell types (8). 
The MaSc is thought to reside in the basal compartment of the epithelium in the ducts 
(Figure 2). Recent research has however suggested that the precursor of the two breast 
epithelial cell types resides in the luminal lineage (for review, see (16)). Luminal 
epithelial cells can, under specific conditions; become immortal and acquire 
myoepithelial/basal-like characteristics (17) (18). The hypothesis that MaSCs reside in 
the luminal lineage is supported by recent studies of breast cancer showing that luminal 
epithelial cells invade more intensely than basal cells and that metastatic tumors often 
have a luminal phenotype (CD24+) even when the primary tumor is enriched in basal-
like cells (CD44+) (16,19).  
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MaSC are ER and PR negative (20) and two recent studies indicate that they are 
regulated by estrogen and progesterone through paracrine mechanisms from receptor 
positive neighboring cells (21,22). High levels of endogenous or exogenous estradiol 
and/or progesterone increased the pool of stem cells (characterized as CD49+/CD24-) 
and that deprivation of these hormones dramatically reduced the amount of cells counted.
Figure 2 A) A hypothetical and simplistic illustration of the relation between the mammary stem 
cell (MaSC) and its progeny. B) An illustration of the normal terminal duct lobular unit. 
Hypothetical location of different cell types (colored as in A). The gray line is the basement 
membrane. CK14: cytokeratin 14; MUC1: mucin 1. From Polyak et al (23) 
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2.2 Anatomy of the breast 
The anatomy of the adult female breast was first described by Cooper in 1840 (24) and 
depicted in Figure 3. The adult breast consists of 15-20 lobes each branched into lobules 
with 10-100 milk producing alveoli called terminal ductal lobular units (TDLUs) (Figure 
1). The ducts lead the milk from the lobules to the nipple. Most breast cancers arise in the 
ductal epithelium. The epithelium of human breasts consists of two main cell types, 
present from 14 weeks of gestation and described by the staining of different keratins: 
Luminal epithelial cells facing the lumen of the ducts and lobules and basal/myoepithelial 
cells lining the basal membrane(16). In the ducts, myoepithelial cells form a continuous 
layer in close contact with the basement membrane and most of the communication with 
the stroma is mediated by these cells. In the alveoli on the other hand, the luminal 
epithelial cells are in direct contact with the basement membrane (25). Surface markers 
specific for luminal and myoepithelial cells are listed in Table 1.  
Figure 3
A) Anatomy of the human breast. From 
http://radonc.ucsd.edu/patientinformation/programs/breastCancer.asp
B) A cross section of the mammary duct. From Adriance et al (26). 
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Table 1 Gene expression markers suggested to identify different mammary cell types 
Celltype Surfacemarker Genesymbol Reference
Mucin1 MUC1/EMA O'Hareetal,1991(27)
3integrin ITGB3/CD61 AsselinLabatetal,2007(28)
Luminal
epithelial
cells Cytokeratins7,8,18and19 K7,K8,K18,K19 Claytonetal,2004(29)
smoothmuscleactin SMA Gugliottaetal,1988(30)
Commonacutelymphoblastic
leukaemiaantigen CALLA/CD10/MME O'Hareetal,1991(27)
Myo
epithelial
cells 6-integrin ITGA6/CD49f Claytonetal,2004(29)
 Cytokeratins5and14 K5,K14 Claytonetal,2004(29)
 Vimentin VIM Claytonetal,2004(29)
Cytokeratins14and19 K19andK141) Villadsenetal,2007(14)Mammary
stemcells Clusterofdifferentiation24 CD242) Shackletonetal,2006(31)
 6-integrin ITGA6/CD49f3) Shackletonetal,2006(31)
 1integrin ITGB1/CD293) Shackletonetal,2006(31)
 Aldehydedehydrogenase1 ALDH1 Ginestieretal,2007(32)

BlymphomaMoMLVinsertion
region1 BMI1 Liuetal,2005(33)

Epithelialcelladhesion
molecule/epithelialspecificantigen
EPCAM/ESA/TACSTD1 Stingletal,1998(34)
1)CoexpressionofK19andK14 
2)CoexpressedwithCD29orITGA6/CD49
3)CoexpressedwithCD24 
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2.3 Physiology of the breast 
Female steroid hormones and receptors 
Estrogen and progesterone are steroid hormones produced in the ovaries. Both hormones 
are needed for normal breast development and function (11,35). Their receptors are 
localized in the nucleus and the activated receptor complexes bind to the promoter region 
of target genes and act as transcription factors (Figure 4). The receptor complexes also 
activate cytoplasmic signaling cascades.  
Figure 4 Estrogen binds to the estrogen 
receptor in the cytoplasm and cause 
dimerization of the receptor and 
translocation to the nucleus. In the nucleus 
the receptor complex binds to estrogen 
responsive elements of the DNA to induce 
transcription of target genes. The activated 
receptor complex may also induce 
cytoplasmic signaling cascades.  
Estrogen receptor (ER) (isoforms  and ), coded by two different genes, is expressed in 
several tissues, including breast, endometrium, prostate and brain. The two isoforms are 
expressed in different cells; they regulate different genes and do sometimes oppose each 
other in function. The expression of ER (but not ER) is down-regulated as estrogen 
levels increase. High expression of mammary epithelial ER is common 
postmenopausally, as a response to reduced estrogen levels, and indicate non-
proliferative cells (36). The two receptors are also affected differently by treatment. In 
breast cancer cells tamoxifen treatment increase the levels of ESR whereas aromatase 
inhibitors increase the levels of ER(37).
Progesterone receptors (PR) (isoforms  and ) exist in several tissues, including the 
breast, endometrium and brain. PR is mostly induced by estrogen receptor (ER)-activated 
transcription in presence of epithelial growth factor (EGF), although some ER-
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independent expression of PR also occurs (38). Progesterone and PR are necess
development and differentiation of the lobules and alveoli (TDLUs) (39). Progesterone 
reduce proliferation and increase apoptosis in normal breast epithelial cells and oppose 
the proliferative action of estrogen (12). Expression of PR is reduced in pregnant and 
parous women and low levels of this receptor is suggested as a marker of reduced risk fo
BC (40).
Epithelial c
ary for the 
r
ell proliferation 
epithelial cells express ER and PR, ER is expressed to a 
e
is
by
ng epithelial cells are PR positive and the effect of progesterone on the 
d
Only 7-10% of normal breast 
higher degree in lobules than in ducts (41). Both receptor types are also expressed in th
stromal cells (36). ER is restricted to the nuclei of some luminal epithelial cells, but 
ER is expressed more widely (at all developmental stages of the breast) and staining 
seen in the nuclei of luminal and basal epithelial cells as well as in stromal cells (both 
fibroblasts and endothelial cells) (42,43). The proliferating epithelial cells are not found
to express ER (44) and most often these are negative to both ER isoforms (43). In 
normal tissue, the estrogen-induced epithelial proliferation is, at least partly, caused 
paracrine signals such as stroma-derived hepatocyte growth factor (HGF) from ER+ 
fibroblasts (45)
Some proliferati
mammary epithelium can be both direct and paracrine through PR positive stromal cells 
(46). In the menstrual cycle, proliferation of the epithelial cells in the TDLU increases 
along with the dramatic increase in serum progesterone level in the luteal phase. The 
proliferative role of progesterone is also supported by animal studies showing increase
proliferation of epithelial cells when estrogen and progesterone are given in combination
compared with estrogen alone (38,46).  
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Endocrinology of menopause 
Menopause is the permanent loss of ovarian function leading to cessation of menstruation 
(for review see (47)). Menopause is recognized one year after the last menstruation. 
Women are born with a fixed number of ovarian follicles that mature one for every 
ovulation. From the late 30s, the number of remaining follicles decline rapidly. When 
only about 10follicles remain, irregular menstruation will start, and at menopause few 
follicles are left (48). The ovarian follicles produce both estrogen and the hormone 
inhibin B, which inhibits secretion of follicle stimulating hormone (FSH) as part of a 
negative feedback-system (see Figure 5). As the number of follicles is reduced, less 
inhibin B is produced, which in turn leads to an increase in FSH-secretion. These 
alterations occur while regular menstruation is still taking place. The elevated levels of 
FHS ensure stable estradiol levels despite reduced number of follicles. Eventually, there 
is loss of ovarian function, decline in production of estradiol and progesterone and 
increase in both pituitary hormones FSH and luteinizing hormone (LH). In the 
menopausal transition, the serum levels of FSH and estradiol are varying, and diagnosing 
menopause on these to parameters alone is not possible (47).
Figure 5 The hypothalamic regulation of 
gonadal sex hormones. Gonadotropin 
increases release of FSH and LH which 
stimulate ovarian secretion of sex hormones 
(estradiol and progesterone) and inhibins. 
The sex hormones and inhibins subsequently 
reduce the secretion of gonadotropin. The 
Anti-Mullerian hormone (AMH) is not 
involved in the feedback-loop. GnRH = 
gonadotropin-releasing hormone; LH 
=luteinizing hormone; FSH = follicle 
stimulating hormone; AMH=Anti-Mullerian 
hormone. From Burger (47).  
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3. Molecular characterization of normal breast tissue 
3.1 Gene expression
There is extensive literature about the molecular biology of breast cancer, but a limited 
number of studies focusing on the molecular patterns in breasts of healthy women.  
There are, a growing number of studies characterizing the gene expression patterns of 
normal mammary epithelium, and partly other cells in the normal breast. Studies of 
protein expression from single genes by immunohistochemistry, gene expression by 
polymerase chain reaction (PCR) or blotting in non-cancer tissues are frequent (49-51). 
Whole genome expression profiling of normal breast tissue is less frequent, but the last 
years, several studies have been performed. Most studies compare different normal breast 
cell types from breasts with cancerous lesions or compare normal and malignant breast 
tissue/cells (52-54). Some studies relate gene expression profiles of normal breast 
tissue/cells to other clinical features (55) or to treatment response (56).  
Cell type specific gene expression profiles 
The first whole genome expression profiling of different cell types from normal breast 
tissue and breast cancers was published by Polyaks group in 2004 (57). They isolated 
epithelial cells, myoepithelial cells, infiltrating lymphocytes, endothelial cells and 
fibroblast-enriched stroma from two mammoplasty reductions, two ductal carcinoma in 
situ (DCIS), 13 invasive carcinomas, a fibroadenoma and a phyllodes tumor. They used 
antibodies against EpCAM/ESA (epithelial cells), CD45 (lymphocytes), P1H12 
(endothelial cells), CD10/CALLA/MME (myoepithelial cells) to separate the cell types. 
Lymphocytes were removed before isolation of myoepithelial cells to avoid 
contamination due to lymphocytic expression of CD10. Serial analysis of gene expression 
(SAGE) was used to generate cell-specific SAGE libraries and Monte Carlo analysis used 
to identify differentially expressed genes. They also demonstrated large differences in 
molecular profiles between normal and malignant cells in all cell types.  
Another group has performed two studies(58,59) providing gene expression profiles 
characteristic of normal luminal and myoepithelial cells. Both studies used 
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immunomagnetically sorting of primary cultures from mammoplasty reductions to 
separate the two cell types with MUC1/EMA as a luminal marker and 
CD10/CALLA/MME as a myoepithelial marker followed by negative selection using 
EpCAM/ESA (epithelial cells) and integrin 4 (ITGB4) (myoepithelial cells). Their 
profiles were partly overlapping, and established myepithelial (LGALS7, S100A2, 
SPARC and CAV1) and luminal (CD24, LCN2, CLDN4, MUC1 and SEMA3B) markers 
were identified in both studies. These studies did not remove lymphocytes prior to 
isolation of myoepithelial cells. Gene ontology-terms enriched in the myoepithelial-
specific gene lists do not, however, include lymphocyte-related terms, and significant 
lymphocyte contamination is therefore unlikely.  
Two groups studied epithelial and stromal cells from mammplasty reductions and breast 
cancer patients after laser capture microdissection and published stromal-related gene 
expression profiles (60,61). Their studies provided gene expression profiles characteristic 
for the stromal cells compared with epithelial cells. The profiles of normal stromal cells 
compared with normal epithelial cells published in the two papers, overlapped with about 
40%.
Polyaks group has analyzed cells from mammoplasty reductions comparing stem-like 
cells (CD44+) suggested to be progenitor cells compared with luminal epithelial cells 
(CD24+) (19). Gene expression profiles of putative progenitor cells are also published by 
Eaves group. They isolated and cultured primitive bipotent and luminal restricted 
progenitor cells and generated gene expression profiles compared to mature luminal and 
myoepithelial cells (62).  
Such cell-specific gene expression profiles give important information about the biology 
of the respective cell. They also serve an important role as a comparison with gene lists 
generated from other studies of different cells/tissues. This study uses several of these 
gene lists to explore the nature of a subgroup of our normal tissue biopsies.  
Subtypes of normal breast tissue 
Variation in gene expression of normal breast tissue is not studied. More than a decade 
ago, study of variation in gene expression of breast tumors resulted in the first 
identification of breast cancer subtypes (63,64). Analyses of whole biopsies of breast 
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cancer tissue allowed an overall profile of biological features from all cell types 
combined. Similar to the clinical relevance of breast cancer subtypes, subtypes of normal 
breast tissue may be related to clinically important variables such as breast cancer risk.
Source of normal material 
Mammoplasty reduction is the most widely accepted normal human breast tissue used for 
research. Several groups have used histologically normal tumor adjacent tissue as control 
in cancer-studies. The impact of the source of normal tissue has been addressed in two 
different studies. Finak and colleagues compared normal tissue from mammplasty 
reductions and from breasts with malignant disease (>2 cm away from the tumor) and 
found no difference (60). Different gene expression profiles between normal epithelium 
from mammoplasty reductions and from breasts with malignancy is, however, found in 
two other studies by Rosenbergs group (65,66). Graham and colleagues examined the 
profiles of breast tissue from prophylactically removed breasts. They found that, based on 
gene expression, normal epithelium from breast cancer patients and from high risk 
women (undergoing prophylactic mastectomy) clustered together and separate from the 
epithelium from mammoplasty reductions. They concluded that the shared characteristics 
between the cancer patients and the high-risk women cannot be a cancer-induced field 
effect and suggest that this is a high-risk profile (66). The method used by these two 
groups is similar, and is not likely to cause the divergent results. Both groups used fresh 
frozen samples, although the Finaks study soaked the tissue in TissueTek OCT 
(Somagen, Edmonton, Alberta, Canada) before storage on liquid nitrogen. Laser capture 
microdissection was used to isolate epithelial cells. For tumor adjacent normal samples, 
more than 2 cm distance to the tumor was a requirement by both groups. The controversy 
between these two studies indicates that further studies are needed.  
3.2 Genomic alterations
Early studies of histologically normal breast tissue from cancerous breasts and of 
epithelial hyperplasias without atypia revealed genomic alterations interpreted to 
represent the initiation or early progression of breast cancer (67,68). The existence of 
genomic alterations in normal tissue has been confirmed in various studies.  
15
Rosenberg’s group has performed several studies comparing genomic events in normal 
breast tissue from reduction mammoplasties, BRCA-mutations carriers and breast cancer 
patients. They found genetic abnormalities in all groups of women (69). Studying the 
DNA of non-cancerous epithelial cells from TDLUs, there was considerably less allelic 
imbalance in the reduction mammoplasties (5%) compared with the breast cancer patients 
and BRCA-mutation carriers (15% and 16% respectively) (70). They also showed that the 
location of allelic imbalance in tumor adjacent tissue was different from that of the 
carcinoma and do not represent precursors of the existing cancer, but rather separate 
clones with possibility of future cancer development (71).
Rennstam and colleagues used high-resolution array comparative genomic hybridization 
(aCGH) to compare genomic alterations in prophylactic mastectomies and reduction 
mammoplasties and confirmed the observation of more frequent alterations in tissue from 
breasts of high-risk women (72). Both tissues had alterations even after removing the 
copy number variations (CNVs) from the analysis. The alterations found in reduction 
mammoplasties were generally small and represented both known polymorphic sites and 
regions without previously known common variants. In prophylactic mastectomies, there 
were more frequent alterations, and the alterations were larger in amplitude than those 
found in non-familial cases, and smaller than those found in carcinomas. The variation of 
alterations between different samples was large, both between and within individuals.
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4. Breast cancer risk 
The last decade has made it increasingly evident that breast cancer is a heterogeneous 
disease with different clinical and biological features. The division of breast cancer into 
estrogen receptor positive and negative tumors has been refined and the disease is now 
further subdivided into subtypes defined by shared gene expression patterns (63,64). 
Since the underlying biology and origin differ between the different breast cancer 
subtypes, the risk factors may also differ (73). Most studies identifying risk factors do, 
however, not take the different subtypes into account. Future stratification on subtypes in 
breast cancer risk studies may reveal new risk factors and patterns of breast cancer risk.  
4.1 Epidemiologic and hormonal risk factors
Already in the 1890ies, the proliferative role of functional ovaries on the mammary gland 
was suggested when Beatson observed that the course of the breast cancer disease was 
affected by oophorectomy (74). By the 1960ies it was well established that prolonged 
administration of large doses of estrogens induced cancer in the breasts and other organs 
(75). Later, it has become clear that high serum estrogen levels are associated with 
increased breast cancer risk for postmenopausal women (76,77). The results are less clear 
for premenopausal women. Dorgan and colleagues recently found that premenopausal 
serum testosterone, but not estradiol, was associated with breast cancer risk (78). The 
hormonal influence on the mammary gland is reflected in the many hormone-related risk 
factors associated with breast cancer (79)(Table 2)
Early menopause and late menarche reduce the total estrogen exposure of the breast and 
hence the breast cancer risk (80). Pregnancy with its high levels of female hormones 
increases the womans risk of developing breast cancer for up to five years (81,82) 
possibly due to a hormonally induced increase in the number of mammary stem cells 
(22). During these first five years after a full term pregnancy, there is also a worse 
prognosis of the disease compared to breast cancer diagnosed more distant to the last 
pregnancy (83,84). 
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Table 2 Breast cancer risk factors. Strength indicates the association between the risk factor and 
breast cancer in terms of relative risk. From Trichopoulos et al, 2008 (79). 
Risk factor Category/change Strength1)
Gender Women vs men ++++
Age Increase ++++ 
Ethnic group Caucasion vs Asian +++
Family history Yes vs no +++
Specific genes Yes vs no ++++
Cancer in other breast Yes vs no +++
Height Increase ++
Postmenopausal obesity Increase ++
Brith weight Increase +
Having been breastfed No vs yes 0
Growth in early life Increase +
Atypical hyperplasia Present vs absent +++
Mammographic density High vs low density  +++
Age at menarche Earlier
Age at menopause Later
Type of menopause Natural vs artificial ++
Age at 1st full term pregnancy Later +++
Age at other pregnancies Later +
Parity overall Lower ++
Pregnancy timing Proximal vs distant +
Lactation No vs yes +
Abortion No vs yes 0
Oral contraceptive use (recent) Increase +
Hormone replacement Increase +
Plant foods and olive oil Reduced intake +
Saturated fat Increased intake +
Physical activity Reduced +
Ethanol intake Increase +
Ionizing radiation Increased   +
Magnetic fields Increased   0
Organochlorines Increased   0
1) Associations: ++++ very strong, +++ strong, ++modest, + weak, 0 null.  
Despite the initial increase in risk, higher parity is protective, the protection starting from 
1years after giving birth. The protection lasts throughout the women’s lifetime, with the 
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greatest effect going from zero to one full term pregnancy (85). Early age at first full term 
pregnancy and breast feeding also protect against breast cancer (80,86,87). Early age at 
first full term pregnancy is particularly preventive for ER+/PR+ breast cancers (88). 
Despite the protective effect of parity, several studies have concluded that high age at 
first or last full term pregnancy confers a higher risk for breast cancer than nulliparity 
(89,90).
The biological mechanisms underlying the different effects of pregnancies on breast 
cancer risk are largely unknown, but the role of female hormones is essential in all 
hypotheses. Several groups are even trying to develop preventive treatments trying to 
mimic pregnancies (85).  
Hormone therapy after menopause is associated with increased risk for breast cancer, 
especially seen for combined estrogen-progesterone regimens (91,92). This is true for 
receptor positive, but not receptor negative breast cancers (88) and for both ductal and 
lobular hitologies (88). Anti-estrogen treatment (Tamoxifen) is associated with reduced 
risk of breast cancer (93,94). The association with ER+ cancers is consistent with 
findings that current hormone therapy use at time of diagnosis is associated with good 
prognosis of the breast tumor and hormone use is therefore suggested to induce breast 
cancers with a less aggressive phenotype (95,96). Progesterone therapy is associated with 
an increase in MD (97-99), increased apoptotic rate, differentiation and proliferation of 
epithelial cells. The effects do, however, vary between different progestins (100). 
Other hormones have also been related to breast cancer risk. A recent meta-analysis 
found that high serum IGF1 levels increase the risk for ER+ breast cancer. There are 
indications that the GH/IGF1-axis contributes to hyperplasia and carcinogenesis 
(101,102). Reduction of IGF1-production by growth hormone antagonists reduced breast 
cancer development in mice and the protein has been proposed a target for prophylactic 
treatment (103). 
Body mass index (BMI) has been found to be associated with breast cancer inversely in 
premenopausal women and positively in postmenopausal women (104). The association 
between BMI and breast cancer also varies with race and hormone receptor status such 
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that high recent BMI increases the risk of receptor-positive breast tumors especially in 
postmenopausal African-American women (73,105). BMI is a result of both genetic and 
environmental factors. Although there are consistent findings on the association between 
BMI and breast cancer risk, there are more uncertainties regarding diet.
A large meta-analysis recently confirmed that diet has a small, but significant effect on 
breast cancer risk. A prudent diet decreases the risk and high alcohol intake increases the 
risk. In this meta-analysis, a prudent diet generally consisted of large amounts of plant 
foods and low amounts of red and processed meat. They do, however, point out the 
evident error of misclassification of diets as detailed information of individual foods 
could not be included in the pooled analysis. The slight effect of diet could therefore be 
due to classification errors (106).
Physical activity reduces the risk for breast cancer, especially for postmenopausal 
women. A recent review found a risk reduction raging from 20-80% in different studies 
and a trend analysis indicating a 6% reduction in breast cancer risk pr weekly hour 
exercise (107). Reduced risk for breast cancer by physical activity is also shown 
experimentally in animal models (108). The underlying mechanisms are unknown. 
Suggested mechanisms are reduced levels of sex hormones and IGF1 and prevention of 
overweight. A recent study found that aerobic exercise reduced the non-dense breast 
tissue relative to the reduction BMI, but the MD was not significantly altered. They 
suggested that the mechanisms for the protective effect of exercise go through other 
mechanisms than MD (109). Alteration in serum-levels of several biomarkers from 
physical activity is shown. Amongst the alterations seen were reduced levels of IGF1, 
growth hormone (GH), tumor necrosis factor alpha (TNF), leptin and estrogen. This 
was interpreted as an alteration in glucose homeostasis and metabolism (108).  
There is evidence that environmental factors affect breast cancer risk already from the 
fetal life on. The role of birth weight in breast cancer etiology is reviewed by Michels and 
Xue (110). They concluded that high birth weight was associated with premenopausal, 
but not postmenopausal breast cancer. This is thought to be caused, at least partly, by 
elevated levels of growth factors leading to an increased number of mammary stem cells 
(110). This is supported by recent findings that women with a birth weight above 4 kg 
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had a 3 fold risk of developing high MD compared to women weighing 3-3.5 kg at birth 
(111). Large initial weight loss after birth, rapid growth in early life as well as growth 
patterns during adolescence are also associated with increased risk of breast cancer 
(112,113).
The group of Trichopoulos has proposed a model explaining the mechanisms underlying 
breast cancer development grouping the different risk factors according to their etiologic 
explanations. They outline four main mechanisms contributing to breast carcinogenensis, 
each associated with specific risk factors, see Table 3 (79). This gives a broad overview 
of underlying physiology, but does not include molecular mechanisms which will be 
reviewed in a separate chapter.
Table 3 Four main mechanisms contributing to breast carcinogenesis and associated specific risk 
factors. From Trichopoulos, 2008 (79).  
General principles 
of carcinogenesis 
Number of mammary 
stem cells 
Growth enhancing 
mammotropic hormones 
Terminal differentiation 
of the ductal tree 
Age
Ionizing radiation 
Family history 
Specific genes 
Mammographic density  
Atypical hyperplasia 
Gender
Birth weight 
Growth in early life 
Height
Ethnic group 
Gender
Age incidence pattern 
Age at menarche 
Age at menopause 
Oral contraceptives 
Hormone replacement 
Pregnancy timing 
Postmenopausal obesity 
Ethanol intake 
Physical activity 
Adult life diet 
Age at 1st full term 
pregnancy 
Age at other pregnancies 
Parity overall 
(Lactation)
4.2 Mammographic density 
Mammograms are x-ray images where fat is represented as dark/lucent areas and 
epithelial and stromal tissues are represented as light/dense areas (114)(see Figure 7).
Methods of determining mammographic density 
Several methods of estimating breast cancer risk from mammographic features have been 
introduced. In 1976, Wolfe presented a classification of breast parenchymal patterns into 
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four classes (115). The low-risk group, N1, was described as primarily fatty tissue. Two 
medium-risk groups, P1 and P2, had <25% or >25% prominent ducts respectively. The 
high-risk group, DY, had mammograms consisting of dense fibroglandular tissue and was 
estimated to have 37 times higher risk of future breast cancer development, an estimate 
that would later be proven too strong (116). An alternative classification of breast 
parenchymal patterns was introduced by Tabar (117). A combination of anatomical and 
mammographic features was used to subdivide the women into 5 groups. Patterns I to III 
were low-risk groups and patterns IV and V consisted of dense tissue of different 
character and were considered high-risk groups.
Quantitative estimation of percent density was first introduced by Wolfe (118). The 
American College of Radiology has, as part of its Breast Imaging Reporting and Data 
System (BI-RADS), developed a quantitative classification system of breast tissue 
densities that is included in clinical practice together with qualitative, descriptive 
methods (119). Semi-computerized quantitative methods have been developed (120,121). 
The qualitative methods add little information to the quantitative, and the introduction of 
digital mammography has made the semi-computerized method suitable for clinical use 
and screening programs (122). The inter-observer agreement in quantitative methods has 
been higher than that of qualitative method (123). During the last years, the use of MRI to 
measure water content of the breast as a marker of fibroglandular tissue (124) and 
volumetric breast density (125) have increased. The correlation between glandular tissue 
as measured by MRI and percent mammographic density is low, particularly for breasts 
with high density (126). 
There is no consensus as to which estimate for mammographic density should be used. 
The use of qualitative techniques is still widespread; particularly the use of BI-RADS in 
the US both for diagnostic and research purposes. In the recent literature, many studies 
use both absolute and percent density, while others use only percent mammographic 
density. A recent study concluded that absolute density predicts breast cancer risk better 
than percent mammographic density (127). 
High MD is a well established risk factor for breast cancer, with an increased risk of 4-6 
even after correcting for other known risk factors (128-130) and regardless of breast 
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cancer subtype (131). The increase in breast cancer risk by using hormone therapy after 
menopause is greater in women who have dense breasts (132). Unlike the use of hormone 
therapy, a high MD increase the risk both for ER+ and ER- breast cancer (133) and is 
associated with both luminal A and triple negative disease (131). However, a recent 
Danish study found that the breast tumors developed in dense breasts are on average, less 
aggressive than those developed in predominantly fatty breasts (dividing all breasts into 
dense or fatty). The overall mortality was still higher in women with dense breasts (134). 
High MD may also conceal a small tumor and a measure of MD can therefore also be a 
sign of the sensitivity of the mammogram as a diagnostic test (4). 
Figure 6 Percent mammographic density: (a) 0, (b) <10%, (c) 10-25%, (d) 26-50%, (e) 51-75%, 
(f) >75%. From Yaffe et al (125). 
The biological basis of mammographic density 
Breasts with high MD have a larger proportion of white/dense areas on the mammogram 
(Figure 6) that represent both epithelial cells and stromal components, such as collagen 
23
and fibrosis (135-137). MD is associated with the relative area occupied by collagen, 
glandular structures and nuclei (of both epithelial and non-epithelial cells) (137). One 
group found the number of epithelial cells to be greatly increased in areas of high MD, 
but found no increase in proliferation as measured by the proliferation marker mindbomb 
homolog 1 (MIB1) (138). High MD is heterogeneous at the histopathologic level and 
may reflect both tissue with few cells but rich in collagen and fibroglandular tissue with 
high cellular activity. There may be different biological processes underlying high MD in 
these varying situations (139). To approach this problem, visual inspection of the 
mammogram can be used to distinguish between glandular and sheetlike structures of the 
densities. MRI may also allow specification of which type of dense tissue to measure, as 
demonstrated by Klifa and others (126).  
Some possible mechanisms for the influence of high MD on breast cancer risk are 
suggested. Firstly, abundant and aberrantly activated fibroblasts may influence epithelial 
cells through secretion of growth factors and chemokines. Vachon and colleagues found 
increased aromatase in stroma and epithelium of dense areas of the breast compared with 
non-dense areas of healthy women. This may lead to higher estrogen-stimulation of 
proliferation and contribute to the carcinogenic process (140). Secondly, increased 
collagen deposition due to excessive fibroblast activity results in a stiffer extracellular 
matrix which has been associated with altered cell signaling and increased epithelial cell 
proliferation. Evidence supporting this view has come from two different groups using 
different approaches. Provenzano and colleagues found that increased collagen promoted 
proliferation and invasion of epithelial cells in the absence of fibroblasts (141) and that 
increased stromal collagen increased tumor formation and invasion significantly (142). 
Similarly Weavers group induced collagen-crosslinking which was accompanied by 
increased focal adhesion and invasion by oncogenic epithelium (143).
Still, much is unclear regarding the regulation of mammographic density and its role in 
breast carcinogenesis. In a recent interview, Valerie Weaver said that “my belief is that 
all folks who claim that they are modeling breast density when they study the effect of 
increased collagen concentration on cell behavior ex vivo are overinterpreting and 
extending data that are not yet conclusive.”(144) Studies on human tissue from a relevant 
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study population would help interpret in vitro studies and generate more relevant and 
specific hypotheses. 
Epidemiologic factors and mammographic density 
The regulators of MD and the impact of MD on breast carcinogenesis was recently 
reviewed by Martin et al (129). The genetic component of MD is substantial, and 
probably account for more than 50% of the variation (145) (146), but environmental 
factors are also important (145). MD is inversely associated with age, BMI and smoking. 
Menopause reduces the proliferative stimulation of the breast and hence MD. High BMI 
with a high fatty component of the breast is associated with reduced MD as adipose tissue 
is radiolucent. Smoking is suggested to have an anti-estrogen effect on the breast tissue 
(147,148). As mentioned previously, it was recently found that high birth weight is also 
associated with high MD in later life (111). This study does, however, not address 
whether birth weight is predominantly genetically or environmentally determined.  
Hormones and mammographic density 
Although exposure to endogenous female hormones is associated with proliferation of 
breast epithelial cells and with an increase in breast cancer risk (149), there is some 
controversy as to weather such exposure increases MD (150,151). Hormone therapy does, 
however, increase MD while anti-estrogen substances reduce MD (152)(for review, see 
Martin et al (129)). There is evidence that sex hormones and MD both independently 
increase the risk for breast cancer and that the underlying mechanisms are unrelated 
(153). Boyd and colleagues(154) have proposed a model for the relation between the 
mechanisms underlying MD and how they relate to breast cancer (Figure 7). 
25
Figure 7 Mechanisms underlying mammographic density and its relation to breast cancer risk 
depicted by Norman Boyd and colleagues (154). Risk factors and genetic variants influence the 
two suggested mechanisms; mutagenesis and mitogenesis. Increased oxidative stress with lipid 
peroxidation increases the risk for mutations and accumulation of events that increase 
proliferation, stromal activity and carcinogenic drive. Hormones and growth factors stimulate 
stromal production of collagen and cell proliferation important both in MD and carcinogenesis. 
A) Scematic summary of suggested mechanisms. B) The biological hypotheses where each cell in 
the breast influence its neighbors. Fibroblasts produce collagen, paracrine factors influencing 
epithelial cells and may differentiate into adipocytes. Epithelial cells and fibroblasts proliferate 
upon hormonal stimuli and could initiate the carcinogenic process.  
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Genetic variation and mammographic density 
Single nucleotide polymorphisms (SNPs) associated with MD have been identified in 
several genes, including COMT, a gene coding for an enzyme inactivating estrogens, in 
ESR1 (reviewed in Kelemen et al (7)) and in and HSD3B1, also involved in the sex 
steroid metabolism. Some of these and other SNPs in the estrogen pathway were tested in 
a recent study, but the association with MD could not be confirmed (155). In the same 
year, Yong and colleagues found SNPs in the sex hormone metabolizing genes SULT1A1
and UGT1A to be associated with MD. SNPs in IGF1 and its related genes have also been 
linked to MD and to the serum levels of IGF1 which is in itself related to MD (153,156). 
Since MD is a strong risk factor for breast cancer, it was expected that SNPs associated 
with breast cancer risk might be associated with MD. This is so far not found (157). 
Molecular variation according to mammographic density 
The molecular background for MD has been explored in several studies, and gene 
expression alterations associated with high MD have been described (55,136). Yang et al 
analyzed histologically normal tissue from breasts harboring breast cancer sampled 
during surgery. Women were divided into high or low MD by BI-RADS. They found 73 
genes differentially expressed between women with high and low MD, with a decreased 
transforming growth factor beta (TGF)-signaling in breasts with high MD (55).
Looking at regional differences within the breast, the expression of the proteoglycans 
lumican and decorin were found increased in regions of the breasts with high MD 
compared with low-MD regions, evaluated by immunohistochemistry. These 
proteoglycans are expressed in the stroma and have previously been reported 
differentially expressed between tumor and normal breast tissue (158). The expression of 
matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in breasts have been 
analyzed for association with MD, but no significance was found (159).
In summary, it is well known that MD confers an increased risk of breast cancer, but the 
underlying mechanisms are still unclear. Specifically, it is not known whether the 
increased risk for breast cancer due to high MD is caused by the increased amount of 
cells at risk of developing cancer or due to altered biological processes. MD seems to 
represent presence of both stroma and epithelium, but is not influenced by the 
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proliferation rate per se. The histologically heterogeneous nature of high MD supports a 
hypothesis that different biological mechanisms lead to MD. Epidemiologic factors 
associated with MD have been identified, but how they are linked with MD at the 
cellular/molecular level is not known. The first evidence of SNPs and transcripts with 
putative association with MD has emerged, but much is still to be elucidated before we 
can identify the mechanisms underlying high MD and its association with breast cancer 
which may eventually allow identification of high-risk individuals in order to introduce 
preventive strategies. This was the main reasons for initiating the current study.
4.3 Molecular alterations associated with breast cancer risk 
Genetic 
The strongest genetic factors affecting the risk of developing breast cancer are mutations 
in the DNA-repair genes BRCA1 and BRCA2 (160,161). The inheritance of one mutated 
allele confers a life-time risk of up to 80% of developing breast cancer (162). Inactivation 
of the wild-type allele leads to defect repair of DNA and increased genetic instability and 
risk for cancer development. Other tumor suppressor genes were inherited mutations lead 
to increased risk of breast cancer are known, such as FANCJ and FANCN (Fanconi 
anemia), TP53 (Li Fraumeni syndrome), PTEN (Cowden syndrome), STK11 (Peutz-
Jeughers syndrome) and CDH1.  
Most breast cancer cases are not due to a known germ line mutation. Acquired genetic 
and epigenetic alterations are thought to be caused by complex interactions of genetic 
predispositions and environmental factors. There is a familial clustering of the disease 
independent of epidemiologic factors, supporting the hypothesis of a genetic component 
in the development for sporadic cases. Most women with first degree relatives with breast 
cancer will never get the disease (163).
A multigene model including common gene variants with lower penetrance most likely 
explains familial relative risk observed and several genome-wide association studies have 
been performed to identify such polymorphisms (for review, see (164) and (165)). Where 
previous studies focused on genes known to be involved in cancer-related biological 
processes (candidate gene studies) the genome-wide association studies (GWAS) 
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examines the whole genome to identify genetic variants and combinations of such that 
are associated with the disease. ATM and CHEK2 are examples of genes where medium 
penetrance polymorphisms have been identified. It is estimated that twelve candidate 
susceptibility SNPs identified explain 5-8% of the familial clustering of breast cancer, 
indicating that much of the underlying biology is still unknown (164,165). 
The Breast Cancer Association Consortium (BCAC) is a forum created to investigate the 
heritability of breast cancer. In this forum, researchers from all over the world combine 
studies from different groups to get reliable data to evaluate the contribution to breast 
cancer risk from SNPs. Their meta-analyses have identified novel SNPs (166) and have 
confirmed some (167), but not all SNPs previously suggested (168). Some of the SNPs 
identified were associated with specific histopathologic subtypes (169).
Recently, pathway analysis has been introduced as a means of identifying genetic 
associations to breast cancer risk with the underlying assumption that different genes may 
affect the same pathway and result the same biological consequences for the cell (170). 
The pathway approach identified a significant association between the estradiol metabolic 
pathway (including CYP19A1 and UGT2B4) and breast cancer risk (171). 
The search for mediators of the identified genetic variants is also ongoing. One approach 
as been to use SNPs identified to be associated with breast cancer and look for difference 
in association between the SNP and breast cancer development according to established 
risk factors for the disease. Recently, two studies used this approach, one with a negative 
result (172) and one found an association between a SNP in MAP3K1 and height (173). 
This indicates that the mediation of the risk conferred by the SNPs identified is complex.  
Gene expression
Little is known about gene expression profiles in normal breast tissue with increased risk 
for breast cancer. Partly, this is because true normal breast biopsies are not easily 
obtained.
One breast cancer gene expression risk signature is published (174). Chen and coworkers 
used histologically normal tissue and tumor tissue from the same breasts . The basic 
assumption was that normal tissue with tumor-like gene expression has higher risk of 
29
developing breast caner. The genes from the histologically normal tissue whose 
expression was correlated with that in the tumor were included in the malignancy risk 
signature. This gene list was dominated by proliferative genes.
4.4 Risk prediction tools 
Estimation of the breast cancer risk of individual women is important to determine who 
should have more frequent examinations and who should receive preventive measures. 
Several models assess the risk of breast cancer or the likelihood of finding a BRCA 
mutation or both (111) (for review, see Amir et al (175)). While some models mainly 
focus on family history, others take hormonal factors into account. They find that 
although some of the models are well calibrated to their target populations, all models 
have only moderate accuracy and most only include a small subset of known risk factors 
(175,176). I the review by Amir et al, none of the models evaluated included MD despite 
the strong correlation with risk and the high reproducibility (177). MD has, however, 
been incorporated in a few risk prediction models (including the Gail model) with a 
modest increase in discriminatory power (178-181). 
The heterogeneous nature of breast cancer is probably reflected in different carcinogenic 
processes and different importance of risk factors. An example is how BRCA1 mutations 
tend to give basal-like breast cancers, whereas BRCA2 mutations tend to give luminal 
breast cancer. Risk assessment studies stratifying for subtype may reveal new knowledge 
of the interplay of different risk factors in the carcinogenic process (182). In the mean 
time, commercial genetic risk tests including breast cancer risk are being offered to 
consumers over internet (eg: 23andme, Navigenics and deCODE Genetics) and to 
clinicians (Intergenetics). These kits are considered medical devices, and the producers 
have recently received information that they require approval by the US Food and Drug 
Administration for marketing (183). Most risk prediction tools are better at a population 
level and the use of the tests currently available for individuals is controversial (184).
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5. Breast cancer development and progression 
Breast cancer is thought to originate in one cell that is transformed from a normal 
epithelial cell to a breast cancer cell. Carcinogenesis is a multistep process affecting the 
cells genome. In order for a cell to become malignant, it must acquire the characteristics 
nicely described by Hanahan and Weinberg in 2000 as the hallmarks of cancer (185). The 
present study does not focus on breast carcinogenesis in itself, but aims at understanding 
the normal biology in order to be able to identify the first deviating steps in the 
carcinogenic path. In paper I, we have identified a group of samples that share certain 
features with stem cells, stromal cells and partly with myoepithelial and mesenchymal 
cell. The role of these cell types in carcinogenesis will therefore be briefly reviewed. 
5.1 Cancer stem cells or clonal evolution? 
One characteristic feature of most cancers is the cellular heterogeneity within each tumor. 
This heterogeneity makes it hard to hit all cancer cells by the same treatment. Studies of 
the difference between the cells of a tumor may reveal its history. The mechanisms 
behind this heterogeneity are debated. The two main theories are the clonal evolution 
model and the cancer stem cell hypothesis (for reviews, see (186-188)).
The cancer stem cell hypothesis (hierarchical model) suggest that the cancer arise in stem 
cells that acquire malignant potential through a multistep carcinogenic process and that 
cancer stem cells further differentiate to form the different cancer cells constituting the 
heterogeneity of the tumor. There is a hierarchical nature where the pluripotent cancer 
stem cells differentiate into lineage restricted non-tumorigenic cancer cells populating the 
tumor. These lineage restricted cells have a limited life span, and are replaced by the 
cancer stem cells other progeny. The cancer stem cells are thought to be responsible for 
invasion and metastasis (186) and they are believed to be resistant towards chemotherapy 
(189).
The origin of cancer stem cells is debated. This debate is partly fueled by results 
indicating that other cells may acquire stem cell-like characteristics (190), in the breast 
illustrated by epithelial cells acquiring stem cell traits after epithelial-mesenchymal 
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transition (191). Initiation of tumor development has also been attributed to cancer cells 
lacking stem cell characteristics, raising concerns about the validity of the stem cell 
hypothesis (192). And there is evidence for separate evolution of CD24+ and CD44+ 
cells existing in the same tumor (193). The uncertain origin is reflected in the multitude 
of names given to the cells; Cancer stem cells, stem-like cancer cells and tumor initiating 
cells.
The model of clonal evolution (stochastic model) closely resembles the model of 
evolution of species and was first proposed by Nowell in 1976 (194). This model 
suggests that cancer arises in a normal cell through a multistep carcinogenic process. The 
cancer cell will continue to divide. The carcinogenic process has rendered the genome 
unstable and new genetic alterations will occur that mark the start of a new clone. The 
tumor cell population is the result of an evolutionary process with selection of the fittest 
cell clones (186,187,195). 
5.2 The role of the microenvironment
The microenvironment of the breast is generally thought of as all breast components 
other than the epithelial cells or tumor cells, the most important being the stromal cells 
(mainly fibroblasts, endothelial cells and immune cells), blood and lymph vessels and 
extracellular matrix. Already in 1973, there was a publication showing how stromal 
tissues influenced proliferation of the mammary gland in a mouse model (196). The 
importance of the microenvironment in cancer was suggested from the early 1980s by the 
Bissell lab (197) and by Dvorak who compared cancer with wounds that do not heal 
(198). The central role in initiation and progression of the disease has only been widely 
accepted the last decade (for reviews, see (199-201)). Even Dvorak’s comparison with 
wound healing has gained support in recent years by a study showing activation of host 
wound responses in the microenvironment of breast cancers (202). 
Parallel with the malignant transformation of the luminal epithelial cells, the stroma 
undergoes morphological changes such as increased number of fibroblasts and 
lymphocytes, angiogenesis and remodeling of the extracellular matrix. It has become 
evident that the stroma not only responds to epithelial changes in breast cancer 
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progression, but have an active role in promoting cancer development and even have 
initial genetic alterations and that the communication between the epithelial cells and the 
stroma is bidirectional (200,203-206).  
Several mechanisms by which the stroma can initiate malignant transformation have been 
proposed. Alterations in the stroma leading to a phenotype promoting a malignant 
transformation can be induced by carcinogens, altered expression of matrix 
metalloproteinases, immune cells and viruses (206). Transdifferentiation of other cell 
types has been suggested as a possible mechanism, with possible cells of origin being 
circulating fibrocytes, bone-marrow derived mesenchymal stem cells and endothelial 
cells going through mesenchymal transition (201). The importance of the stroma in 
epithelial carcinogenesis corresponds well with the role of stromal cells in regulating 
epithelial cell proliferation as discussed in section 2.3.  
The stroma also defines the stem cell niche which regulates the stem cells. According to 
the cancer stem cell hypothesis, the first malignant cell is a stem cell. This is supported 
by evidence that dormant stem cells may be activated by changes in the local 
microenvironment, leading to cell fusion and cancer initiation (207) and by studies 
indicating that the extracellular matrix has a role in regulating tumor evolution through 
the stem cell niche (188).  
5.3 Myoepithelial cells 
Myoepithlial cells are localized between the luminal epithelial cells and the stroma and 
form a barrier for the cancer cells during carcinogenesis (Figure 3) (208-210). Their role 
as natural tumor suppressors with importance in the early stages of tumorigenesis has 
been confirmed in molecular studies. The extensive molecular characterization of breast 
cells performed by Allinen and colleagues showed that the cell type with the largest and 
most consistent alterations between normal tissue and both DCIS and invasive cancer was 
the myoepithelial cells (57). Further loss of function of these cells is suggested as the 
initiating event in the transition from in situ to invasive cancer (211). 
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5.4 Epithelial-mesenchymal transition 
Epithelial-mesenchymal transition (EMT) describes a process where differentiated 
epithelial cells loose epithelial characteristics such as polarity and adherence to 
neighboring cells and tissues and gain immature, mesenchymal characterstics such as a 
loss of polarity and migratory and invasive properties. These properties are also 
important in cancer progression and metastasis. The process is regulated by and can be 
induced by TGF (212).
Several groups have shown that induction of EMT results in the gain of stem cell-like 
characteristics indicating a role of EMT in carcinogenesis (191,213,214). The combined 
features of EMT and stem-like characteristics are also seen in residual breast cancers 
after conventional chemotherapy and in the claudin-low subtype and is associated with 
bad prognosis (215,216).
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6. Material and methods 
6.1 Subjects 
Women participating tin the present study were included from 2002 to 2007. The 
inclusion was done by radiologists at breast diagnostic centers. Breast diagnostic centres 
in six hospitals in Norway included patients to the study. The six hospitals are Oslo 
University Hospital Radiumhospitalet, University Hospital of North Norway, Vestfold 
Hospital, Innlandet Hospital, Buskerud Hospital and Sørlandet Hospital. Two groups of 
women were eligible: 1) Women with mammographically normal breasts (with no signs 
of malignancy) and at least one area with some of mammographic density (healthy 
women) and 2) Newly diagnosed breast cancer patients before any treatment. In total, 
186 women were included, 120 healthy and 66 breast cancer patients. All women were 
above the age of 20 and signed informed consent. Exclusion criteria were breast implants, 
anticoagulant therapy, current pregnancy or lactation. Women with a history of breast 
cancer and no suspicion of malignancy could be included in the group of healthy women 
with a biopsy of the contralateral breast. The study was approved by the ethical 
committee (S-02036).  
Table 4 Referral to the breast diagnostic centre of women included in the study 
Referral Total Healthy women  Breast cancer patients 
n (%) n (%) n (%)
Screening  69 (37) 50 (42) 19 (29) 
Findings/risk 1) 83 (45) 41 (34) 42 (64) 
Unknown 34 (18) 29 (24) 5 (7) 
186 (100) 120 (100) 66 (100) 
1) Palpable lump/clinical findings/increased risk of breast cancer (family history or previous 
benign breast lesion or breast cancer).  
The women were referred to the breast diagnostic center in various ways (see Table 4 and 
Figure 9). Most women were referred from their doctor due to a palpable lump, clinical 
finding or high risk (family history or previous breast cancer or benign breast lesion). A 
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total of 69 women were referred from the National Breast Cancer Screening Program 
(217) due to irregular findings. Each woman provided two breast biopsies, blood 
samples, mammograms and filled in a questionnaire about parity, hormone use and 
family history of breast cancer.  
6.2 Core biopsies 
From each woman two biopsies were collected by use of a 14 gauge needle. Biopsies 
from Oslo University Hospital Radiumhospitalet were snap frozen in liquid nitrogen and 
stored at -80C. In the other hospitals one biopsy from each woman was soaked in 
RNAlater (for RNA-extraction) and another on 70% ethanol (for DNA-extraction). These 
biopsies were transported to Oslo University Hospital Radiumhospitalet, Deptartment of 
Genetics, and stored at -20C until extraction.
Figure 8 Unsupervised hierarchical clustering of gene expression from 79 healthy women (9767 
probes). Biopsies taken from lesions do not consistently cluster together, and are not significantly 
enriched in any of the main clusters. Source of referral is significantly different in the two main 
clusters. P-values from ANOVA-tests.  
The biopsies from the breasts of healthy women were taken from an area with some 
mammographic density in order to avoid purely fatty biopsies. One hospital (including 17 
healthy women) sampled biopsies from the benign lesion/suspect area and not from 
normal tissue with some density. These included 5 fibroadenomas, 8 fibroadnomatous 
breasts, one microcalcification and three without mammographic lesions (biopsy was 
taken from a palpable structure not found on mammography). These 17 samples did, 
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however, not consistently cluster together in unsupervised, hierarchical clustering and 
there is no significant difference in biopsies taken from a lesion as opposed to from 
healthy tissue in the two main clusters observed (see Figure 8). In breast cancer patients, 
the biopsies were taken from the tumor itself.  
6.3 Whole genome expression analysis  
DNA microarrays are developed to perform whole-genome analyses of DNA-level or 
mRNA-expression. Several different types of microarrays are used. We have used two-
colour olignucleotide microarrays with printed 60-mer probes. On each array, nucleotide 
sequences of 6base pairs are printed on separate spots. A common reference is used for 
all experiments. We used a commercially available reference prepared from 10 different 
cell lines to obtain a general background for our test samples. Separate labelling is used 
for the test and reference RNA before they are mixed into one solution and dispensed 
onto the slide.
RNA from the test and reference samples will hybridize competitively to the printed 
nucleotide sequences and the relative expression of each mRNA transcript can be 
determined from the scanned ratio of signalling from the two dyes. The array will not 
give information about the exact level of expression of the particular probe, but rather the 
expression level in the sample compared with the control for each probe. The protocol 
used in these studies is described in more detail in the following, and is illustrated in 
Figure 9. For more detailed description of the experiments in this study, see paper II.  
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Figure 9 Fluorescent cRNA Synthesis Procedure illustrated in the Agilent Low RNA Input 
Fluorescent Linear Amplification Kit Protocol, Version 2.0. August 2003.
6.4 RNA data processing  
Normalization 
After hybridization, the microarray slide is scanned and the colour intensities are 
converted into numbers. In a two-channel RNA-microarray experiment, the output value 
for each spot is typically the log2-ratio of red (test-sample) over green (control) signal 
intensity. There may be differences in signal intensity between probes on one array 
leading to technical bias in the experiment. Both labelling efficiency and scanning 
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properties may influence the relative intensity of each dye. Within-array normalization is 
a set of techniques to correct for these technical biases. A typical technical bias is 
different hybridization intensity for the two dyes used in the experiment. This will lead to 
a non-linear relationship between spots dominated by each colour. This can be illustrated 
by an MA-plot. A standard, normalized measure for the intensity in a spot is given by 
M=log2R-log2G, where R=red intensity and G=Green intensity in a spot. A measure of 
the overall brightness of a spot is given by A=(log2R+log2G)/2. These two measures, A 
and M, are used to visualize the distributions of the intensities on an array and in a dataset 
in the MA-plot. In Figure 10A), we see an MA plot representing a non-normalized 
microarray experiment. The banana-shape of the distribution of intensities indicates a 
non-linearity. After normalization, the same data has become linear and the distribution 
of red and green intensities is more equally represented on the array B)(218,219).
Figure 10 MA-plot with 
A) non-normalized data 
and B) normalized data.  
From Yang Y H et al, 
2002 (218). 
Locally weighted scatterplot smoothing (Lowess) is a linear regression method that is 
commonly used for normalization of two-channel microarray data (220). The method 
adjusts for dye-biases within one array. This occurs because the dyes do not fluoresce at 
the same intensity at different levels. Lowess-normalization ensures that the log2-ratio-
intensities achieved from all spots in one array are comparable. The normalized log2-
ratios are calculated by subtracting a constant c(A) from the original log2-ratios. This 
constant is found by estimating a local weighted linear regression and calculating the 
best-fitting average log2-value from the log2-ratios observed in each data point (219). 
MA-plot of a normalized sample is shown in Figure 11.  
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Figure 11 MvsA plot for lowess normalized 
log2-ratios for MDG011 in this study. 
6.5 Mammograms 
Mammograms were collected with routine description of the mammograms by the local 
radiologist. Craniocaudal mammograms were digitized using a high resolution Kodak 
Lumisys 85 scanner (Kodak, Rochester, New York). We obtained successfully scanned 
mammograms from 176 women (115 healthy women and 61 breast cancer patients). MD 
was estimated using the well established, semi-digital University of Southern California 
Madena assessment method (121). A reader, trained by Giske Ursin, outlined the total 
breast area using a computerized tool. Giske Ursin then defined the region of interest, 
being the areas of the breast containing densities except those representing the pectoralis 
muscle or scanning artifacts. The computer then colors yellow all pixels within the region 
of interest and above a specified threshold. The colors pixels then represent the area of 
absolute density. Percent MD is the absolute density area divided by the total breast area 
(see Figure 12). We use the average percent density for both breasts, whenever an 
estimate was available from both sides or from the one side we had images if only one 
side was available. Test-retest reliability was 0.99 for absolute density.
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Figure 12 A) The total breast area is delineated. B) The region of interest is defined as the region 
containing densites, excluding artifacts and the pectoralis muscle. C) The computer colors areas 
within the region of interest with density above a user-set threshold. Percent area is this dense, 
colored area divided by the total breast area.  
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6.6 Exploratory data analysis 
Visualization of high dimensional data 
Visualization of microarray data in the initial phase may identify outliers and give a 
broad view of the distribution of the samples included in the study. Principle component 
analysis (PCA) is a commonly used method of reducing the dimensions of high 
dimensional data for visualization. The variation in the data is reduced to a few 
independent components that can be plotted two at a time in a graph. Singular value 
decomposition (SVD) is a general method for decomposition of a complex matrix into 
multiple, independent factors. It resembles PCA in that the data can be displayed in a 
graph representing the contribution of two separate factors at a time in explaining the 
total variation in the data. In many cases, the two methods will be identical.  
Multidimensional scaling (MDS) is a method of visualizing similarities and 
dissimilarities between objects represented as n-dimensional vectors (n>2). The vectors 
are mapped to points in a low-dimensional space IRm (where m=2 or 3) suitable for 
visualization. Points located close to each other represent vectors with a similar shape 
(egarrays with a similar gene expression pattern).
In this study, the dataset was checked for date- and batch-effect and samples with a 
questionable quality were re-run. We used MDS and SVD to look for unexpected 
clustering that could be due to technical issues. By visual inspection, these methods could 
identify a possible effect of batch, but not of other parameters (egstorage medium), 
exemplified by multidimensional scaling.  
Clustering is another way of visualizing high dimensional data. During this process, the 
samples are assigned to subgroups/clusters with a similar expression profile. In 
hierarchical clustering, the output is a hierarchy of clusters depicted in a tree. 
Hierarchical clustering (Figure 13) is an example of unsupervised learning and can be 
used for description and visualization of the variation in the data. In agglomerative 
algorithms, the dendrogram is built from the bottom up, starting with each sample as a 
separate cluster, joining those with the most similar distribution as the tree grows. In 
divisive algorithms, the whole set is treated as one cluster splitting it into clusters as the 
dendrogram builds, but these are more computationally complicated and are rarely used.  
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Figure 13 Clustering by agglomerative algorithm where the dendrogram is built from the bottom 
up.
6.7 Statistical testing 
Correcting for multiple testing 
A test for statistical significance is a hypothesis testing. The hypothesis we are testing is 
called null hypothesis and is rejected if our result is less likely to occur by chance, 
relative to a significance level we have decided. With a significance level of 5%, we say 
that if our observed outcome is less than 5% likely to occur under the null hypothesis, the 
null hypothesis is rejected. That means that there is a 5% likelihood of falsely rejecting 
the null-hypothesis for every test we perform. As we perform an increasing number of 
tests, the likelihood that one of them will be an unlikely event, even under the null-
hypothesis, is growing. To avoid a large number of false positive results, we need to 
adjust the p-value as we increase the number of tests.  
One commonly used method is the Bonferroni-correction. The nominal p-value is 
multiplied with the number of tests performed. This is a conservative method that is 
suitable if it is important to control the number of false positives and will typically result 
in a large number of false negative tests.
False discovery rate (FDR) is a less conservative method used to correct for multiple 
testing. The FDR is set to the proportion of false positives among all positives that you 
are willing to accept. Each of the tests performed returns a q-value, which indicates the 
maximal FDR at which the test becomes significant (221). This is loosely analogous to 
the p-value and is used in a similar way. FDR is used for correction of multiple testing in 
our analyses for differentially expressed genes by significance analysis of microarrays 
(SAM) and for gene ontology analyses by DAVID.
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Significance Analysis of Microarrays 
SAM identifies gene differentially expressed in two or multiple groups (two-class or 
multiclass SAM) or according to a continuous variable (quantitative SAM) (222,223). In 
SAM, each gene is tested for significant difference in expression separately. The test used 
is a modified t-test. To correct for multiple testing, SAM calculates FDR by 
permutations. In our study, two-class unpaired SAM was used for analysis of 
differentially expressed genes between two groups of data. The data were not gene 
centred for the SAM analysis. A total of 50permutations were used. Quantitative SAM 
analysis was used to identify genes differentially expressed according to MD as a 
continuous variable.
Regression models 
Regression models can be used to identify the contribution of different independent 
variables in predicting a dependent variable. Different types of regression models exist 
which all aim at explaining the variation in a dependent variable Y as a function of one or 
more independent variables (X1,…,Xp). Linear regression models are structured as 
follows: 
Y = 0 + 1X1 + 2X2 +…+ iXi +
Y is the dependent variable (eg: mammographic density). 0 is the constant that 
represents the intercept with the y-axis if the equation is plotted in a two-dimensional 
graph. i is the factor to be multiplied with the explanatory variable Xi and indicates the 
magnitude and direction of the influence of Xi on the dependent variable. Here, p is the 
number of explanatory variables included in the model and  is an error added.
Envisage is a linear model for the analysis of microarray data developed by Sam Robson, 
University of Warwick (224). The model can be used to perform variable selection but 
can also be used to check the effect of including variables other than those of interest on 
the gene expression. The model creates a regression equation for the expression (y) of 
each of n genes (gi, i=1-n). The i coefficient for each variable indicates how much that 
variable influences the expression of a gene (ygi). The number of genes whose expression 
is significantly associated with each covariate is estimated. In this study, Envisage was 
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used to look for effects of batch, experiment date, storage medium and hospital of 
inclusion in the gene expression in healthy women. In a model including experiment date, 
batch, hospital of inclusion and storage medium, experiment date seemed to be of a 
certain importance of determining the expression (16% significantly changing genes). It 
is, however a variable that is difficult to use in this model due to the large number of 
degrees of freedom. In a model excluding experiment date, batch was affecting 29% of 
the genes. The remaining variables seemed to be correlated with only a small percentage 
of the genesHospital of inclusion (7%) and storage medium (0%). When the samples are 
clustered, visual inspection does not identify an effect of these variables. We therefore 
conclude that there might be an uncorrected effect of experiment date/batch. It does not 
seem to affect the clustering. We cannot exclude a slight obfuscation of the results. 
In order to find a model that suits the distribution of the data, the Akaike information 
criterion can be used (225). Comparing the Akaike information criterion for different 
models, the lower criterion indicates the model that best predicts the dependent variable. 
In this study, we used the Akaike information criterion to select a linear regression model 
as the model fitting the distribution of the data better than a gamma model. Stepwise 
variable selection was performed, starting with all variables included in the model. For 
every step, the variable with the highest p-value was rejected from the model and the 
model was refitted. This was repeated until all variables included in the model had a p-
value <0.05.
Other tests for statistical significance 
To test whether the mean of a parameter is different in two groups, a t-test can be used. 
This test is suitable for continuous variables and for tests between two groups only, and 
assumes normal distribution within each subgroup. The null hypothesis is that the mean is 
equal for the two groups. Two-sided t-test accounts for the possibility of either group 
having largest mean. We have used two-sided t-tests to test different continuous variables 
(MD, age, BMI) for difference in mean between two clusters. When there are more than 
two means to be compared (more than two groups/clusters) analysis of variance 
(ANOVA) was applied. To test for difference between groups/clusters in categorical 
variables (use of hormone therapy, parity and claudin-low status), the chi-squared ((2) 
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test was used. When the size of observations for eat least one subcategory was smaller 
than 5, Fishers exact test was applied (226).
6.8 Bioinformatic Analyses 
Gene ontology and KEGG pathway 
Gene ontology analysis gives information about biological processes, molecular 
pathways and cellular compartments overrepresented in a given gene list. The KEGG 
pathway database has curated lists of genes involved in different pathways. The 
bioinformatic tool, DAVID Bioinformatics Resources 2008 from the National Institute of 
Allergy and Infectious Diseases, NIH (227) returns information about gene ontology-
terms and KEGG-pathways enriched in the gene list uploaded compared with a general 
human background. In papers II and III, gene ontology-analysis was performed by the 
use of DAVID. Functional annotation clustering was applied and the following gene 
ontology categories were selected: Biological processes (all), molecular function (all) and 
the KEGG pathway database. We included gene ontology terms with a p-value (FDR-
corrected) of <0.01 containing between 5 and 50genes. 
UCSC browser 
The UCSC browser (228) allows you to browse the genome and zoom in on areas of 
interest. For all locations in the genome, information about genes, expressed sequence 
tags (ESTs), microRNA, SNPs and several other trackd can be viewed. In this study, the 
UCSC browser was used to map the different UGT-probes to the genome and to blast (by 
use of the BLAT-tool) the probe sequences to verify the homology to the gene the probe 
was expected to represent.
Gene set enrichment analysis (GSEA) 
GSEA is used to test if gene sets (curated or entered by user) are significantly different in 
two different sets of samples, usually determined by a phenotype of interest (229). The 
software provided by the Broad Institute (230) rank each gene in the gene set according 
to the enrichment these genes in each sample set. GSEA was used with user-defined gene 
sets in paper I. 
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7. Brief summary of results
Paper I 
Gene expression profiles of breast biopsies from healthy women identify a 
group with claudin-low features 
Studies of the normal breast are essential to understand the normal breast biology and to 
identify biological mechanisms underlying breast cancer risk and initiation. In this paper, 
we wanted to explore the biology in normal breasts, as representative as possible of the 
women we meet in a diagnostic setting. The aim was to look for variation and to identify 
differences in biology that can be used to generate hypotheses about biological risk 
factors and initiation of breast cancer. Unsupervised hierarchical clustering of whole 
genome expression microarrays from normal breast tissue from 79 healthy women 
identified a group of twelve samples that consistently clustered tightly together (cluster 
1). The standard epidemiologic data (age, BMI, hormone therapy use) or mammographic 
density could not explain the difference between these clusters. We did, however, note 
that none of these twelve samples were referred from the mammographic screening 
programme, but rather from a doctor due to clinical findings or family history (as 
opposed to 42% from mammographic screening for the remaining samples). Exploration 
of the biology of the gene expression in the cluster 1 samples showed that the expression 
profile resembled that of breast stroma and stem-like cells and shared features with the 
newly diagnosed claudin-low breast cancer subtype with up-regulation of mesenhcymal 
genes, down-regulation of cytokeratins and claudins. Biological mechanisms of breast 
cancer risk and initiation related to these features should be studied in the future. With 
longer follow-up, we will get true information about breast cancer risk in women 
belonging to these two clusters.
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Paper II
Expression levels of uridine 5-diphosphoglucuronosyltransferase genes in 
breast tissue from healthy women are associated with mammographic 
density 
 
In paper II we identified genes associated with mammographic density in breasts of 
healthy women. Of 24 genes significantly down-regulated in samples with high MD, 
three were in the UGT-familiy, coding for enzymes inactivating estradiol by 
glucuronidation. This down-regulation was seen in women under estrogen-influence; 
younger women and women on hormone therapy. The UGT-expression in tumor samples 
resembled the expression in samples from breasts with high mammographic density more 
than the expression seen in samples from low-dense breasts. ESR1 was also down-
regulated, which may be due to a higher level of estradiol in the breasts with high 
mammographic density. The hypothesis generated from this study is that a down-
regulation of UGT-expression in breasts under estrogen influence increases 
mammographic density and may also be linked to increased risk for breast cancer. This 
should be verified in future studies.
Paper III 
Serum estradiol levels associated with specific gene expression patterns in 
normal breast tissue and in breast carcinomas 
In paper III we identified genes associated with serum estradiol in normal breast tissue 
from healthy women and in breast carcinomas. In normal breast tissue, three new genes 
were differentially expressed according to circulating estradiol (used as a continuous 
variable) were identified. SCGB3A1 (HIN1) and TLN2 were up-regulated and PTGS1
(COX1) down-regulated in samples from women with high estradiol levels. SCGB3A1 is 
a tumor suppressor, TLN2 increases cell adhesion which may prevent migration and 
invasion and PTGS1 is associated with carcinogenesis. In samples from women with high 
serum estradiol, the high expression of SCGB3A1 and TLN2 alsong with the low 
expression of PTGS1 indicates control of cellular growth, proliferation and migration. In 
tumor tissue, SCGB3A1 and TLN2 are down-regulated and PTGS1 is up-regulated, 
indicating an increased proliferation and migration.  
48
In breast carcionomas, AREG and GREB1 were significantly up-regulated in samples 
with higher levels of serum estradiol in quantitative SAM analysis. These genes have 
previously been found estradiol-responsive in malignant(231) and normal(232) breast 
tissue. The findings are discussed in relation to previous studies on serum estradiol levels 
and breast biology.
Paper IV 
Identification of SNP markers with putative influence on mammographic 
density and breast cancer risk 
In paper IV, we identified SNPs associated with MD and their association with gene 
expression and serum estradiol levels. Twenty-eight unique SNPs were found associated 
with MD in two separate datasets used (p<0.1). One of the 28 SNPs, residing in 
HSD3D1, has previously been found associated with MD (233). Of the 28 SNPs 
associated with MD at p<0.01, ten were significant at a standard significance level 
(p0.05). These ten SNPs were residing in EPOR, UGT2B28, SLC7A5, TBP, PTGER3, 
SULT2A1 and UGT2B15 and have not previously been identified. Seven of these ten 
SNPs associated with MD were correlated with the expression of genes in cis of the SNP. 
Among the genes whose expression was associated with these ten SNPs were H2AFJ,
one of the genes found associated with MD in paper II. This gene was significant in all 
stratifications (according to hormone therapy use) in the current study.  
Of the 28 SNPs associated with MD at p<0.01, two SNPs, residing in CDK2 and 
CYP17A1, were significantly associated with serum estradiol leves (p0.05). The SNP in 
CDK2 was also correlated with the expression of two genes (SCAMP1 and RPS26) which 
were in themselves associated with serum estradiol levels.   
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8. Discussion 
8.1 Sample collection and methodological considerations 
“Finding the question is often more important than finding the answer” Tukey, 1980
Study design 
Most normal breast tissue biopsies for research purposes are currently taken from 
histologically normal tissue adjacent to tumor in breast cancer patients or from reduction 
mammoplasties. Tumor adjacent normal tissue may be influenced by the presence of a 
tumor in the same organ (234), and mammoplasty reductions tend to be very adipose-rich 
and may therefore have different expression profiles from the population at risk. In some 
cases, the source of the normal tissue may bias the results. This present study is a 
prospective study of normal breast tissue from healthy women. The unique aspect of the 
study is that the tissue analyzed is from tru-cut biopsies from healthy women who are not 
subject to any surgery. They are not breast cancer patients with the cancerous effect on 
the normal tissue and they are not mammoplasty reductions with a possible bias towards 
an adipose-related biology. That does not, however, mean that there is no bias in our 
normal samples. These biopsies are taken from women who are referred to a breast 
diagnostic centre for examination either due to uncertainties in the screening 
mammogram or due to a clinical finding/risk. This population is likely to have a higher 
risk of developing breast cancer than the average women in the total population. Hence, 
the selection of healthy women in this study is biased compared with women in the total 
population. Our sample set is, however, representative of the population the radiologists 
meet in the diagnostic setting in a breast diagnostic center. 
In the future, representative breast tissue from healthy women may be more easily 
available. The US National Cancer Institute is now launching a program to collect breast 
tissue from all stages of breast cancer development, as well as healthy breasts (235).
Another issue is the problem of obtaining a biopsy representative of the breast it is taken 
from. It is not known how homogenous gene expression is within one breast, and 
therefore we are currently unable to determine how representative one single biopsy 
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would be. Further, obtaining a tru-cut biopsy is an invasive procedure and would not be 
suitable for screening purposes. It could, however, be useful for high-risk groups of 
women. Most importantly, we lack knowledge of the biology in high-risk breasts and 
how to identify the earliest stages of breast carcinogenesis. In this study, the radiologists 
were instructed to take a biopsy from an area of the breast with some density to avoid 
purely fatty biopsies. This lead to a bias toward inclusion of women with high MD. This 
is reflected in the fact that, in this study, the mean MD is higher in the healthy women 
compared with the breast cancer patients. Therefore, direct comparison of the biology 
underlying MD in the two populations included in the study is not possible.
The women answered questions about parity, height, weight, hormone use and family 
history of breast cancer. Menopausal status was determined based on serum hormone 
levels. Women with uncertain biochemical menopausal status were left out from the 
stratified analyses.
Histopathology of biopsies 
The biopsies in this study were taken with a 14 Gauge needle, which allows for large 
amount of high-quality RNA from tumors, but more limited amounts from normal tissue 
where the cellular density is lower. Two specific options of histopathologic evaluation of 
the biopsies from normal breasts were discussed within the project group. 
Immunohistochemical analysis of the biopsy would require almost the whole biopsy to be 
cast in paraffin and we would not be able to extract RNA and DNA for the microarray 
experiments. Imprint was not in routine use in the hospitals and would have made the 
inclusion procedure more of a burden to the personnel. In addition, the intact adhesion of 
normal epithelial and stromal cells prevents the cells of normal tissues to shed off the 
biopsy to the glass slide. Test imprints showed mostly adipose tissue, a couple of stromal 
cells and no epithelial cells; even if the macroscopic evaluation was that the biopsy was 
not dominated by adipose tissue. Knowledge about the cellular content of the biopsies 
would have improved our understanding of the biology greatly, but was, unfortunately 
not possible to obtain. A third biopsy for histologic examination was refused for ethical 
reasons. The inclusion was surprisingly smooth and at a later stage, both the health 
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personnel involved and the ethical committees agreed that we could sample a third biopsy 
which is now done for our follow-up study.
Whole genome expression profiling 
Gene expression is the process in which a gene is transcribed to RNA which subsequently 
serves as a template for protein production. The pattern of gene expression reflects the 
biological activity in the cells. We measured gene expression using Agilents 44K whole 
genome arrays.  
The mean RNA amount extracted from normal biopsies was considerably lower than that 
extracted from tumor biopsies. Correspondingly, more normal samples (n=39) than tumor 
samples (n=1) were excluded due to low RNA or poor RNA quality. Of the arrays 
hybridized, three were excluded due to bad technical quality, one tumor sample and two 
normal samples. The MD of the women whose breast biopsies resulted in successful gene 
expression profiling (n=79) was significantly higher than the MD of women whose breast 
biopsies did not yield enough high quality RNA to obtain profiling (n=42) (p=0.02, mean 
MD=37 versus 29). Low density breasts with higher adipose component are likely to 
yield less mRNA and this has contributed a certain bias. Both the inclusion criteria and 
the biological study methods selected for samples with some epithelial and stromal 
content. The observation that the healthy women had higher MD than the breast cancer 
patients was true for the samples with successful gene expression profiling, and for the 
whole cohort of women included and was therefore not only due to technical issues.
Gene expression from small amounts of RNA warrants amplification before 
hybridization. The amplification step introduces an extra source of error to the 
experiment. King and colleagues(236) tested the reliability and reproducibility of gene 
expression experiments using small and larger tissue samples. They found a high 
correlation between replicates and between small samples (with amplified RNA) and 
moderate between small and larger tissue samples. They concluded that the biological 
variability exceeded the technical variability in the gene expression studies (236). They 
used microdissected epithelial tissue and Affymetrix arrays, but there is no reason to 
believe that technical reliability and reproducibility should be less using whole tissue and 
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Agilent arrays. Biological variation between two whole tissue biopsies might off course 
be greater, due to differences in cellular content of the biopsies.  
To get a picture of the overall biology in the normal breast related to MD we decided to 
extract RNA from the whole biopsy. Our aim was to get an overall picture of the biology 
at a given point of time and the profiles obtained represent the collective contribution 
from all cells in the sample. The last decade it has become evident that the carcinogenic 
process involves not only the epithelial cells, but all its neighboring cells as well (199). 
Using the whole biopsy for extraction and lacking histopathology, we do not have 
information about the contribution to the final signature of individual cell types. This will 
be the focus of future studies.
Mammographic density 
Estimation of MD has been done in several different ways. When estimating MD in 
breast cancer patients, some studies have preferred to use the breast contralateral to the 
one with cancer for MD estimation (237,238). Estimation of MD in women with no 
malignancy has followed different reasoning. If there is a lesion in one breast that is 
diagnosed as benign, one could argue that the estimation should be made on the 
contralateral breast (analogous to the studies mentioned above) assuming that the lesion 
might influence the MD estimate. Some prefer to use the ipsilateral breast, arguing that 
the MD estimation and the biopsy should be from the same breast in order to infer about 
the biological associations. Bremnes and colleagues (239) preferred to use only the left 
breast consistently, because the women are healthy and the MD assessment should not be 
influenced by our more or less well founded suspicions. The same reasoning lies behind 
the choice of randomly choosing the breast to use for MD estimation as done in Ursin et 
al (128). Titus-Ernstoff and colleagues estimated MD from both breasts separately, and 
used the estimation with the breast with highest density (240). Another approach is to 
estimate MD for both breast and use an average of the two estimated figures. This 
approach is, perhaps, more likely to embrace the totality of the biology influencing the 
breast, although one could also argue for using the ipsilateral breast as best representation 
of the biology in the specific biopsy. A study by Vachon and colleagues concluded that 
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the risk of breast cancer was predicted equally well regardless of which side was used for 
density estimation (241).  
In the current study, we decided to use an average of the MD estimation from both 
breasts, whenever available. This was partly in order to encompass the wider aspects of 
the biology influencing the breasts and partly because we lacked information about which 
side some of the biopsies were taken from in the healthy women.  
Statistical considerations 
The gene expression dataset obtained from the microarray experiments of 79 healthy 
women contained information about 40792 probes, a too high dimension for many of the 
statistical tools used. A high number of probes included in statistical tests will also dilute 
the power of the tests due to the problem of multiple testing. Filtering of the gene list is 
therefore sensible. Using genes with no variation between samples will not help us 
understand the differences and similarities in the biology of the samples in the study. 
Therefore gene filtration based on variation (or standard deviation) was performed in 
adittion to the removal of probes with low quality (a value in less than 80% of the arrays).
Exploratory data analysis differs from confirmatory data analysis in that it generates 
rather than tests hypotheses. It is used to explore areas with little previous knowledge in 
order to get an idea about the landscape and use this as a basis for hypothesis testing. The 
concept of exploratory data analysis was introduced by John W Tukey. In 1980 he wrote 
“Finding the question is often more important than finding the answer. Exploratory data 
analysis is an attitude, a flexibility, and a reliance on display, NOT a bundle of 
techniques” (242). 
Exploratory data analysis is typically based on visualization of data. Methods of 
visualization include commonly used box plots and scatterplots and more complex 
methods such as multidimensional scaling and unsupervised hierarchical clustering. In 
paper I, the main aim was an impartial exploration of the data to get a description of the 
variation and to generate ideas for further studies in order to explore normal breast 
biology and identify mechanisms contributing to breast cancer risk in healthy women. 
The most important tool in this paper is therefore hierarchical clustering as an example of 
unsupervised learning.
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The complexity of high-dimension data is too great to grasp without reducing the number 
of factors. The identification of separate clusters effectively reduces the complexity to 
more graspable entities. In our case, study of the two sample clusters helped us point to 
parity and referral source as parameters important in explaining the larger part of the 
variation. Does this indicate that there is a difference between the clusters in breast 
cancer risk? If so, what is the mechanism by which the risk increases? The exploration 
has not given all answers, but shown us enough to enable us to make questions for further 
analyses. Some of these will be pursued in future projects (se future perspectives).  
Many tools exist for clustering and visualization of microarray data, both open source and 
commercial products. Most researchers find a handful of tools that they like and use. R is 
an open source language and platform widely used in medical research for 
bioonformatics. Most new methods are published as R-scripts within a short time. The 
two main limitations are the need to learn the programming language and the lack of 
advanced options for visualization and browsing of visual output.
During this study, we developed a tool for exploratory data analysis with the advanced 
visualization options of the commercial software MatLab (243). Special features needed 
for publication have been added to the tool as well as statistical methods of determining 
the number of sample clusters present.  
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8.2 Biological considerations 
“The important thing in science is not so much to obtain new facts as to discover new 
ways of thinking about them.” William Lawrence Bragg 
Interpretation of gene expression profiles 
Identifying gene expression profiles characteristic for subgroups of subjects is one of the 
most common ways to analyze gene expression data. There is, however, great 
inconsistency or instability in the profiles generated for the same traits in different studies 
(244). One study found several different 70-gene signatures predicting breast cancer 
survival with the same accuracy as the established signature published by vant Veer (245) 
and there is most often little overlap between the lists (246).
Part of the inconsistency may be explained by use of different platform and technology. 
In addition, the expression of many different genes is highly correlated and different 
genes may therefore represent the same process in a signature. Roepman et al showed 
how this may result in different gene lists with equally good predictive power and an 
apparent inconsistency (247). In support of this, Yu and colleagues found 
overrepresentation of the same pathways, represented by different genes, in five separate 
gene signatures (246).
Another important cause of the inconsistency of different gene lists meant to predict the 
same trait is, however, that the studies are based on too few samples (245). Ein-Dor and 
colleagues found that several thousand samples was required to establish robust gene lists 
for outcome for early breast cancers (248). Increased consistency of the signatures with 
increasing sample sizes was indeed confirmed by a group that pooled data from different 
studies and acquired a dataset of a total of 1372 samples (249). Such a pooling is feasible 
only for traits and sample populations that are extensively studied. As classification of the 
studied disease improves, the problem of not having large datasets increases. Prediction 
of risk for each subtype of breast cancer needs inclusion of a large amount of women who 
develop each subtype and this represents the main challenge in molecular prediction of 
breast cancer risk. In the near future, increased predictive power may be achieved 
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through integration of information from different levels, eg micro-RNA, protein 
expression, SNPs, metabolomics and epigenetics (244).  
Variation in normal breast tissue 
Whole genome expression profiling of normal breast tissue has previously been 
performed as a control and reference for tumor tissue. However, during the last decade, 
there has been increasing interest in the biology in normal breast tissue per se and in 
relation to breast cancer risk and initiation. One line of interest has been to characterize 
the gene expression profiles of different cells and tissues co-existing in the breast. 
Another line of interest is to study gene expression profiles in normal breast tissue in 
relation to a particular phenotypic trait, such as parity (250), the effect of radiotherapy 
(56) or MD (55,251). Paper I is pursuing a third approach to the study of normal breast 
tissue; unsupervised exploration of the variation in gene expression present in the dataset. 
This exploration revealed that distinct subgroups exist in normal breast tissue. Supervised 
analyses were included to interpret the initial results as described in the results section.  
The biology underlying mammographic density 
One study has previously looked at whole genome expression profiles related to MD 
(55). The published a gene list of 73 genes found differentially expressed between high 
and low MD. The gene ontology terms associated with the list of differentially expressed 
genes in Yang et al included tissue morphology and many of the genes were involved in 
cell-cell signaling. At the pathway level, the analyses pointed toward decreased TGF-
signaling in breasts with high density. This pathway is important in many processes, 
including tissue differentiation and apoptosis. There was no overlap between the genes 
differentially expressed according to MD in Yang et al and in paper II and TGF-pathwy
genes are not enriched in the genes differentially expressed in paper II. This is probably 
due to the difference in tissues studied; normal tissue from breast cancer patients as 
opposed to from healthy women. The relation between the biology in breasts with high 
and low MD is probably affected by the presence of a tumor. The TGF-pathway has a 
dual role in breast cancer development with a tumor suppressor function in early stages 
and a promoting role in later stages (252). The alterations in TGF-signaling in the tumor 
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may also affect the surrounding tissue. The relatively high MD in the sample population 
in paper II may have influenced the interrogation of biological processes related to MD.  
MD increases the risk both for ER+ and ER- breast cancer (133). This is different from 
many of the other risk factors (such as BMI and postmenopausal hormone therapy) which 
increase the risk of ER+ breast cancer only (253). This suggests a different mechanism 
for the increased risk of breast cancer from MD. Decreased expression of UGT-genes 
could be one such mechanism. The function of the UGT-enzymes in inactivating estrogen 
metabolites (254) suggests that it increases the risk of ER+ tumors only, but this is 
currently unknown. Our data indicate an association with risk for breast cancer in that the 
correlation between the UGT2B-probes and MD was low for samples from women who 
never had breast cancer (-0.01 - -0.36), but high for samples from women with breast 
cancer (0.3-0.95, particularly for UGT2B15/17 (0.95), UGT2B7 (0.91) and UGT2B17 
(0.82). All these cancers were histologically ER+. Further studies are needed to confirm 
the observed association between UGT-expression and MD and to explore any possible 
relation to breast cancer risk and development. 
High MD may result from a high proportion of cells (epithelial and/or stromal cells) or 
from high proportions of collagen. There may be different biological processes resulting 
in biological structures representing density on the mammogram. When percent or 
absolute density is used, these different mechanisms are not taken into account and 
information about underlying biological differences may be lost. One way of dissecting 
the problem of differing types of MD is to use qualitative assessment of the 
mammograms in addition to the quantitative measurements. The parenchymal pattern of 
mammographically dense tissue may be classified into glandular/nodular or sheetlike. 
The nodular pattern may represent a higher proportion of epithelial cells lining the ductal 
tree, whereas the sheetlike pattern may represent more collagen and possibly other non-
glandular stromal structures. The mammograms in this study have been classified 
according to parenchymal pattern by the epidemiologist, Giske Ursin. Initial analyses 
identify differential expressed genes between the two growth patterns in dense breasts. 
This will be analyzed further in the near future (see Future perspectives). Previously, a 
nodular pattern has been linked with increased risk for breast cancer (255,256). In the 
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current study, the few women who developed breast cancer after inclusion in the study 
did not have the same parenchymal patterns.  
The genetic component probably account for more than 50% of the variation in MD (145) 
(146)). Several studies have tried to identify SNPs responsible for this genetic 
component. Some groups have identified SNPs associated with MD (7,153,156,233), 
whereas others have found no association (155). A recent study reported that SNPs in the 
estradiol metabolic pathway was associated with breast cancer, indicating the importance 
of further studies of the SNPs in this pathway (171). Our study of estrogen-related SNPs 
associated with MD identified seven new SNPs associated with MD and confirmed one 
SNP previously reported. This strengthens the hypothesis that the estradiol pathway is 
important for MD as well as for BC. One major issue of studies of genetic variation is the 
vast number of SNPs existing in the human genome. Studying all these SNPs 
simultaneously would result in a low statistical power due to correction for multiple 
testing. The use of tag SNPs reduces the number of SNPs needed to obtain the biological 
information somewhat. The number of tag SNPs is, however, vast and would require very 
large study populations to achieve a reasonable statistical power. Most groups circumvent 
this problem by selecting a smaller number of SNPs to study. The SNP selection is 
frequently different for different studies resulting in a small overlap of SNPs from study 
to study. Few SNPs are therefore verified. Of 281 SNPs included in the current study, we 
found that five had been studied in relation to MD previously. Only one of these five 
(rs1047303 residing in HSD3B1) had been found significantly associated with MD. We 
reproduced the previous results in these five SNPs.
Four of the seven SNPs found significantly associated with MD in paper IV were 
associated with the expression of H2AFJ, one of the genes found significantly associated 
with MD in paper II. These associations may indicate that this gene is mediating a 
significant proportion of the genetic component of MD. Over the last years, there have 
been fewer than expected significant SNPs identified in relation to both breast cancer and 
MD. A verification of the current findings along with an expansion of the SNP-panel 
studied is warranted to get a complete picture of the biology responsible for the genetic 
component of MD. Several genome-wide association studies and large epidemiologic 
studies focusing on SNPs in relation to breast cancer have been launched and results have 
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started to be published (166,172,173). Some have information about MD (155), but most 
of these studies do, however, lack breast biopsies for gene expression analysis.
Estrogen-related regulation of breast biology 
The three genes  whose expression was found associated with serum estradiol levels in 
paper III (SCGB3A1, PTGS1 and TLN2) have all been linked to breast carcinogenesis 
itself (257) and/or mechanisms possibly important in breast carcinogenesis (258). Much 
is however unknown about their role in breast biology and breast carcinogenesis. The 
current study strengthens the need for further exploration of the role of these genes and 
suggests several studies that will be pursued in the future.
Aromatase (CYP19A1) is responsible for the final conversion of androgens to estrogens 
in mammary adiopocytes. The expression levels of the enzyme are therefore expected to 
reflect the level of local production of estradiol. PTGS1, in our study found to be down-
regulated in breast tissue from women with high serum estradiol, has been found to 
increase production of prostaglandin E2 which in turn increases the expression of 
aromatase (CYP19A1) (259) (Figure 15). We did, however, not find a correlation 
between the expression of PTGS1 and CYP19A1 in our material. Nor did we find 
CYP19A1-expression to be correlated to serum estradiol.  
Figure 15 The cyxloocygenases increase 
prostaglandin E2 activity which induces 
aromatase and its conversion of androgens 
to estrogens in adipose cells. Estradiol binds 
to nuclear ER-receptors that act as 
transcription factors. From Richards et al 
(260).
Several UGT2B-genes were found down-regulated in breasts with high MD.These 
enzymes inactivate estradiol. Samples with high expression of UGT2B10 tended to have 
low expression of CYP19A1 (-0.73 versus -0.54, p=0.09) and come from women with 
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lower levels of serum estradiol (0.19 versus 0.35, p=0.09). They do, however, have a high 
expression of ESR1 (1.95 versus 1.2, p=0.002). The UGT2B-genes do not seem to be up-
regulated as a response to high estradiol concentrations in the tissue as might be 
expected. The anticorrelation of serum estradiol and local expression of ESR1 is 
previously found in breast cancer (231), and in normal breast tissue in monkeys (36) and 
in mice (261). Does the high level of ESR1 allow increased impact of the estradiol 
present and hence reduce the estrogen production (locally and systemically) as well as the 
inactivation of the hormone? Or is the high expression of ESR1 a result of the low 
estradiol available in the breast tissue?  
There is considereable uncertainty about the regulation of the expression of these genes 
and this should be explored in future studies.
In this study, serum sex hormone levels have been studied and several estrogen-related 
enzymes have revealed significant associations with the study parameters in the various 
papers. Figure 16 gives a schematic and simpstic overview of human estrogen synthesis 
and metabolism.  
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Figure 16 Androstendione and estrogen metabolism adapted form Yoshimura et al (262) 
and KEGG. The presentation is not complete. Enzymes in blue and hormones/metabolites 
in black. Enzymes/hormones figuring in the results of the current study are marked in red.  
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9. Main conclusions and future perspectives 
Main conclusions 
This study has found that there are distinct subgroups of normal breast tissue and that one 
subgroup shares features with stromal cells, stem cells and the claudin-low breast cancer 
subtype.
We have also found that down-regulation of UGT2B-genes in breasts with high MD. 
Reduced glucuronidation of estrogen and androgen metabolites by UGT2B-genes may 
increase the stimulation of mammary cells leading to increased MD. This may be through 
a high number of epithelial or stromal cells or increased production of collagens. Seven 
SNPs associated with MD have been identified and H2AFJ has been put foreward as a 
putative gene expression mediator of some of the genetic component of MD.  
Gene expression of SCGB3A1 (HIN1) and TLN2 is up-regulated and that of PTGS1
(COX1) is down-regulated in samples from women with high levels of serum estradiol 
indicating intactregulation of growth control. This regulation is lost in breast cancers 
where the levels of the tumor suppressor SCGB3A1 are reduced and the expression of 
PTGS1-expression is increased.
Major unknown issues 
This is a small, explorative study and all results need to bee verified in other studies in 
order to draw final conclusions. The study has, however, also pointed out specific 
questions that we are unable to answer at this point in time.  
1. What are the biological subgroups of high MD and how are they differentially 
regulated? 
2. Is the association of UGT2B-genes with MD restricted to a specific biological 
mechanism of MD?  
3. Is there a difference in risk for breast cancer for women with similar MD with 
varying local expression of UGT2B-genes? 
4. Is the putative role of UGT2B-genes in breast carcinogenesis restricted to ER-
positive tumors? 
65
5. Is the cluser 1-phenotype (paper I) specific to the woman or representing traits 
present in all breasts to a certain degree? 
6. Is the cluster 1-phenotype associated with increased risk of breast cancer? 
7. Do claudin-low tumors arise from cells with a cluster 1-phenotype? 
8. What are the regulatory mechanisms responsible for the cluster 1-phenotype? 
9. What are the gene expression profiles associated with high risk for breast cancer? 
10. Are there serum markers that may identify high risk for breast cancer or early 
breast carcinogenesis? 
11. Why is SCGB3A1-expression reduced in basal-like tumors compared with other 
subtypes? Is it due to a myoepithelial cell of origin or transformation to a 
myoepithelial phenotype? 
12. Are the alterations in gene expression according to serum estradiol levels caused 
by the circulation estradiol or associated due to a confounding factor? 
13. Is there a direct regulation of local estradiol-production (measured by CYP19A1-
expression) by the circulation estradiol? 
14. What induces the increase in expression of PTGS1 seen during carcinogenesis?  
15. Is there a relation between parenchymal mammographic patterns and biological 
features such as: 
a. Expression of specific genes in the breast tissue 
b. Overall gene expression profiles (such as the cluster 1 phenotype) 
c. Serum levels of estradiol 
16. ¨How can we combine information from different levels in the cell to characterize 
normal breast tissue and identify breast cancer risk? 
17. Are the SNPs identified in paper IV also associated with breast cancer 
development? 
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Future perspectives 
Technology capable of genome-wide analyses of human cells and tissue has opened new 
possibilities for exploration of biological associations. The next few years we will see an 
integration of genome-wide information from several cellular levels to a wider extent. It 
has become evident that genomic alterations, methylation and histone acetylation at the 
DNA-level and expression of mRNA, micro-RNA, non-coding RNA and proteins are 
linked. The nature of the regulations is currently explored by many. Development of new 
biostatistical methods may enable genome-wide profiles accounting for alterations at 
several levels simultaneously.  
The main challenges of the molecular sciences today is not obtaining biological 
information, but rather to interpret the results achieved from the various laboratory 
analyses. This is primarily a biostatistical challenge, but does also challenge our 
biological understanding and ability to comprehend complex patterns.  
This study has obtained valuable biological material that allows for many future studies. 
As we have data from DNA and RNA both in breast tissue and blood, integration from 
different cellular levels would be possible in this material and would provide new 
information about the biology in normal breast tissue. Analyses of DNA methylation, 
genomic variation and gene expression in blood are already under way. Exploration of 
the biology related to different parenchymal mammographic patterns is an obvious line to 
follow in order to explore the current results. Specifically, genes differentially expressed 
in dense breasts with differing parenchymal patterns will be identified. The parenchymal 
patterns will also be explored for differences in other phenotypic traits such as 
epidemiologic data, serum hormone levels and breast cancer development.  
With increasing observation time, the number of women in our cohort of healthy women 
developing breast cancer is expected to increase. This will provide a unique opportunity 
to explore the possibility of identifying molecular risk factors and predictors.  
This study may be viewed as a pilot study generating hypotheses for future research in 
new studies. We are currently sampling new biopsies, blood samples, mammograms and 
questionnaires from a subgroup of the women included in this study. The main aims of 
this follow-up study is to see how the gene expression pattern in the breast evolve over 
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time and to find out whether the cluster 1-phenotype (paper I) is specific for each woman 
or for cellular compartments present in all breasts.
Comparison of gene expression from normal breast tissue from different parts of the 
same breast will provide knowledge about the variation in gene expression within the 
breast of each woman. This will be important in the search for local molecular profiles. 
Such profiles are primarily important in the search for good serum markers. A breast 
tissue molecular profile with high predictive power may, however, be a clinically 
alternative for high-risk women.  
Other future studies inspired by the questions raised by the current study include the 
effects of high and low exogenous estradiol administration in the gene expression and 
protein profiles of normal human cell lines and normal mouse breast tissue. The analysis 
of further serum proteins such of leptin, adiponectin, IGF1 and IGFBP3 in relation to the 
current findings is interesting and feasible in a short term perspective.  
Breast cancer risk prediction
Breast cancer risk evaluation is only used to a limited extent in Norway today. Genetic 
counseling is offered to those with known familial clustering of the disease, mainly 
families with BRCA1 and 2-mutations. MD is one of the major risk factors for breast 
cancer, but is hardly used clinically in Norway. Several risk prediction models are 
developed and are used to a limited extent in the US. The main information incorporated 
in these models is family history of breast cancer, epidemiologic parameters and some 
times MD (175,178-181,263).  
At present, mammographic screening every second year is offered to women aged 45/50-
69 in Norway. Critique of the one-size fits all approach to screening has emerged with the 
call for more individualized risk assessment. Better risk prediction could tailor the 
examinations offered to subgroups of women. The discriminatory power of the risk 
predicors existing today is, however, limited and not able to identify high- or low risk 
women with sufficient accuracy. Several alternative strategies for differentiated 
recommendations according to risk have been suggested (264,265). The idea of assessing 
an individual breast cancer risk and stratify into screening groups according to this risk is 
alluring (particularly based on these studies of MD and variation in normal breast tissue). 
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This could reduce the harm and the cost of screening in the low-risk population and could 
increase the detection of cancers in the high-risk population. However, predictive tools 
with higher discriminatory power are needed before such strategies can be applied in 
large scale.  
There are a few examples where differentiated recommendations may be considered 
based on epidemiologic evidence. Younger women more often develop more aggressive, 
rapidly growing tumors, leading to a higher risk of interval cancers and late stage cancers 
supporting annual screening (266). If the screening program is extended to include 
women below 50 years of age, yearly screening chould be considered for this group. For 
women older than 50, biennial screening seems sufficient (267). African-American 
women generally have a lower MD, but a higher risk of developing breast cancer. They 
also develop triple-negative, rapidly growing, and aggressive tumors more frequently. 
Earlier entry into the screening program and/or more frequent screening could be 
considered for this group. New diagnostic methods, such as gamma-imaging, are being 
studied and may be introduced for improved sensitivity in women with high MD (268).
Breast cancer risk prediction will probably be improved the coming years, with the 
identification of SNPs, methylation patterns and gene expression patterns in healthy 
women associated with future breast cancer development. One of the main challenges 
here is the heterogeneity of the disease combined with the difficulty of obtaining 
representative normal breast tissue.  
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Abstract
Increased understanding of the variability in normal breast biology will enable us to 
identify mechanisms of breast cancer initiation and the origin of different subtypes, and 
to better predict breast cancer risk. In this pilot study we have explored the variation in 
gene expression patterns in breast biopsies from 79 healthy women referred to breast 
diagnostic centers in Norway.
Unsupervised hierarchical clustering identified 12 samples consistently clustering tightly 
together (cluster 1) regardless of clustering algorithm and gene filtering used. Genes up-
regulated in cluster 1 samples code for proteins involved in extracellular matrix, vascular 
development, response to hormones and metabolism. Proteins involved in cell-cell 
junction and plasma membrane were over-represented in the genes down-regulated in 
cluster 1. Validation in a separate dataset consisting of histologically normal tissue from 
both breasts harboring breast cancer and from mammoplasty reductions identified a 
similar cluster with up-regulation of the same functional categories. Comparison of the 
expression profile of the cluster 1 samples with several published gene lists describing 
breast cells showed that these samples share characteristics with stromal cells and stem 
cells, and to a certain degree with mesenchymal cells and myoepithelial cells. The 
samples in cluster 1 share many features with the newly identified claudin-low breast 
cancer intrinsic subtype, which also shows characteristics of stromal and stem cells.   
Further studies are needed to fully elucidate the variation in the biology of normal 
breasts, its relation to breast cancer risk and possible link to the origin of the different 
molecular subtypes of breast cancer.  
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Introduction
Early diagnosis of breast cancer is essential for reducing both mortality and morbidity of 
the disease. Knowledge of the initial steps of breast carcinogenesis is important for 
development of early detection strategies. Breast carcinogenesis, with the transition of 
normal breast epithelial cells through hyperplasia to invasive cancer, is increasingly well 
understood (1,2), but there is uncertainty as to the exact mechanisms of tumour initiation 
and in which cells these first steps occur (3). In order to obtain a better understanding of 
breast cancer biology, breast carcinogenesis and origin of the different molecular 
subtypes of breast cancer, information about normal breast biology and its variability 
among women is essential.  
In breast carcinomas, the variability of gene expression is extensively studied. Several 
expression subtypes have been identified (4,5). These subtypes are partly believed to 
originate from different cell types of the breast, the luminal subtypes from luminal 
epithelial cells and the basal-like subtype from a myoepithelial or a possible luminal 
progenitor cell type (6). Recently, an additional subtype has been identified (7), the 
claudin-low subtype, which, based on gene its expression profile, is characterized by low 
expression of luminal markers and high expression of mesenchymal markers. This 
subtype is associated with bad prognosis and is thought to be derived from stem cells (8).  
The normal breast consists of epithelial cells, extracellular matrix with stromal cells, 
adipose tissue and breast stem cells that reside in the stem cell niche (9). The stem cell 
niche prevents the epithelial stem cells from differentiating and is defined by stroma (10).
Epithelial breast cells may be of luminal or myoepithelial type and they may undergo 
epithelial-mesenchymal transition and gain mesenchymal characteristics. Several groups 
have published lists of genes characterising these various cell-types (11-19).
Whole genome expression profiling of normal breast tissue (all cell types included) from 
women with no malignant disease has been performed to a limited extent in studies with 
other aims and with few samples included (5,20-22). In this study we explore the 
expression profiles of normal breast tissue from a series of healthy women in order to 
characterize the variability that exists and associate that to demographic data like age, 
body mass index, hormone therapy use and parity to improve our understanding of 
normal breast biology. The expression profiles obtained mirror the combined gene 
activity of the different cell types in the biopsy, reflecting a fingerprint of the breast tissue 
of that particular woman. Analyzing normal breast tissue may identify biological 
significant subtypes of normal breast tissue from healthy women. This could be of 
importance for understanding the different expression patterns seen in the various breast 
cancer subclasses (4,5). 
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Materials and methods 
Materials 
MDG – mammographic density and genetics 
The mammographic density and genetics (MDG) project was initiated to study the breast 
biology of healthy women and in particular the biological/genetic basis for 
mammographic density. Women included in the study were recruited from several 
mammographic centers in Norway between 2002 and 2007 as previously described (23). 
Most women were referred to the mammographic center after some irregular or 
questionable findings in an initial mammogram. A total of 120 women who were 
evaluated as cancer-free from routine diagnostic procedures were included in the study. 
Women with some visible areas of mammographic density were included in order to 
obtain biopsies from these areas with epithelial and stromal components. If there was a 
suspicious lesion in one breast, the study biopsy was taken from the breast contralateral 
to the lesion. Women who used anticoagulants, had breast implants, were pregnant or 
breast feeding were excluded. All women signed an informed consent and answered a 
questionnaire with information about parity, family history of breast cancer and hormone 
use. Breast biopsies and blood samples were collected. The hospital research protocol 
board and the regional ethical committee (ref: S-02036) approved the study. Data from 
the questionnaires was stored in a database organized by the Office for Clinical Research 
at the Oslo University Hospital; Radiumhospitalet.  
Core biopsies were taken for RNA-extraction using a 14 gauge needle. The biopsies were 
taken from an area without pathology but with some mammographic density. Six healthy 
women included by one hospital, had the biopsy taken from a non-malignant lesion (five 
from fibroadenomas and one from a microcalcification). The biopsies from one hospital 
(77 women) were fresh frozen and stored at -80C. The remaining hospitals placed the 
biopsies directly on RNAlater (Applied Biosystems/Ambion, Austin, TX) before 
transportation and storage at -80C.
Mammographic density was estimated using the University of Southern California 
Madena assessment method (24) as previously described (23). Briefly, the total breast 
area was outlined by an operator. The area containing densities and excluding the 
pectoralis muscle and artifacts was marked and the threshold set to select the densities 
within this area. Percent density is the dense area divided by the total breast area and was 
used as a measure of mammographic density. Information about which of the included 
subjects that had developed breast cancer by April 2010 was collected from the 
Norwegian Cancer Registry.
Other datasets 
Gene expression profiles from breast biopsies of healthy women included in the MDG 
study were compared with one published and two unpublished gene expression datasets. 
The two unpublished dataset were from the AHUS hospital. The AHUS1-samples were 
histologically normal tissue collected from two different cohorts; breasts harboring breast 
cancer (hereafter called cancer normals) and mammoplasty reductions. The AHUS2-
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samples were collected from different sources selected to different proportion of fatty and 
connective tissues. Breast tissue was sampled from mammoplasty reductions, 
fibroadenomas and normal tissue from breast cancer mastectomies. In addition, 
subcutaneous fat was collected from the abdominal area. The samples were grouped into 
biopsies with high and low fraction of fat tissue based on visual inspection. In both 
AHUS datasets, RNA was extracted from whole tissue. In addition, one published dataset 
containing reduction mammoplasties and cancer normals was used (20).  
Previously published lists of genes differentially expressed between epithelial cells and 
stem-like/progenitor cells, stromal cells, myoepithelial cells or epithelial cells after 
epithelial-mesenchymal transition were used to describe our dataset. The genes from each 
publication are listed in Supplementary file 1. 
Gene expression analysis 
RNA-extraction and hybridization to microarrays were done as previously described (23). 
Briefly, RNeasy Mini Protocol (Qiagen, Valencia, CA) was used for RNA-extraction. 
Agilent Low RNA input Fluorescent Linear Amplification Kit Protocol was used for 
cDNA-synthesis, transcription and labeling of RNA with cyanine 5 (Amersham 
Biosciences, Little Chalfont, England) for the samples and cyanine 3 (Amersham 
Biosciences, Little Chalfont, England) for the Universal Human total RNA reference 
(Stratagene, La Jolla, CA). After exclusion of 38 samples due to low amount of RNA or 
poor RNA-quality, 82 samples were hybridized onto two-channel 44K Agilent Human 
Whole Genome Oligo Microarrays (G4110A) (Agilent Technologies, Santa Clara, CA). 
Three arrays were excluded due to poor quality, and 79 samples were included in further 
analyses and are available in Gene Expression Omnibus (GEO) GSE18672.  
Data processing 
An Agilent scanner (Agilent Technologies, Santa Clara, CA) was used for scanning and 
Feature Extraction 9.1.3.1 (Agilent Technologies, Santa Clara, CA) was used for data 
processing. Normalization was done by locally weighted scatterplot smoothing (lowess) 
and flagged spots were removed. The Stanford Microarray Database (SMD) 
(http://genome-www5.stanford.edu//, 8/31/2010) was used for data storage. For further 
analysis the log 2 transformed data were used. The genes were filtered so that only genes 
with 80% good data and a log2-value of more than 1.6 standard deviation away from the 
mean in three samples or more were included leaving 9767 probes. The data were gene-
centered for cluster analysis, but not for other analyses. Missing values were imputed in 
R using the method impute.knn in the library impute 
(http://rss.acs.unt.edu/Rdoc/library/impute/html/impute.knn.html, 8/31/2010). The 
AHUS1-dataset was filtered to include the probes in the filtered MDG-dataset, leaving 
8519 probes.
The data were checked for effect of handling (fresh frozen versus RNAlater) and batch 
using significance testing, Envisage 
(http://www2.warwick.ac.uk/fac/sci/moac/currentstudents/2003/sam_robson/linear_mode
ls/, 8/31/2010) and visualization by multidimensional scaling and single value 
decomposition. Samples with questionable array quality were re-run. The conclusion was 
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that a slight effect of batch and date of hybridization using uncorrected data is seen, but 
this did not affect the clustering. Fisher exact and chi-squared tests were used to analyze 
for difference between our two main clusters using batch, experiment date, storage 
medium, RNA-concentration and hospital of inclusion as variables. The results of these 
were all negative showing no effect of sample handling or collection site. Also, there was 
no correlation between sampling method/storage medium and RNA-amount or quality. 
Statistical Analysis
Clustering was performed in MatLab (version R2007b) (The MathWorks Inc., Natick, 
MA) using ward linkage and Euclidean distance measure. The gap statistic was used to 
determine the number of clusters (25). Two-sided t-tests (assuming equal variance) and 
chi-squared/Fisher’s exact tests were used to test for significance of different phenotypic 
variables between the different clusters. Significance Analysis of Microarrays (SAM) 
(version 3.02, http://www-stat.stanford.edu/~tibs/SAM/, 8/31/2010) (26) for Excel with 
500 permutations was used for analysis of differentially expressed genes. The empirical 
null distribution was estimated to ensure that the genes identified as differentially 
expressed between the two clusters were not merely the tails of a wider null distribution. 
Unsupervised hierarchical clustering was performed using the complete gene list filtered 
as described above. Supervised analyses were performed using different published gene 
lists to look for similarities with the different cell types from which the respective gene 
sets were derived.
Prediction of the claudin-low subtype was done using the claudin-low predictor 
developed in Prat et al (27). An expression dataset with 807 genes and 52 cell line 
samples (described in Neve et al, (28)), of which 9 were classified as claudin-low, was 
merged with our data using Distance Weighted Discrimination (29) with the 52-sample 
dataset used as the training data. In the same software, the single sample prediction (SSP) 
function with Euclidean distance was applied on the adjusted datasets and then used to 
define claudin-low samples in the test set. 
A similar predictor was developed for prediction of the previously identified intrinsic 
subtypes. A dataset containing both the original intrinsic subtypes and the claudin-low 
subtype (7) was merged with our data set as described above for the cell line data. The 
Herschkowitz-dataset was used as the training data. The single sample prediction was 
applied to assign expression subtypes to the samples. 
Microsoft Access 2003 was used to limit our dataset to the gene lists of interest. 
Hierarchical clustering was performed to see whether the gene list of interest separated 
the cluster 1-samples from the remaining samples in our dataset. SAM of cluster 1 versus 
cluster 2 was performed to identify genes from the published gene list that were 
differentially expressed between cluster 1 and cluster 2. Tests for significance between 
the number of up- and down-regulated genes (false discovery rate (FDR)<10%) between 
the two clusters identified and the cell types in question were performed. Gene set 
enrichment analysis (GSEA) (version 2) (http://www.broadinstitute.org/gsea/, 8/31/2010) 
with 1000 permutations was used to check for significance of the gene lists in separating 
the clusters. DAVID 6.7 (http://david.abcc.ncifcrf.gov/home.jsp, 8/31/2010) was used to 
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identify gene ontology terms and KEGG pathways significantly enriched in the lists of 
genes differentially expressed between the two main clusters with an FDR<0.01 
considered significant.
Clustering combining the MDG dataset with datasets containing biopsies from normal 
tissue containing different proportions of adipose tissue was performed to see whether 
samples in cluster 1 consistently clustered with samples with a high fraction of fat tissue 
and was driven by a high number of adipocytes. 
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Results
Unsupervised hierarchical clustering 
Unsupervised hierarchical clustering of the expression of 9767 genes in the 79 breast 
biopsies separated the samples into two main groups, confirmed by the gap statistic 
(25)(Figure 1). The smaller cluster (cluster 1, far right), consisting of twelve samples, 
consistently clustered tightly together regardless of clustering method and gene filtering 
used. There was a significantly higher proportion of women referred to mammography 
due to increased risk; family history of breast cancer (4) or a palpable breast lump (5) in 
cluster 1 compared to the remaining women (cluster 2) although no malignancy was 
found in any of the women included in the study by standard diagnostic procedures. 
There was a borderline significance that more women belonging to cluster 1 were 
nulliparous, compared to cluster 2. There was no difference in age, age at first birth, 
hormone use, body mass index or percent mammographic density between women 
belonging to the two clusters (Table 1).
Differentially expressed genes 
SAM revealed 2621 genes differentially expressed between cluster 1 and cluster 2 with 
an FDR=0, of which 1516 were up-regulated in cluster 1 (Supplementary file 2).  
Genes up-regulated in cluster 1 were enriched for the gene ontology terms extracellular 
region, vascular development, response to hormone/insulin stimulus, glucose and 
triclyceride metabolism, plasma membrane, cell motion, protein dimerization, regulation 
of inflammatory response and mitochondrion. Genes down-regulated in cluster 1 were 
enriched for the terms of proteins involved in actin-binding, adherens junction, 
cytoskeleton and the plasma membrane (Supplementary file 3, Table S1). Gene ontology 
terms associated with subsets of genes in the various gene clusters (A-E) are shown in 
Figure 2. 
Supervised analyses  
In order to explore the nature of the cells in the biopsies of cluster 1, we used previously 
published gene lists describing stroma (17,18), breast stem cells (15,19,30), myoepithelial 
cells (12,14), progenitor cells (14), mesenchymal cells (13), high-risk normal cells (16), 
epithelial cells from parous women (31), intrinsic genelist (5) and a genelist for 
prediction of the claudin-low subtype (27).
Both hierarchical clustering, SAM analysis and GSEA indicated that the expression in the 
cluster 1-biopsies resembled expression in stem-like cells and stromal cells (Table 2) 
(Supplementary file 3, Table S2). There were also certain shared expression 
characteristics with progenitor cells, mesenchymal cells and myoepithelial cells. More 
detailed information about the cells used when generating the gene lists, the samples used 
and the number of genes from the respective gene lists differentially expressed in our 
clusters are listed in Supplementary file 3, Table S3. The cluster 1 samples were not 
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associated with the expression profiles of any of the original breast cancer subtypes (5). 
However, when a gene list developed to classify the newly identified claudin-low subtype 
was used (27), we found that the cluster 1 samples were highly associated with the 
claudin-low gene expression profile (Table 2). This was confirmed when we used this 
method to create a predictor for one subtype at a time. All samples in cluster 1 were 
classified as claudin-low as opposed to only three samples from cluster 2 (Figure 1) and 
the cluster 1 samples were not assigned to any of the other subtypes tested using these 
predictors. In figure 2, selected genes associated with the claudin-low subtype, stem cells, 
mesenchymal cells, stroma and epithelial cells and their expression in cluster 1 are 
shown. Hierarchical clustering based on the various gene lists is shown in Supplementary 
file 3, Figure S1. These analyses could not confirm any association of cluster 1 with 
parity (31). 
When the filtered expression dataset was clustered with three separate datasets including 
biopsies from breasts of healthy women with high and low content of fatty tissue (two 
unpublished and one published (20) dataset), the samples did not cluster according to fat-
content (Supplementary file 3, Figure S2).
Four of the women from the cohort have been registered with a breast cancer diagnosis, 
one before she was included and four had developed the disease after inclusion, all in the 
breast contralateral to the biopsy. The samples from these five women did all belong to 
cluster 2. The observation time varied from 34 to 86 months with a mean of 59.1 and a 
median of 58. All five cancers were estrogen receptor positive. Two of the breast cancers 
developed after inclusion were infiltrating lobular carcinoma, the other three cancers had 
ductal histology. 
Validation
Unsupervised hierarchical clustering of the AHUS1-dataset yielded two distinct clusters 
of samples (Figure 3). The smaller cluster (n= 18) includes 8 reduction mammoplasties, 
while the larger cluster (n=22) included 6. A total of 3102 of 8519 probes were 
differentially expressed between the two clusters using SAM. Of the 2045 genes up-
regulated in the smaller cluster with an FDR of 2%, 1057 were also up-regulated in 
cluster 1 in the MDG dataset whereas none were down-regulated. Of the 2278 genes 
down-regulated in the smaller cluster with and FDR of 2%, 962 were down-regulated in 
cluster 1 and none were up-regulated.
Gene ontology terms enriched in the genes up- regulated in the smaller AHUS1-cluster 
was very similar to those found in the cluster 1 samples, including: response to 
hormone/insulin, glucose and triglyceride metabolism, vasculature development, 
mitochondrion, membrane, protein dimerization and regulation of inflammatory 
response. In addition, the gene ontology terms vitamin B6-binding , iron ion binding and 
aerobic respiration were enriched in the genes up-regulated in the smaller cluster of 
AHUS1. The genes down-regulated in this smaller cluster were enriched for adherens 
junction, acting binding, extracellular matrix and cytoskeleton – the majority of terms 
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being in common with those down-regulated in the cluster 1 samples. The full list of gene 
ontology terms for both datasets is available in Supplementary file 3, Table S1.  
Application of the claudin-low predictor on the AHUS1-samples showed that no samples 
in the larger cluster were assigned claudin low as opposed to 14 of 15 in the smaller 
cluster.
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Discussion
Little is known about gene expression patterns in normal breasts. We have identified a 
cluster of twelve normal breast tissue samples (cluster 1) that cluster tightly together 
using different clustering algorithms and different gene lists and that share characteristics 
of stromal cells, stem cells and the claudin-low phenotype.  
The cluster 1 samples have a reduced expression of the epithelial defining keratin genes 
and have an up-regulation of several mesenchymal markers such as TWIST1, SPARC and 
VIM. This may lead to the hypothesis that the cluster 1 samples represent more immature 
or dedifferentiated epithelial cells, and/or enrichment for stromal cells. This is supported 
by our findings that the cluster 1 samples have an expression of genes that resembles 
published gene lists characterizing stromal tissue and have an overrepresentation of gene 
ontology terms associated with the extracellular matrix. Reliable and specific stem cell 
markers are still unavailable (32), but cells in the cluster 1 samples show similarities with 
stem-like or progenitor-like cells.  
The interindividual differences observed may reflect true differences between women 
with different risk or exposure histories, or may represent different normal tissue 
subtypes that are present within a single woman, at different sites in the breast, at 
different times during the lifespan or in different proportions. For example, stem cell 
niches may be oversampled in the cluster 1 biopsies. 
Stem cell niches are thought to be present in the breasts of all women, but some women 
may have more than others. The immature breasts of nulliparous women may contain 
larger volumes of stem cell niches than the post-lactationally involuted breasts. This 
could explain why there are more nulliparous women in cluster 1 than in cluster 2. 
Understanding the intra- and inter-individual variation in normal breast tissue is 
important and this investigation raises the question as to whether the clustering patterns 
observed represent only a fraction of women or if all women have cells/niches with these 
characteristics, with some women having a higher fraction than others.
The stem cell niche refers to a zone of the breast epithelium where stem and progenitor 
cells reside. The microenvironment constitutes the niche and influences the stem cells 
(33)(for review, see (34)). This would explain the combined stem-like and stromal-like 
characteristics identified in cluster 1 samples. In breast cancer, the stem cell niche may 
contain mesenchymal cells derived from the normal breast stroma or recruited from the 
bone marrow (10) and the current results raise the hypothesis that mesenchymal cells 
may be present in normal breast stem cell-niches. The link between mesenchymal and 
stem cell traits is also made clear by Mani and colleagues who showed that immortalized 
breast cells undergoing epithelial-mesenchymal transition acquire stem-cell like 
characteristics and that normal mouse mammary stem cells express mesenchymal 
markers(35).  
This study is not designed to predict risk of developing breast cancer. However, when we 
apply the Chen risk predictor (16), the cluster 1 samples tend to have a slightly decreased 
risk. There is no difference in mammographic density, one of the strongest risk factors for 
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breast cancer, between the two clusters (Table 1). The malignancy risk predictor is 
dominated by proliferative genes. The fact that the cluster 1 samples are associated with a 
low malignancy risk profile may be a reflection of the low expression of proliferative 
genes. Low proliferation rate is also seen in stem cells. Looking at the referral source, 
women in cluster 1 are mainly referred to the mammographic centers due to palpable 
breast lumps or positive family history and not from the screening program. There were, 
however, no breast cancers in cluster 1 as opposed to one previous and four developed 
breast cancers in cluster 2. This is not statistically significant, and we cannot conclude 
about the breast cancer risk in women belonging to these two clusters. It is, however, 
worth noting that all the cancers did arise in the breast contralateral to the biopsy. That 
may be explained by the fact that, if there was a lesion present in one of the breasts at the 
mammogram, the biopsies were taken from the breast contralateral to the lesion. All the 
breast cancers were estrogen receptor positive. Since the cluster 1 samples have a stem-
like gene expression profile and have certain myoepithelial/basal characteristics, one may 
speculate that these women, if they develop breast cancer, will have a greater proportion 
of estrogen receptor negative cancers. 
All the 12 samples in cluster 1 were classified as claudin-low, compared to only three of 
the remaining 67 samples. Similarly in the validation dataset, the claudin-low samples 
were exclusively in the smaller cluster. The claudin-low subtype is developed for 
classification of breast cancers and was not thought to be a group of normal breast 
samples. The claudin-low nature of the cluster 1 samples is, however, striking. Down-
regulation of E-cadherin, occludin, claudin 3, 4, 7 as well as up-regulation of the 
mesenchymal genes and SNAI2 is in line with the features described in claudin-low 
tumor samples. The low expression of ESR1 corresponds with the estrogen receptor 
negative trend of the claudin-low subtype (7). The claudin-low tumours are thought to 
arise from mammary stem cells (8). The hypothesis that the cluster 1-samples are 
enriched for immature cells is further supported by the down-regulation of GATA3 seen 
in these samples compared to the cluster 2 samples (p=3.8E-9), a protein that is also 
down-regulated in claudin-low samples (27).  
The biopsies used in this study are unique in that they represent the group of women that 
are examined at breast diagnostic centers. Since the sample size is small, the use of 
additional datasets may indicate if the current results represent a larger population. The 
AHUS1 dataset consists of two main types of samples; mammoplasty reductions and 
cancer normals. Mammoplasty reductions are widely used as representing normal breast 
tissue, although one can expect the biology to be slightly biased toward fat-related 
processes. Cancer normals may be influenced by the biology in the tumor (36) or they 
may represent normal tissue in high-risk breasts (37). A dataset consisting of these two 
tissue-types, therefore represent a variety of normal tissue, despite its’ obvious 
shortcomings. The fact that the AHUS1 dataset clusters into two clusters with biology 
similar to those seen in the MDG dataset is interesting and indicates that these results 
may be reproducible in similar populations.  
The reduced expression of epithelial surface makers may be explained by a large 
component of adipocytes in the biopsies. This is, however, unlikely, as the biopsies were 
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taken from mammographic dense areas. In addition, when this dataset was clustered with 
other datasets containing biopsies from normal breast tissue with varying proportions of 
fatty tissue, the cluster 1 samples do not segregate with the adipocyte-rich biopsies 
(Supplementary file 3, Figure S2). 
There was a greater proportion of nulliparous women in cluster 1. The association 
between cluster and parity was, however, not confirmed using a gene list describing post-
pregnant epithelial cells (31)(Table 2 and Supplementary file 3, Table S2 and Figure S1). 
The breasts of nulliparous breasts are not fully matured and the fraction of differentiated 
epithelial cells is lower than in post-pregnant breasts. The genelist published by Asztalos 
et al is short and may not capture all parity-related gene expression alterations. The 
cluster 1 samples may represent more immature breasts with increased number of type 1 
lobules, but this study does not give enough power to conclude, and the association 
between the cluster 1 type gene expression profile and parity needs to be elucidated 
further.
The difference between cluster 1 samples and the remaining normal samples could be due 
to difference in fractions of the cell types present in the biopsies. For ethical reasons, the 
number of biopsies pr woman was limited and we did not have enough tissue to do both 
RNA-extraction and get histology. The lack of histology of the biopsies prior to 
extraction prevents exact knowledge of the cell types contributing to the expression 
profiles. It has become evident that the development and progression of breast cancers are 
not limited to epithelial cells and that the total microenvironment is important. 
Approximately 95% of normal breast tissue may be composed of stroma, and therefore 
cell type differences in stroma are most likely captured rather than subtle differences in 
epithelial content. For evaluation of the putative interplay between all the cells at this 
location of the breast, expression analysis of the entire biopsy provides the most realistic 
picture of the situation. Previous studies have shown that different biopsies from whole 
one tumor share similar gene expression profile (4). The variability of gene expression 
from different locations of one breast is not known, but King and colleagues have shown 
that microdissected and bulk tissue samples from normal breasts have a high similarity in 
gene expression and that such technical differences are minor compared with biological 
differences (38).
This study is limited by the relatively low number of women included. Larger datasets 
with several biopsies representing different parts of the breast will be needed to allow 
further elaboration of the variation in the normal biology of the breast.  
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Conclusion
Gene expression analyses of biopsies from breasts of healthy women show two main 
groups of expression patterns. The samples of the smaller group of biopsies cluster tightly 
together independent of clustering algorithm and gene filtering used. These samples share 
characteristics with stromal cells and stem cells and are all classified as claudin-low. 
These findings are validated in a separate dataset of normal breast tissue. Whether these 
characteristics represent traits of the woman or cell niches present in all breasts is 
unknown. This cluster may represent the stem cell niche, defined by stromal tissue and 
containing stem-like cells. There are more nulliparous women in this cluster. The 
described signature may be a feature more prominent of the immature breasts of 
nulliparous women. We cannot conclude about breast cancer risk between the two 
clusters, although we see an overrepresentation of women a positive family history of 
breast cancer or a palpable breast lump in the smaller cluster. Further studies are needed 
to verify the hypotheses generated by this pilot study.
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Table 1 Women included in the study, descriptive statistics 
all non-cancer 
(%) cluster 1 (%) cluster 2 (%) 
p-value
(cluster 1 vs 2) 
Age mean 50.2 49.3 50.4 0.52 *)
<50 31 (39) 5 (42) 26 (39) 
50-69 45 (57) 7 (58) 38 (57) 
missing 3 (4) 0 (0) 3 (4) 
Parity 0 10 (13) 4 (33) 6 (9) 0.05 †)
1+ 65 (82) 8 (67) 57 (85) 
missing 4 (5) 0 (0) 4 (6) 
Age at first mean 24.4 24 24.4 0.21 *) 
birth no children  10 (13) 4 (33) 6 (9) 
<25 30 (38) 4 (33) 26 (39) 
25+ 26 (33) 3 (25) 23 (34) 
missing 13 (16) 1 (8) 12 (18) 
Hormone never 55 (70) 8 (67) 47 (70) 0.62 †)
therapy current 11 (14) 2 (17) 9 (13) 
use past 6 (8) 0 (0) 6 (9) 
missing 7 (9) 2 (17) 5 (7) 
Body mean 24 23 24 0.24 *)
mass <20 5 (6) 2 (17) 3 (4) 
index 20-<25 44 (56) 6 (50) 38 (57) 
25-<30 21 (27) 4 (33) 17 (25) 
30+ 6 (8) 0 (0) 6 (9) 
missing 3 (4) 0 (0) 3 (4) 
Mammographic mean 37 40 37 0.62 *) 
density 0-<23 19 (24) 2 (17) 17 (25) 
23-<37 21 (27) 4 (33) 17 (25) 
37-<52 19 ((24) 3 (25) 16 (24) 
52+ 17 (22) 3 (25) 14 (21) 
missing 3 (4)  0 (0) 3 (4) 
Serum mean 0.27 0.30 0.27 0.81*)
estradiol 0-<0.1 27 (34) 3 (25) 24 (36) 
0.1-<0.2 20 (25) 4 (33) 16 (24) 
0.2+ 31 (39) 5 (42) 26 (39) 
missing 1 (1) 0 1 (1) 
Referral risk/lump 32 (41) 9(75) 23 (33) 0.002 †) 
source screening 28 (36) 0 (0) 28 (42) 
unknown 19 (24) 3 (25) 16 (24) 
*) Two-sided t-test for continuous variables
†) Fisher exact test for categorical variables with <5 observations in certain cells
Table 2 Comparison of cluster 1 and cell types/subtypes from published gene lists. Chi-
squared test is used to illustrate the extent to which genes describing different cell types 
are equally regulated in the two clusters. Significant p-values are in bold type. For more 
information on the publications and comparisons, see Supplemental file 1, Table S3.  
Comparison Reference Cluster 1 resembles p-value
Epithelial vs stem-like cell Shipitsin, 2007 Stem-like cell 2.20E-16 
Stroma vs epithelium Finak, 2006 Stroma 2.20E-16 
Mesenchymal vs epithelial Jechlinger, 2003 Mesen-chymal 6.90E-14 
Revised subtypes Herschkowitz, 2007 Claudin-low 1.52E-12 
Fibroblasts vs epithelial cells Casey, 2008 Fibroblasts 1.9E-12
Risk predictor Chen, 2009 Low risk 1.30E-09 
Stem-like cell vs epithelial Liu, 2007 Stem-like 1.30E-05 
Myoepithelial vs progenitor Raouf, 2008 Progenitor 2.40E-05 
Luminal vs progenitor Raouf, 2008 Progenitor 0.001
Stem-like vs progenitor cells Villadsen, 2007 Lineage restricted progenitor  0.008
Myoepithelial vs luminal Jones, 2004 (Myepithelial) 0.06
Classical subtypes Sorlie, 2001 -  0.76 
*) Chi squared test for significance
Figure 1: Unsupervised hierarchical clustering of 79 samples from healthy individuals 
and 9767 genes filtered on variation. Phenotypes with tests for significant difference in 
values between cluster 1 (blue) and cluster 2 (red). Continuous variables are categorized 
for the illustration, but significance tested as continuous variables. P-values from two-
sided t-tests assuming equal variance for continuous variables (*) and chi-squared tests 
(†) for categorical variables are given. The numbers along the y-axis denotes the number 
of genes. Age= Age at time of inclusion. BMI: Body mass index. HT: Use of hormone 
therapy. MD: Mammographic density. 
Figure 2: Selected genes from gene clusters up- and down-regulated in cluster 1. Gene 
functions/ontology terms associated with the respective gene clusters are given. In cluster 
1 there is an up-regulation of mesenchymal genes and stem-cell related genes (A, C and 
D) and down-regulation of epithelial markers and claudins (B and E).
Figure 3: Unsupervised hierarchical clustering of 40 samples from the validation dataset 
AHUS1. Reduction mammoplasties and cancer normal samples are split between one 
larger and one smaller cluster, the smaller cluster containing slightly more mammoplasty 
reductions.
Supplementary material 
Table S1 Gene ontology termes enriched in the genes differentially expressed between 
the two main samples in the MDG dataset (cluster 1 and 2 in Figure 1) and the AHUS1 
dataset (small and large cluster in Figure 2) 
Cluster 1 AHUS1 small cluster  
up extracellular regioin mitochondrion 
vascular development response to hormone/insulin 
signal peptide glucose metabolism 
regulation of lipid metabolism vasculature development 
response to hormone/insulin vitamin B6-binding 
glucose metabolic process regulation of lipid metabolism 
triglyceride metabolism carboxylic acid biosynthesis 
membrane organization triglyceride metabolism 
protein dimerization aerobic respiration 
regulation of inflammatory response regulation of lipid storage 
cell motion membrane 
organic acid biosynthesis protein dimerization 
regulation of catabolic process iron ion binding 
oxygen and reactive oxygen species regulation of inflammatory response 
mitochondrion 
down actin binding adherens junction 
adherens junction actin binding 
cell-cell junction extracellular matrix 
cytoskeleton cytoskeleton 
plasma membrane cell-cell junction 
Table S2 Gene set enrichment analysis (GSEA) of cluster 1 versus cluster 2 using 
selected gene lists from the literature. Significant FDR-values are marked red.  
Genelist FDR Cluster1
STROMA(FINAK) 0.00 Up
STROMA(CASEY) 0.02 Up
CD44+(SHIPITSIN) 0.01 Up
BIPOLAR(VSLUM)(RAOUF) 0.10 Up
BIPOTENT(VSMYO)(RAOUF) 0.08 Up
MYOEPITHELIAL(JONES) 0.13 Up
IGS/CD44+(LIU) 0.20 Up
EPITHIAL(FINAK) 0.00 Down
CD24+(VSCD44)(SHIPITSIN) 0.03 Down
IGS/CD10(LIU) 0.07 Down
RISK(CHEN) 0.24 Down
LUMINAL(JONES) 0.48 Down
EPITHIAL(JECHLINGER) 0.70 Down
MESENCHYMAL(JECHLINGER) 0.66 Down
Table S3 Comparison of cluster 1 and cell types/subtypes from published gene lists.  
The number of genes up- and down-regulated is given for genes characterizing each cell type 
and each cluster. Chi-squared test is used to illustrate the extent to which genes describing 
different cell types are equally regulated in the two clusters. The right column shows samples 
correctly identified by hierarchical clustering of the normal breast samples based on the gene 
list from the corresponding publication (see Supplemental file 1, Figure S2)  
Samplescorrectly
identifiedbyclustering
Publication Celltype Method
upin
cluster1
downin
cluster1
cluster1
resembles Cluster1 Cluster2
Shipitsin, Epithelial CD24+ 132 152 12/12 66/67
2007 Stemcelllike CD44+ 394 89
CD44+

 Unchanged  0 106  
 Sum  526 347  
 	
 pvalue 2.2E16   
Jechlinger, Mesenchymal 61 17 11/12 67/67
2003 Epithelial 38 32 
 Unchanged
Beforeand
after
TGFbeta
induced
EMT 0 36
Mesen
chymal


 Sum  99 85  
 	
 pvalue 6.9E14   
Samplescorrectly
identifiedbyclustering
Table S3 cont 
PublicationCelltype Method
upin
cluster1
downin
cluster1
cluster1
resembles Cluster1 Cluster2
Raouf,
2008 Luminal
CD49flow/
MUC1high/
CD10low 521 442
Progenitor
12/12 67/67

Bipotent
progenitor
CD49fhigh/
MUC1low/
CD10high 259 162


 Unchanged  343 338  
 Sum  1123 942  
 	
 pvalue 0.001   
Raouf,
2008 Myoepithelial
CD49flow/
MUC1low/
CD10high 139 88
Progenitor
12/12 67/67

Bipotent
progenitor
CD49fhigh/
MUC1low/
CD10high 232 128


 Unchanged  156 171   
 Sum  527 387   
 	
 pvalue 2.40E05   
Liu, Stemcelllike CD44+ 50 17 Stemlike 11/12 67/67
2007 Epithelial CD10+ 34 58 Invasive  
 Unchanged  36 27 cells  
 Sum  120 102   
 	
 pvalue 1.30E05    
Jones, Myoepithelial MUC1+ 65 91  12/12 66/67
2004 Luminal CD10+ 21 47  
 Unchanged  30 28  
 Sum  116 166  
 	
 pvalue 0.06   
Chen,2009 IDClikenormal 11 81 Lowrisk 11/12 62/67
 Othernormalc
Basedon
gene
expression 17 4


 Unchanged  0 0  
 Sum  28 85  
 	
 pvalue 1.3E09   
Finak, Stroma 457 91 12/12 67/67
2006 Epithelial
Micro
dissection 51 317
Stroma

 Unchanged  59 92  
 Sum  567 500  
 	
 pvalue 2.2E16   
Samplescorrectly
identifiedbyclustering
Table S3 cont 
PublicationCelltype Method
upin
cluster1
downin
cluster1
cluster1
resembles Cluster1 Cluster2
Casey, Fibroblasts 330 140 11/12 64/67
2008 Epithelial
Micro
dissection 119 134
Fibroblasts

 Unchanged  224 228  
 Sum  673 502  
 	
 pvalue 1.9E12  
Villadsen, Stemlike K19+/K14+ 71 104 7/12 29/67
2007 K19+/K14 46 30 
 K19/K14+ 4 5 

Lineage
restricted
progenitors K19/K14 48 81 
 Unchanged  0 0
Lineage
restricted
progenitor
K19+/K14
 
 Sum  169 220   
 	
 pvalue 0.008    
Asztalos, nullipara Micro 8 2 Post  
2010 postpregnant dissection 5 4 pregnant  
 Unchanged  0 0   
 Fisher  0.34   
Sorlie, Basallike 62 66  12/12 67/67
2001 HER2enriched 72 69   
 LuminalA
Basedon
gene
expression 73 80   
 LuminalB  70 60   
 Normallike  80 91   
 Unchanged  0 0   
 Sum  357 366   
 	
 pvalue 0.76   
Basallike 56 79 claudinlow 12/12 67/67
Claudinlow 121 33   
Hersch
kowitz,
2007 HER2enriched 76 98   
 Luminal
Basedon
gene
expression 70 95   
 Normallike  76 67   
 Unchanged  163 116   
 Sum  562 488   
 	
 pvalue 1.52E12   
Chen et al, 2008
IDC-like normal cells vs
other normal cells
Shiptisin et al, 2007
Luminal (CD24+) vs 
stem-cell like (CD44+) cells
Jechlinger et al, 2003
Epithelial cells before and after 
TGFbeta-induced EMT
Raouf et al, 2008
Luminal (MUC1+ vs 
bipotent (CD49f+, CD10+) cells
Raouf et al, 2008
Myoepithelial (CD10+) vs 
bipotent (CD49+, CD10) cells
Liu et al, 2007
Stem-cell like (CD44+) vs 
luminal (CD10+) cells
Jones et al, 2004
myoepithelial (MUC1+) vs 
luminal (CD10+) cells
Figure S1
Finak et al, 2006
Stroma vs epithelial cells
Villadsen et al, 2007
stem-cell like vs lineage
restricted progenitor cells
Sorlie et al, 2001
Intrinsic genes
Prat et al, submitted
Claudin-low genelist
Hierarchical clustering of gene expression from 79 samples from breasts of healthy women. The samples are clustered based on gene
lists from the literature, describing different cell types.  The two last panels are clusterd based on gene lists used to identify breast 
cancer subtypes. Cluster 1-samples are marked light blue and cluster 2-samples dark blue. The dendrogram colors represent the two 
main clusters in the clustering performed based on the gene list in question.  
Asztalos et al, 2010
Nulliparous vs postpregnant women
Breast biopsies
MDG cluster 1 
MDG cluster 2 
AHUS1 mammoplasty reductions 
AHUS1 tumor adjacent 
A
C
MDG cluster 1 
MDG cluster 2 
Nicolau mammoplasty reductions 
Nicolau tumor adjacent 
MDG cluster 1 
MDG cluster 2 
AHUS2 high fraction of fat 
AHUS2 low fraction of fat 
B
Figure S2 Biopsies from healthy women (MDG) clustered with two unpublished datasets 
from the hospital AHUS A) AHUS1 with breast biopsies from mammoplasty reductions 
(yellow) and tumor adjacent (red) tissue and B) AHUS2 with breast biopsies containing 
different known proportions of fat tissue and C) a dataset previously published by 
Nicoalu et al(1) with breast biopsies from mammoplasty reductions (yellow) and tumor 
adjacent (red) breast tissue. In all cases, the two datasets are merged by use of Distance 
Weighted Discrimination (DWD). This resulted in datasets with A) 8520 genes, B) 10078 
and C) 3555 genes. Hierarchical clustering with Eucledian distance and Ward linkage 
was performed as described.
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Abstract
Introduction: Mammographic density (MD), as assessed from film screen mammograms, is determined by the
relative content of adipose, connective and epithelial tissue in the female breast. In epidemiological studies, a high
percentage of MD confers a four to six fold risk elevation of developing breast cancer, even after adjustment for
other known breast cancer risk factors. However, the biologic correlates of density are little known.
Methods: Gene expression analysis using whole genome arrays was performed on breast biopsies from 143
women; 79 women with no malignancy (healthy women) and 64 newly diagnosed breast cancer patients, both
included from mammographic centres. Percent MD was determined using a previously validated, computerized
method on scanned mammograms. Significance analysis of microarrays (SAM) was performed to identify genes
influencing MD and a linear regression model was used to assess the independent contribution from different
variables to MD.
Results: SAM-analysis identified 24 genes differentially expressed between samples from breasts with high and low
MD. These genes included three uridine 5′-diphospho-glucuronosyltransferase (UGT) genes and the oestrogen
receptor gene (ESR1). These genes were down-regulated in samples with high MD compared to those with low
MD. The UGT gene products, which are known to inactivate oestrogen metabolites, were also down-regulated in
tumour samples compared to samples from healthy individuals. Several single nucleotide polymorphisms (SNPs) in
the UGT genes associated with the expression of UGT and other genes in their vicinity were identified.
Conclusions: Three UGT enzymes were lower expressed both in breast tissue biopsies from healthy women with
high MD and in biopsies from newly diagnosed breast cancers. The association was strongest amongst young
women and women using hormonal therapy. UGT2B10 predicts MD independently of age, hormone therapy and
parity. Our results indicate that down-regulation of UGT genes in women exposed to female sex hormones is
associated with high MD and might increase the risk of breast cancer.
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Introduction
Breast cancer is a common disease in women. Knowl-
edge about the first steps in tumour initiation is impor-
tant for early detection. However, the exact mechanisms
of tumour initiation are still unknown.
Mammographic density (MD), captured on film screen
mammograms, refers to the content and architectural
structure of the adipose, connective and epithelial tissues
in the female breast [1]. In epidemiological studies, a high
percentage of MD confers a four to six fold elevated risk
of developing breast cancer [1-3] and has been proposed
as a possible surrogate marker for the disease [4]. The
relative risk associated with MDs remains at this magni-
tude even after adjustment for all other known breast can-
cer risk factors. Breasts with high MD have greater tissue
cellularity and more tissue collagen [5]. Still, little is
known as to how MD confers the increased breast cancer
risk. MD is to a large degree an inherited trait, although it
is also influenced by environmental factors, hormone ther-
apy being an evident example [6]. The genetic factors
determining the inheritability are largely unknown.
In order to elucidate how MD increases the risk of
breast cancer; we searched for the biological correlates
to MD. Gene expression analysis on biopsies from
breasts of healthy women with varying degrees of MD
was performed. The gene expression profiles represent
the gene activity of the different cell types in the biopsy,
producing a fingerprint of the breast tissue within the
biopsy of that particular woman.
The breast is an oestrogen-sensitive organ. MD varies
with levels of female hormones, and is reduced after
menopause. The uridine 5′-diphospho-glucuronosyl-
transferase (UGT) genes encode enzymes inactivating
several endogenous and exogenous compounds, includ-
ing sex hormones (Figure 1) [7]. UGT1A1 is known to
be responsible for the glucuronidation of bilirubin, but
is also shown to glucuronidate catechol oestrogens [8,9].
Polymorphisms in this gene have previously been linked
to MD in premenopausal women [10]. UGT2B7 is
known to conjugate oestrone, one of the active oestra-
diol metabolites. This enzyme has previously been found
to be down-regulated in tumour tissue compared with
non-malignant tissue, leading to the conclusion that
UGT expression could lead to the promotion of carcino-
genesis [11] but there are no reports on this gene in
relation to MD in the literature. Less is known about
the other UGT2B genes, although there is extensive
structural homology. We will use the UGT genes as a
term describing three UGT2B genes significantly down-
regulated in our analyses (UGT2B7, UGT2B10 and
UGT2B11). Other UGT genes are specified in the text.
In this study we analysed biopsies from breasts of
healthy women and found genes whose expression is
associated with MD.
Materials and methods
Subjects
The women included in this study had all attended one
of six breast diagnostic centres in Norway that are part
of the governmentally funded National Breast Cancer
Screening Program between 2002 and 2007 [12].
Women were eligible if they did not currently use
Figure 1 UGTs conjugate oestrogen-substrates into biologically inactive oestrogen glucuronides. The figure gives a schematic view with
focus on glucuronidation and not a complete picture of oestradiol metabolism. Androgens are also inactivated by uridine 5’-diphospho-
glucuronosyltransferases (UGTs), but are not included in this illustration.
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anticoagulants, did not have breast implants and were
not currently pregnant or lactating. A total of 186
women were recruited to the study; 120 healthy women
with no malignant disease but some visible density in
the mammograms, referred to here as healthy women,
and 66 women with a newly diagnosed breast cancer. Of
these, quality tested expression data were obtained from
biopsies from 79 healthy women and 64 breast cancer
patients.
The women were either referred to a breast diagnostic
centre for a second look due to some irregularity of the
initial screening mammogram (n = 69) or due to clinical
findings (n = 83). For 34 women the type of referral was
unknown.
The women provided information about height,
weight, parity, hormone therapy use and family history
of breast cancer. Two breast biopsies and three blood
samples were collected from each woman. All women
provided signed informed consent. The study was
approved by the local ethical committee and local
authorities (IRB approval no S-02036).
Core biopsies
Two breast biopsies were obtained from each woman
with a 14 gauge needle, for RNA- and DNA-extraction.
In healthy women, the biopsies were taken from an area
with no visible pathology, but with some MD to ensure
that the biopsies did not contain only fatty tissue, which
yields little RNA. The sampling was guided by ultra-
sound. At one hospital, six of the biopsies from breasts
of healthy women were collected from a benign lesion
(mostly fibroadenomas). For the cancer patients, all
biopsies were taken from the tumour. The tissue was
either fresh-frozen at -80°C or soaked in ethanol and
RNAlater (Ambion, Austin, TX, USA), transported and
subsequently stored at -20°C.
Pathology
The haematoxylin eosinofil sections from the tumours
of the breast cancer patients were evaluated locally and
then re-evaluated by one pathologist (YC). Information
about tumour size, histological grade and type, oestro-
gen and progesterone receptor status, human epidermal
growth factor receptor (HER) 2 status and sentinel node
status was recorded and entered into a database mana-
ged by the Office for Clinical Research at Oslo Univer-
sity Hospital, Radiumhospitalet. Pathology evaluations
were not available for the biopsies from breasts of
healthy women.
RNA-expression analysis
Homogenisation, cell lysis and RNA extraction were
performed using the RNeasy Mini Protocol (Qiagen,
Valencia, CA, USA). RNA quality was controlled by
Agilent 2100 Bioanalyzer (Agilent Technologies, Palo
Alto, CA, USA) and concentration was determined
using NanoDrop ND-1000 spectrophotometer (Thermo
Scientific, Wilmington, DE, USA). A total of 40 samples,
mostly from normal breast tissue, were excluded from
further analyses due to a low RNA amount (< 10 ng) or
poor RNA quality. RNA was then amplified and labelled
using the Agilent Low RNA input Fluorescent Linear
Amplification Kit Protocol. Amplified tumour RNA was
labelled by Cy5 (Amersham Biosciences, Little Chalfont,
England, UK) and amplified RNA from Universal
Human total RNA (Stratagene, La Jolla, CA, USA) was
labelled by Cy3 (Amersham Biosciences, Little Chalfont,
England, UK). RNA from the remaining 146 biopsies
was further hybridised on Agilent Human Whole
Genome Oligo Microarrays (G4110A) (Agilent Technol-
ogies, Santa Clara, CA, USA). Three arrays had to be
excluded due to poor quality leaving data from 143 sub-
jects (79 healthy individuals and 64 breast cancer
patients) for further analysis. Of the 79 biopsies from
healthy women, 5 had been obtained from a benign
lesion. By ultrasound and mammography these 5 were
described as fibroadenoma (n = 4) or microcalcification
(n = 1).
RNA-data processing
The microarrays were scanned by an Agilent scanner
(Agilent Technologies, Santa Clara, CA, USA) and
processed in Feature Extraction 9.1.3.1 (Agilent Tech-
nologies, Santa Clara, CA, USA). Locally weighted scat-
terplot smoothing (lowess) was used to normalise the
data. The normalised and log2-transformed data were
stored in the Stanford Microarray Database [13] and
retrieved from the database for further statistical ana-
lyses. Flagged spots were treated as missing values. The
dataset now counted 40,791 probes. Clone IDs with 20%
or more missing values were excluded. Gene filtering
was performed to include only probes with variation
across samples, so that probes with less than three
arrays being at least 1.6 standard deviations from the
mean were excluded. For the 79 healthy women, this
probe filtration resulted in an expression dataset of
9,767 probes and 79 arrays each representing one indivi-
dual. For the breast cancer women, a dataset of 64 arrays
and 10,153 probes were obtained after filtration, and for
both groups combined, a dataset of 143 arrays and
13,699 probes were obtained. Missing values were
imputed in R using the method impute.knn in the
library impute [14].
Genotyping
Blood DNA was extracted by phenol/chloroform extrac-
tion followed by ethanol precipitation (Nuclear Acid
Extractor 340A; Applied Biosystems, Foster City, CA,
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USA) according to standard procedures. UGT genotype
data was retrieved from two sources: genome wide asso-
ciation studies (GWAS) using the Human-1 109K Bead-
Chip (Illumina Inc, San Diego, CA, USA) and candidate
gene-based study using iPlex, Sequenom. For the
GWAS, each sample was subject to whole genome
amplification using Illumina proprietary reagents [15].
The amplified DNA was fragmented and hybridised
according to the protocol. The BeadArray reader
(Illumina Inc, San Diego, CA, USA) with the BeadScan
software (Illumina Inc, San Diego, CA, USA) was used
to image the beadchips. Non-polymorphic probes and
probes with more than 20% missing values and were
excluded and data processed as described previously
[16]. The candidate gene single nucleotide polymorph-
ism (SNP) analyses were performed using the iPLEX
assay in conjunction with the Sequenom MassARRAY
platform. Multiplexing was performed in 384 plates
using 1 ul DNA per well with one well containing up to
29 reactions. The technology is described in detail on
the sequenom web-page [17].
Mammograms
Routine descriptions of mammograms by local radiolo-
gists were collected. Craniocaudal mammograms of both
breasts were digitised using a high-resolution Kodak
Lumisys 85 scanner (Kodak, Rochester, NY, USA). Den-
sity was quantified using the University of Southern
California Madena assessment method [18]. In brief, the
method works as follows: a reader (trained by GU) out-
lines the total area of the breast using a computerised
tool, the software then counts the number of pixels.
This represents the total breast area. MD is assessed (by
GU), first by identifying a region of interest that incor-
porates all dense areas except those representing the
pectoralis muscle and scanning artifacts, and then by
applying a yellow tint to all pixels within the region of
interest shaded at or above a threshold intensity of gray.
The software then counts the tinted pixels, which repre-
sents the area of absolute density. The percent density is
the absolute density area divided by the total breast area
and is the value used for these analyses. Test-retest
reliability was 0.99 for absolute density.
Statistical analysis
Clustering was performed using MatLab (version
R2007b) (The MathWorks Inc., Natick, MA, USA) with
Ward linkage and Euclidean distances. Before clustering,
the data were gene centred, that is, for every probe the
mean expression across all samples was calculated and
was subtracted from the log2-ratios for that gene. This
was performed for visualisation purposes only, clustering
with uncentred data returns the same clusters. Signifi-
cance analysis of microarrays (SAM, Stanford University,
CA, USA) (version 3.02) [19,20] for Excel (Microsoft,
Redmond, WA, USA) was used for analysis of differen-
tially expressed genes between two groups of data. The
data were not gene centred for the SAM analysis. A
total of 500 permutations were used. Quantitative SAM
analysis was used to identify genes differentially
expressed according to MD as a continuous variable.
Statistical significance tests and regression analysis were
performed in R 2.9.0 [21]. To test for difference in the
mean of phenotypic variables (MD, age, body mass
index (BMI)) in different clusters of women, we used
two-sided t-tests (assuming equal variance in the
groups) and analysis of variance (ANOVA) for continu-
ous variables and chi-squared/Fisher’s exact tests for
categorical variables [22]. To investigate the similarities
of distributions of UGT genes between tumour samples
and normal samples with low MD and high MD respec-
tively, Kullback-Leibler distances between normalised
distributions of the histograms of the data were calcu-
lated by use of MatLab (The MathWorks Inc., Natick,
MA, USA). The cancer samples in our study were
grouped into subtypes and assigned a risk group using
the PAM50 gene list published by Parker et al [23].
SNP-analysis was performed using R 2.9.0 [21]. The
association between gene expression and SNPs was
assessed using expression quantitative trait loci (eQTL)
[24]in cis (106 bp on each side of the gene) using the R
package eMap v1.1 [25]. Comparing the akaike informa-
tion criterion for different models predicting MD, the
lower criterion singled out a linear regression model as
the model fitting the distribution of the data best. A lin-
ear regression model was fitted in R 2.9.0 with MD as a
continuous response variable and the following covari-
ates: UGT2B7, two probes for UGT2B10, UGT2B11,
ESR1, age, BMI, current hormone therapy, age at first
birth and parity. Gene expression, age, age at first birth
and BMI were entered into the model as continuous
variables. Stepwise variable selection was performed,
starting with all variables included in the model. For
every step, the variable with the highest P value was
rejected from the model and the model was refitted.
This was repeated until all variables included in the
model had a P value less than 0.05. To correct for
the influence of age, this variable was forced to stay in
the model. A sensitivity analysis was performed exclud-
ing extreme ages (30 years or younger) to check the
robustness of the data. We also fitted linear regression
stratified on age (younger or older than 50 years of age)
and current use of hormone therapy. Gene ontology
analysis was performed by the use of DAVID Bioinfor-
matics Resources 2008 from the National Institute of
Allergy and Infectious Diseases, NIH [26]. Functional
annotation clustering was applied and the following
gene ontology categories were selected: biological
Haakensen et al. Breast Cancer Research 2010, 12:R65
http://breast-cancer-research.com/content/12/4/R65
Page 4 of 11
processes (all), molecular function (all) and the KEGG
pathway database. We included gene ontology terms
with a P value (false discovery rate (FDR)-corrected) of
less than 0.01 containing between 5 and 500 genes.
The normalised, log2-transformed data are available in
Gene Expression Omnibus with accession number
[GEO:GSE18672]. The data are not gene centered or
gene filtered.
Results
Gene expression and mammographic density
To identify genes differentially expressed according to MD
we performed quantitative SAM with MD as a continuous
variable using gene expression data from the normal biop-
sies. Of 9,767 probes, only 25 probes, representing 24
genes, were differentially expressed according to MD, with
reduced expression associated with higher MD (FDR <
25%; Table 1) [see Additional file 1]. Gene ontology analy-
sis revealed no significant terms and we found no pathway
associated with this gene set. The UGT genes and oestro-
gen receptor gene (ESR1) were among the genes signifi-
cantly down-regulated in breasts with high MD. The
percentage of samples with low UGT expression was
higher in tumour samples than in normal samples with
low MD, whereas the percentage was more similar
between tumour samples and normal samples with high
MD [see Figure S1 in Additional file 2]. The function of
UGT-enzymes in oestradiol metabolism is illustrated in
Figure 1. In healthy women, the expression of the different
UGT genes was highly correlated with each other and the
four probes clustered together [see Figures S2 and S3 and
Table S1 in Additional file 2].
MD was lower in women with BMI of 25 or more com-
pared with those with BMI of less than 25 (P = 0.01), but
unrelated to other epidemiological variables. UGT
expression was not significantly associated with age, BMI,
age at first birth or current hormone therapy use in the
healthy women [see Table S2 in Additional file 2].
To dissect the impact of age and hormone therapy
use, we performed SAM analyses to identify differen-
tially expressed genes according to MD, whereas strati-
fying for age and postmenopausal hormone therapy
use. For healthy women younger than 50 years of age,
the UGT genes were not significant at a FDR of 25%.
For healthy women aged 50 years or older, 49 probes
were significantly down-regulated in breasts with MD
of 30% or higher (FDR < 25%). Of these, 17 were over-
lapping with those significantly down-regulated among
healthy women in the unstratified analysis. The UGT
genes were not in this list. We then stratified the
women aged 50 years or older on current hormone
therapy use. When only those currently using hormone
therapy were included in the analysis, UGT2B7 and
UGT2B11 were among the six genes differentially
expressed with an FDR less than 10E-5 and UGT2B28
with FDR less than 25%. For healthy women above 50
years of age and not currently using hormone therapy,
several of the 24 genes were differentially expressed
according to MD with an FDR of less than 25%, but
again the UGT genes were not in this list [see Addi-
tional file 3].
These analyses were confirmed fitting a linear regres-
sion model. Although the other variables were excluded
from the model with insignificant P values, age was kept
in the model to control for the age-effect. After stepwise
variable selection, the only significant variables remain-
ing in the model were UGT2B10 (A_23_P7342)(P =
0.005) and BMI (P = 0.015). Sensitivity analysis exclud-
ing extreme ages (30 years and younger) did not alter
the results (UGT2B10 P = 0.003, BMI P = 0.016) and
indicates the robustness of the results. ESR1 was border-
line significant in both these analyses. These results
were not significantly altered when MD was log2-trans-
formed. For further stratification see Table 2.
Unsupervised hierarchical clustering of the 79 samples
from healthy women showed two main clusters. MD
was not significantly different between these two clus-
ters [see Figure S3 in Additional file 2].
Table 1 Genes differentially expressed according to
mammographic density in non-cancer samples
Gene symbol Agilent ID Cytogenetic band
729641 A_24_P932736 8p21.1
FLJ10404 A_23_P427472 5q35.3
VPS18 A_24_P18802 15q15.1
UGT2B10 A_23_P7342 4q13.2
CABP7 A_24_P177236 22q12.2
CD86 A_24_P131589 3q13.33
UGT2B11 A_23_P212968 4q13.2
580687 A_23_P152570 17p11.2
DIAPH2::RPA4 A_23_P254212 Xq21.33
LMOD1 A_32_P199824 1q32.1
UGT2B10 A_24_P521559 4q13.2
PIK3R5 A_23_P66543 17p13.1
ATG7 A_32_P107994 3p25.2
LRRC2 A_23_P155463 3p21.31
RBL1 A_23_P28733 20q11.23
NPY1R A_23_P69699 4q32.2
810781 A_23_P144244 3q13.33
593535 A_32_P80016 15q26.1
H2AFJ A_23_P204277 12p12.3
666399 A_32_P35668 20p12.3
Transcribed A_24_P640617 2p25.2
Transcribed A_32_P20997 20q13.13
UGT2B7 A_23_P136671 4q13
ESR1 A_23_P309739 6q25.1
SAPS1 A_23_P119448 19q13.42
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In the breast cancer group, MD was significantly asso-
ciated with age and BMI, with higher MD in the
younger women and in those with BMI less than 25.
Both MD and UGT expression tended to be higher in
women with receptor positive tumours, but this was not
significant for any type of receptor. UGT-expression in
tumours was unrelated to age, BMI, age at first birth
and current hormone therapy (data not shown). There
was a higher proportion of oestrogen receptor positive
tumours among the breast cancer patients with high
MD (≥ 30%) compared with low (< 30%) MD (10 of 10
vs 36 of 40, Fisher’s = 0.001). There was no significant
association between tumour subtype and level of MD as
assessed by ANOVA. There was no indication that
degree of MD was associated with the risk of relapse as
assessed by the method of Parker et al [23] [see Figure
S4 of Additional file 2].
Nine probes were differentially expressed according to
MD in cancer samples (FDR < 25%; Table 3). None of
these were overlapping with the 24 genes differentially
Table 2 Linear regression analysis of factors predicting mammographic density in all women and stratified for age
and hormone therapy use
Women in model N Variables Beta value P value
All women 76 UGT2B101) -0.6 0.902
UGT2B7 1.8 0.631
UGT2B11 4.8 0.275
ESR1 -3.8 0.055
UGT2B102) -5.6 0.005
BMI -1.5 0.015
age -0.4 0.074
50 years or older 46 UGT2B11 0.2 0.987
UGT2B101) 1.0 0.946
UGT2B7 3.5 0.486
UGT2B102) -3.7 0.073
BMI -1.4 0.052
ESR1 -6.0 0.016
age -0.9 0.061
50 years or older, currently on hormone therapy 11 UGT2B101) 7.2 0.771
UGT2B11 -5.8 0.695
BMI -2.9 0.103
UGT2B7 6.8 0.418
UGT2B102) -27.0 0.000
ESR1 -8.1 0.011
age -0.9 0.103
50 years or older, never used hormone therapy 28 UGT2B11 -0.7 0.948
UGT2B101) 3.3 0.809
UGT2B7 3.1 0.555
UGT2B102) -1.4 0.607
BMI -0.9 0.348
ESR1 -6.0 0.033
Age -1.5 0.004
Younger than 50 years 30 UGT2B7 0.4 0.950
UGT2B101) -1.2 0.866
ESR1 -0.9 0.835
UGT2B11 8.4 0.225
BMI -1.4 0.216
UGT2B102) -6.2 0.040
Age -0.3 0.610
1) A_24_P521559, 2) A_23_P7342
Factors predicting mammographic density (MD) after stepwise exclusion of non-significant factors are shown. Variables listed in the order of exclusion from the
model. P value from the last equation including the variable is shown. Age is forced to stay in the model. UGT2B10 (A_23_P7342) is a significant, independent
predictor of MD in all analyses with a majority of women under influence of female hormones; women younger than 50 years of age and women currently on
hormone therapy. BMI, body mass index.
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expressed in the samples from the breasts of healthy
women.
Genetic polymorphisms
In order to identify genetic determinants of the expression
of the UGT genes found to be associated with MD, we
performed eQTL analyses of SNPs in these genes as avail-
able from an array based GWAS study and a candidate
gene study. Twenty one SNPs in UGT genes were present
on the 109 K array from Illumina, and 9 SNPs from the
candidate gene analysis. Of these, 5 SNPs were associated
with the expression of UGT genes or other genes in their
vicinity at P = 0.05 [see Additional file 4]. Two of these
SNPs, both located in UGT2B10 (rs1828705, rs1828705),
were significantly associated with gene expression of
another UGT gene (UGT2B7 and UGT2B28).
Discussion
Previously, whole genome expression profiling of normal
breast tissue (all cell types included) has been performed
to a limited extent [27,28]. Yang et al recently per-
formed a study of cancer-free breast tissue obtained
from mastectomies in breast cancer patients with high
and low MD [29]. They identified a list of 73 genes dif-
ferentially expressed between high and low MD samples.
Specifically, this included the down-regulation of several
transforming growth factor (TGF) b-related genes in
samples with high MD. In the present study we analysed
breast biopsies from 79 healthy women and tumours of
64 women with breast cancer. Twenty-four genes were
differentially expressed according to MD in the healthy
samples. In breast tumours, none of these 24 genes were
found differentially expressed according to MD.
Tumour-specific deregulation of a large number of
mRNA transcripts may be expected to overshadow the
MD signature. In addition, the sample size is limited
and the two sample sets (cases and controls) are not
directly comparable with respect to MD [see Figure S5
in Additional file 2].
In our study, three UGT genes (UGT2B11, UGT2B10
and UGT2B7) were differentially expressed according to
MD in the breasts of healthy women. All these three
enzymes had decreased expression in dense breasts. Pre-
vious knowledge links the UGT enzymes to the metabo-
lism of female hormones known to influence the
mammary glands (Figure 1). The over-representation of
UGT genes on the list of significant genes along with a
biological link makes these genes particularly interesting.
In a linear regression model with age as a confounding
factor, BMI and one of two probes for UGT2B10 were
the only significant variables independently predicting
MD, with ESR1 as a borderline significant covariate.
The expression of these three UGT2B genes is highly
correlated to each other and as expected only one probe
remained in the regression model as an independent
predictor of MD. BMI is known to be the strongest and
most consistent epidemiological predictor of MD, and is
expected to remain in the model. It is noteworthy that
one of the UGT genes has an independent predictive
value of a greater significance and magnitude than BMI.
MD is determined by multiple factors. In a study of lim-
ited sample size, we can only expect to identify the
strongest predictors.
UGT2B7 is postulated to protect the breast tissue
from oestrogen metabolites locally [30], and this is con-
sistent with our findings that breasts with higher MD
have reduced expression of this gene. The main metabo-
lites of oestradiol and oestrone (hydroxyl- and methoxy-
oestrogen compounds) bind to the oestrogen receptor,
but with a reduced affinity compared with oestradiol.
UGT2B10 and 11 are not yet reported to be associated
with MD or breast cancer, but UGT2B10 is involved in
the metabolism of tobacco-related nitrosamines [31].
Less is known about UGT2B11. The different UGT2B
genes are located close to each other on chromosome 4
and there is great homology between the genes [see Fig-
ure S6 in Additional file 2]. UGT1A1, previously linked
to MD and breast cancer [32], is not represented on the
microarray used in this study.
We have identified a set of genes differentially
expressed according to MD. Interestingly, the UGT
genes seem, to a greater extent than the other genes, to
be more similarly expressed between tumour samples
and normal samples from breasts with high MD as com-
pared with normal samples from breasts with low MD
[see Table S4 and Figure S7 in Additional file 2]. The
other differentially expressed genes generally express the
same levels in the tumours and in the biopsies from the
healthy women with low MD. We cannot exclude that
the UGT genes confer risk for breast cancer develop-
ment through increasing MD, but further studies would
be needed to investigate this.
Table 3 Genes differentially expressed according to
mammographic density in cancer samples
Agilent ID Gene name FDR (%)
A_32_P171923 730402 0.00
A_32_P480177 TNN 0.00
A_23_P200298 AGL 0.00
A_24_P87036 TMEM16A 0.00
A_23_P312150 EDN2 14.87
A_23_P83388 EPPK1 14.87
A_32_P60065 F2RL2 19.82
A_32_P158272 MRNA 19.82
A_23_P105012 HRASLS2 19.82
FDR, false discovery rate.
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We found the UGT genes to be differentially
expressed in young women and women over 50 years of
age currently on hormone therapy. SAM analysis of MD
in women younger than 50 years did not give any differ-
entially expressed genes with an FDR of less than 25%.
However, several UGT-probes are on the top of the list
of genes down-regulated in samples from breasts with
high MD. The lack of significance could be due to low
sample size (n = 30). As UGT enzymes conjugate oes-
tradiol metabolites, its effect will be greater when there
is an increased level of oestradiol present, whether the
oestradiol is endogenous or exogenous. The linear
regression analysis showed that UGT2B10 was predict-
ing MD independent of age in all women, younger
women and women older than 50 years currently using
hormones. This leads to the hypothesis that decreased
UGT expression in the breast of a woman with
increased levels of female hormones confers an
increased MD and possibly an increased risk of breast
cancer.
The biology in breasts with high and low MD may dif-
fer, partly due to differences in proportion of fatty tis-
sue. Therefore, we looked for differentially expressed
genes in a subset of samples including only samples
from breasts with MD of more than 20%. The fact that
the UGT2B gene family is so strongly represented
among the down-regulated genes (six probes represent-
ing five different UGT2B genes are the only genes differ-
entially expressed with an FDR < 10E-5) indicate that
reduced UGT expression is of greater significance in
breasts with higher MD and lower content of fatty
tissue.
We find that ESR1 is down-regulated in biopsies from
healthy women with high MD compared with those
with low MD. This is not consistent with previous find-
ings [33] and contrary to what one would expect
because ESR1 induces transcription and epithelial
growth and high MD may contain increased amounts of
epithelial cells [34,35]. However, increased levels of oes-
tradiol have been shown to decrease levels of ESR1 in
breast cancer [36], and in normal breast tissue in mon-
keys [37] and in mice [38]. Increased levels of oestradiol
may increase MD. Elevated expression of ESR1 is com-
mon postmenopausally [37] and represents non-prolifer-
ating cells. The association between reduced levels of
ESR1 and high MD may reflect high levels of oestradiol.
We found that ESR1 was only a borderline significant
predictor of MD in models with stepwise exclusion of
covariates. In a model including ESR1 with only age or
age and UGT2B10, ESR1 was significantly predicting
MD. The independent contribution of ESR1 in predict-
ing MD was significant in older women, where the effect
of UGT2B10 was not present. There could be a link
between UGT-expression and ESR1-expression in that
reduced metabolism of oestradiol-metabolites increases
the levels of ESR1-ligands (oestradiol metabolites) and
hence reduces ESR1-levels. The UGT-enzyme activity
may be the cause of the alterations leading to increased
MD by this mechanism. Reduced ESR1 is only border-
line significant in predicting MD and could also be an
intermediate factor.
MD is the result of complex biological processes with-
out any single determining factor. BMI is the single
most important factor found to date, and is also signifi-
cant in this study. Age seems to have its effect mainly
through hormonal influence, except for in postmeno-
pausal women not taking hormones, where age has a
significant, independent effect on MD. MD is not signif-
icantly different between the two main clusters from
unsupervised hierarchical clustering of the samples from
healthy women. MD is hence not related to the main
variation in the normal samples.
The genes whose expression we have found to be
associated with MD do have a fairly high FDR in a SAM
analysis and are not significant in all stratified analyses,
suggesting that they may play a role in only subsets of
individuals and other factors also have a significant con-
tribution. Despite this, in linear regression models
UGT2B10 is an independent predictor of MD along
with BMI.
There is a substantial heritable proportion of MD.
SNPs in UGT genes with influence on the UGT expres-
sion have been described [8,39]. We identified two
UGT-SNPs associated with the expression of other UGT
genes. Due to their homology and co-localisation on the
chromosome, they may share common control loci that
affect the expression of multiple UGT genes. It remains
to be investigated in larger and better powered epide-
miological studies whether any of these SNPs are asso-
ciated to MD per se.
We do not know enough about the variability of
gene expression within normal breasts to know if the
genes relevant for MD are adequately represented by
one biopsy taken from an area with some MD. It is
previously shown that two biopsies from the same
breast tumour, before and after chemotherapy, cluster
together [40]. The tumours may, however, be more
homogenous than normal breast tissue. Variability in
gene expression within each breast will make it diffi-
cult to detect genes with only a minor influence on
MD so that only the strongest factors are identified. In
an unpublished dataset we found no significant differ-
ence between UGT-expression in tumours and normal
adjacent tissue tested by paired t-test [see Table S5 in
Additional file 2]. This is merely an indication that the
expression in one breast might be similar for different
locations in the breast and hence be used to look for
associations with MD.
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In this study, healthy individuals had higher MD than
the breast cancer patients. The women recruited in the
study had been referred to a breast diagnostic centre for
a second look. As high MD confers an increased risk for
breast cancer and mammograms with high MD are
more difficult to interpret, they most likely had a higher
MD. In addition, the inclusion criterion of some visible
MD for biopsy may have influenced the mean MD of
the study population. The two populations are not
directly comparable with respect to MD and related
parameters. This lack of comparability on MD does not
affect the analyses of gene expression among the healthy
women only.
We obtained good quality microarrays from only 79 of
120 healthy women and from 64 of 66 breast cancer
patients. This was due to low mRNA-yield or low
mRNA-quality. The biopsies from healthy women con-
sistently yielded less mRNA than the tumour samples.
There is significantly higher MD in the breasts of
healthy women with successful microarrays than in
those with unsuccessful microarrays (37% vs 29%, P =
0.03). As samples from breasts with low MD are under-
represented in the microarray study, it is more difficult
to identify genes that are differentially expressed
between breast tissue with high and low MD. Despite
these limitations, we have identified differentially
expressed genes. These genes might have a greater sig-
nificance than shown in this study.
Normal breast tissue yields less RNA than tumour tis-
sue. The biopsies in this study were small and in agree-
ment with the pathologist, all tissue from normal
breasts was prioritised for RNA-extraction rather than
histological evaluation. Imprint was not in routine use
in the hospitals where we started this study. In order to
make it possible for the staff to include women in this
study in a busy schedule we had to use procedures
already established. We do therefore not have any infor-
mation about the cell types of the normal biopsies.
Knowledge about the cell types present in the biopsies
would have facilitated the analysis.
The two UGT2B10-probes behave differently in our
dataset. Both probes map to the 3′end of the UGT2B10-
gene by BLAT (98.4% homology for A_23_P7342 and
100% homology for A_24_P521559). The discrepancy in
UGT2B10-expression detected by the two probes may
be due to the fact that they both also share substantial
sequence homology with other, but different UGT2B-
genes.
Conclusions
We have identified a set of genes that are differentially
expressed according to MD in breast samples from
healthy women. Some of these genes are known to
influence MD and breast cancer, such as ESR1 and
UGT2B7. Two less described UGT genes, UGT2B10 and
UGT2B11, are also differentially expressed. The expres-
sion of the three UGT genes is reduced in samples with
high MD and also in tumour samples, but does not vary
between different tumour subtypes or risk groups. The
UGT enzymes are known to conjugate active oestrogen-
metabolites. We show that UGT2B10 expression and
BMI are independent predictors of MD. The influence
of reduced UGT expression was strongest in women
under exposure of female hormones. Two candidate
SNPs are associated with the UGT gene expression in
cis. We hypothesise that reduced expression of UGT
genes in women exposed to female sex hormones,
increase MD and that this may be associated with an
increased risk of breast cancer. Further studies of these
genes are needed to test the hypothesis that the gene
products from these genes protect the breast from the
oestrogen-induced MD and thereby reducing the risk of
breast cancer.
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Additional file 1 - SAM MD, healthy women
Quantitative
USANN
0.1128214
0
standard
standard
USANN
500
Automatic
10
1234567
0.9931402
0.0010565
0
50.528184
Row Gene ID Gene NameScore(d) Numerator Denominator(s+q-value(%)
4650 A_24_P756 LOC730057 2.8605802 0.015238 0.005326743 34.05052
8807 A_24_P329 BTN3A1 2.8288494 0.011028 0.003898406 34.05052
9112 A_24_P311 BTN3A3 2.7601417 0.009886 0.00358167 34.05052
Row Gene ID Gene NameScore(d) Numerator Denominator(s+q-value(%) FDR<25
6760 A_24_P932 729641 -2.939794 -0.024561 0.008354769 0
6129 A_23_P427 FLJ10404 -2.898094 -0.017947 0.006192794 0
9647 A_24_P188 VPS18 -2.874372 -0.020757 0.007221398 0
4530 A_23_P734 UGT2B11 -2.870324 -0.020651 0.007194816 0
6993 A_24_P177 CABP7 -2.868285 -0.025244 0.008800965 0
9508 A_24_P131 CD86 -2.834444 -0.025353 0.00894473 0
2950 A_23_P212 UGT2B11 -2.791517 -0.029178 0.010452204 0
3485 A_23_P152 580687 -2.7432 -0.020484 0.007467054 0
7883 A_23_P254 DIAPH2::RP -2.68794 -0.020478 0.0076185 8.276168
8366 A_32_P199 LMOD1 -2.675115 -0.023358 0.008731604 8.276168
7637 A_24_P521 UGT2B10 -2.656355 -0.023386 0.008803889 8.276168
2978 A_23_P665 PIK3R5 -2.655412 -0.017592 0.006625019 8.276168
6371 A_32_P107 ATG7 -2.590986 -0.021892 0.008449193 8.276168
5506 A_23_P155 LRRC2 -2.573214 -0.019142 0.007439063 15.681161
4399 A_23_P287 RBL1 -2.537519 -0.009507 0.003746516 15.681161
1537 A_23_P696 NPY1R -2.536482 -0.025025 0.009866086 15.681161
8728 A_23_P144 810781 -2.511297 -0.018144 0.007224783 15.681161
4605 A_32_P800 593535 -2.510476 -0.019579 0.007798728 15.681161
4562 A_23_P204 H2AFJ -2.505133 -0.011728 0.00468148 15.681161
5316 A_32_P356 666399 -2.481846 -0.016741 0.006745418 15.681161
6564 A_24_P640 Transcribed -2.434159 -0.016788 0.006896857 18.916956
6272 A_32_P209 Transcribed -2.418337 -0.011417 0.004721011 21.590004
2288 A_23_P136 UGT2B7 -2.403406 -0.029123 0.012117417 21.590004
3534 A_23_P309 ESR1 -2.388786 -0.017364 0.007268849 21.590004
2471 A_23_P119 SAPS1 -2.365048 -0.016886 0.007139654 23.835364
9547 A_24_P125 PPM1F -2.329502 -0.013608 0.00584143 26.738389
Number of neighbors for KNN
Current settings
Input parameters
Data type?
Arrays centered?
Delta
Minimum fold change
Test statistic
Regression method
Are data are log scale?
Number of permutations
Input percentile for exchangeability factor s0
List of Significant Genes for Delta = 0.113
Positive genes (3)
Negative genes (54)
Seed for Random number generator
Computed values
Estimate of pi0 (proportion of null genes)
Exchangibility factor s0
s0 percentile
False Discovery Rate (%)
8792 A_24_P180 UGT2B28 -2.294363 -0.023268 0.010141551 28.375433
7921 A_24_P693 ZNF552 -2.29271 -0.014196 0.006191895 28.375433
9066 A_24_P368 RAP1GAP -2.277258 -0.014689 0.006450451 30.821591
9523 A_24_P287 PLCB2 -2.264593 -0.013956 0.006162608 33.104672
7706 A_24_P178 LOC132205 -2.251632 -0.010829 0.004809546 33.104672
3043 A_23_P256 EEF1A2 -2.245056 -0.009618 0.004283879 33.104672
4986 A_24_P176 UGT2B17 -2.191409 -0.017356 0.007920074 40.262439
2186 A_23_P902 CHST8 -2.184548 -0.011603 0.00531145 40.262439
3978 A_23_P436 OSTbeta -2.173318 -0.015595 0.007175527 40.262439
6354 A_24_P844 710943 -2.154978 -0.010026 0.004652441 40.744212
8645 A_24_P734 CDNA -2.139041 -0.011402 0.005330588 40.744212
8396 A_24_P913 797019 -2.126743 -0.013371 0.006287243 40.744212
4352 A_32_P163 NFE2L1 -2.122614 -0.00828 0.003900752 40.744212
27 A_32_P149 537146 -2.121891 -0.011736 0.005530906 40.744212
8825 A_24_P872 HIST2H2AC -2.116853 -0.007738 0.003655275 40.744212
9195 A_24_P315 825337 -2.103838 -0.011041 0.005248156 44.139563
2652 A_32_P595 GFRA1 -2.089581 -0.010792 0.005164611 44.139563
9608 A_24_P585 837185 -2.089248 -0.008928 0.004273281 44.139563
9565 A_24_P575 835938 -2.085134 -0.013291 0.006374112 44.139563
4339 A_23_P556 SLC14A1 -2.080633 -0.010976 0.005275552 44.139563
3525 A_23_P140 KRT8 -2.073511 -0.0086 0.00414763 44.139563
5841 A_24_P171 DKFZP547L -2.072369 -0.014788 0.007135751 44.139563
6833 A_23_P102 A_23_P102 -2.066516 -0.012184 0.005895961 44.139563
1659 A_23_P428 HIST1H2AD -2.062726 -0.009283 0.004500294 44.139563
2325 A_23_P407 OSTalpha -2.060191 -0.009576 0.004648155 44.139563
6618 A_23_P735 CITED1 -2.048192 -0.014632 0.007143821 47.851299
7156 A_24_P464 RBM22 -2.039381 -0.015274 0.007489543 48.770276
7002 A_23_P384 SLC45A4 -2.021144 -0.012841 0.006353311 50.528184
Quantiles Cutpoints Miss Rate(%)
0 -> 0.05 -2.012 -> -1.228 0
0.05 -> 0.1 -1.228 -> -0.969 3,49
0.1 -> 0.15 -0.969 -> -0.783 0
0.15 -> 0.2 -0.783 -> -0.633 0
0.2 -> 0.25 -0.633 -> -0.5 0
0.25 -> 0.75 -0.5 -> 0.533 0,44
0.75 -> 0.8 0.533 -> 0.654 8,29
0.8 -> 0.85 0.654 -> 0.807 0,71
0.85 -> 0.9 0.807 -> 1.002 0,76
0.9 -> 0.95 1.002 -> 1.254 11,81
0.95 -> 1 1.254 -> 2.505 0
Estimated Miss rates for Delta=0.112821421147983
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Figure S1: The percentage of samples with low expression of UGT genes (<-0.5) within tumour 
samples and healthy women with high (30%) or low (<30%) MD.
Figure S2: Clustering of the genes significantly down regulated in high MD samples. The three UGT 
genes cluster separately and tightly together. Samples are sorted according to MD. 
2Figure S3: The expression of the different UGT genes is highly correlated. Expression of the 
four probes representing UGT-transcripts (y-axis) for each sample (x-axis) for A) healthy women 
and B) breast cancer patients respectively
Table S1: Correlation between the expression of different UGT genes 
  A_23_P136671 A_23_P212968 A_23_P7342 A_24_P521559
  UGT2B7 UGT2B11 UGT2B10 UGT2B10
A_23_P136671 UGT2B7  0.92 0.91 0.90
A_23_P212968 UGT2B11 0.92  0.93 0.94
A_23_P7342 UGT2B10 0.91 0.93  0.90
A_24_P521559 UGT2B10 0.90 0.94 0.90 
Table S2: MD and expression of UGT genes in samples from healthy women  
  MD
A_23_P136671
UGT2B7
expression
A_23_P7342
UGT2B10
expression
A_24_P521559
UGT2B10
expression
A_23_P212968
UGT2B11
expression
age mean<50(n=31) 40.4 0.83 0.15 0.74 0.07
 mean50(n=45) 35.2 0.68 0.22 0.70 0.07
 pvalue 0.25 0.72 0.78 0.92 0.99
BMI mean<25(n=49) 41.2 0.84 0.12 0.77 0.11
 mean25(n=27) 30.0 0.57 0.31 0.63 0.02
 pvalue 0.01 0.53 0.45 0.66 0.73
mean<25(n=38) 31.5 0.66 0.25 0.60 0.03Ageatfirst
birth mean25(n=18) 39.0 0.64 0.22 0.48 0.00
 pvalue 0.14 0.96 0.93 0.77 0.95
meanyes(n=64) 46.5 0.97 0.12 1.04 0.50
meanno(n=12) 35.6 0.71 0.24 0.64 0.01
Current
hormone
therapy pvalue 0.07 0.65 0.25 0.35 0.30
MD and expression of UGT genes in samples from healthy women in relation to 
epidemiological factors. All p-values are from two-sided t-tests not corrected for multiple 
testing.
3Figure S3: Unsupervised hierarchical clustering showed two main clusters. MD was not 
significantly different between these two clusters. 
Figure S4: MD in relation to tumour subgroups 
a) Boxplot of MD vs subtypes b) Boxplot of MD for each pam50 risk 
group (1=high, 3=medium, 5=low risk).  
4Figure S5: Distribution of MD in a) all samples (mean=), b) healthy women 
(mean=37%) and c) breast cancer patients (mean=16%) 
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Figure S6: Localisation of UGT genes on chromosome 4
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5Table S4: Gene expression in samples from healthy women with 
differing MD compared with tumour samples.  
A) MD < 30% vs MD>30%: The mean expression of all four probes representing 
UGT genes is not significantly different between tumour samples and normal 
samples from breasts with high MD. For three UGT probes, mean expression is 
significantly different between tumour samples and normal samples from breasts 
with low MD. This is not the case for most other genes.  
AgilentID SYMBOL
mean
t
meann
MD
<30%
meann
MD>30%
ttesttvs
MD<30%
ttesttvs
n
MD>30%
A_23_P119448 SAPS1 0.87 0.98 0.13 0.693 0.000
A_23_P136671 UGT2B7 1.00 0.21 1.24 0.005 0.402
A_23_P144244 810781 1.16 1.12 0.28 0.889 0.000
A_23_P152570 580687 1.53 1.78 0.87 0.430 0.003
A_23_P155463 LRRC2 1.39 1.60 0.65 0.478 0.001
A_23_P204277 H2AFJ 1.62 1.20 0.79 0.047 0.000
A_23_P212968 UGT2B11 0.43 0.77 0.50 0.003 0.768
A_23_P254212 DIAPH2::RPA4 1.50 1.62 0.68 0.705 0.000
A_23_P28733 RBL1 0.90 0.77 1.12 0.306 0.010
A_23_P309739 ESR1 2.32 1.96 1.32 0.282 0.000
A_23_P427472 FLJ10404 1.21 1.44 0.51 0.466 0.002
A_23_P66543 PIK3R5 0.89 0.95 0.07 0.833 0.000
A_23_P69699 NPY1R 1.42 2.01 1.35 0.267 0.902
A_23_P7342 UGT2B10 0.16 0.79 0.13 0.010 0.054
A_24_P131589 CD86 1.57 1.93 0.79 0.305 0.002
A_24_P177236 CABP7 1.63 1.95 0.68 0.378 0.000
A_24_P18802 VPS18 1.44 1.64 0.69 0.510 0.000
A_24_P521559 UGT2B10 0.70 0.07 1.08 0.072 0.148
A_24_P640617 Transcribed 0.97 1.04 0.18 0.801 0.000
A_24_P932736 729641 1.55 1.68 0.59 0.714 0.000
A_32_P107994 ATG7 1.51 1.78 0.74 0.413 0.001
A_32_P199824 LMOD1 1.55 1.91 0.77 0.320 0.002
A_32_P20997 Transcribed 0.25 0.56 0.10 0.008 0.092
A_32_P35668 666399 1.31 1.51 0.62 0.499 0.001
A_32_P80016 593535 1.59 1.72 0.75 0.676 0.000
6Table S4 cont B) MD<20% vs MD>40%: The mean expression of all four 
probes representing UGT genes is not significantly different between 
tumour samples and normal samples from breasts with high MD, as 
opposed to most other probes. There is no significant difference in mean 
expression between tumour samples and normal samples from breasts 
with low MD. Contrary to most other probes, the mean expression of the 
UGT genes in tumours is more similar to the mean expression in normal 
samples from breasts with high than low MD.
   MD<20%vs>40%     
AgilentID SYMBOL meant
meann
MD<20%
meann
MD>40%
ttestt
vsn
MD
<20%
ttestt
vsn
MD
>40%
tn
low
MD
|tnlow
MD|
tn
high
MD
tcloser
to
A_23_P119448 SAPS1 0.87 1.31 0.18 0.23 0.01 0.44 0.44 0.69 low
A_23_P136671 UGT2B7 1.00 0.39 1.22 0.22 0.52 0.61 0.61 0.21 high
A_23_P144244 810781 1.16 1.46 0.37 0.42 0.00 0.31 0.31 0.79 low
A_23_P152570 580687 1.53 2.12 0.98 0.13 0.04 0.59 0.59 0.55 high
A_23_P155463 LRRC2 1.39 1.78 0.72 0.29 0.01 0.39 0.39 0.67 low
A_23_P204277 H2AFJ 1.62 1.18 0.73 0.11 0.00 0.44 0.44 0.89 low
A_23_P212968 UGT2B11 0.43 0.24 0.52 0.15 0.75 0.66 0.66 0.09 high
A_23_P254212 DIAPH2/RPA4 1.50 1.98 0.75 0.23 0.01 0.48 0.48 0.76 low
A_23_P28733 RBL1 0.90 0.70 1.15 0.18 0.01 0.20 0.20 0.26 low
A_23_P309739 ESR1 2.32 1.89 1.21 0.32 0.00 0.43 0.43 1.12 low
A_23_P427472 FLJ10404 1.21 1.70 0.53 0.24 0.01 0.49 0.49 0.68 low
A_23_P66543 PIK3R5 0.89 1.14 0.17 0.51 0.01 0.25 0.25 0.72 low
A_23_P69699 NPY1R 1.42 2.21 1.26 0.25 0.73 0.78 0.78 0.16 high
A_23_P7342 UGT2B10 0.16 0.50 0.15 0.20 0.07 0.34 0.34 0.30 high
A_24_P131589 CD86 1.57 2.26 0.87 0.10 0.02 0.68 0.68 0.70 low
A_24_P177236 CABP7 1.63 2.25 0.77 0.17 0.01 0.62 0.62 0.86 low
A_24_P18802 VPS18 1.44 1.88 0.77 0.23 0.01 0.44 0.44 0.67 low
A_24_P521559 UGT2B10 0.70 0.38 1.14 0.52 0.17 0.32 0.32 0.44 low
A_24_P640617 Transcribed 0.97 1.25 0.32 0.42 0.01 0.28 0.28 0.65 low
A_24_P932736 729641 1.55 2.10 0.64 0.19 0.00 0.55 0.55 0.91 low
A_32_P107994 ATG7 1.51 2.07 0.83 0.17 0.02 0.57 0.57 0.68 low
A_32_P199824 LMOD1 1.55 2.22 0.84 0.12 0.02 0.67 0.67 0.71 low
A_32_P20997 Transcribed 0.25 0.69 0.15 0.00 0.28 0.44 0.44 0.10 high
A_32_P35668 666399 1.31 1.71 0.71 0.28 0.02 0.41 0.41 0.60 low
A_32_P80016 593535 1.59 2.02 0.82 0.26 0.00 0.42 0.42 0.78 low
7Figure S7: The Kullback-Leibler divergence between UGT expression in 
tumours and healthy samples with high and low MD respectively. Small 
divergence means more similar distribution in the two populations tested. 
For three of four UGT probes, the distribution in tumour samples is more 
similar to the distribution in healthy individuals with high-MD than with low-
MD. (The first UGT2B10-probe is A_23_P7342, the probe that is significant 
in the GLM-analysis, the second is A_24_P521559). 
8Table S5: Gene expression of UGT2B10 in tumour samples (T) and 
normal adjacent samples (N) from the same breast in an unpublished 
dataset. There is no significant difference in mean expression by pair wise 
t-test.
A_23_P7342 A_23_P7342
UGT2B10 UGT2B10 
CM  1N 9.75 CM  1T 7.52
CM  9N 8.62 CM  9T 8.49
CM 10N 8.77 CM 10T 7.27
CM 11N 9.26 CM 11T 6.65
CM 13N 10.32 CM 13T 7.43
CM 18N 10.69 CM 18T 8.79
CM 19N 9.12 CM 19T 9.11
CM 26N 8.78 CM 26T 7.31
CM 31N 8.00 CM 31T 8.07
CM 32N 7.73 CM 32T 7.23
CM 38N 10.96 CM 38T 7.32
CM 41N 9.07 CM 41T 11.71
CM 46N 8.74 CM 46T 11.21
CM 47N 11.08 CM 47T 8.00
CM 54N 7.80 CM 54T 13.14
CM 56N 7.92 CM 56T 17.48
CMG24N 6.66 CMG24T 13.89
CMG43N 8.24 CMG43T 10.59
CM 44N 8.89 CM 44T 7.75
average 8.97 average 9.42
p-value 0.60 (pair wise t-test) 
Table S6: Range of MD in the breasts of healthy women  
max 77.3133466
min 1.28417454
mean 28.1668549
median 23.5504612
9Supplemental discussion
Gene expression microarray analyses using tissue adjacent to a breast tumour have 
previously been done [1,2]. The expression profile in these normal samples will be 
influenced by the neighbouring breast tumour [3]. Breast reduction mammoplasties have 
also been used in analysis of healthy breast tissue [4]. These samples are generally 
collected from large breasts with a higher than average proportion of fatty tissue which 
may also skew the analyses to some extent.  Our study analysed a population more 
representative of the population of women at risk for developing breast cancer, since we 
have studied normal breast tissue from women with no malignant disease and not 
undergoing breast reduction mammoplasties.
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AdditionalFile3SAMMD,healthywomen,stratified
HealthywomenMD20+ Healthywomenage<50
n=61 n=30
DownregulatedinhighMD DownregulatedinhighMD
GeneID GeneName Score(d) qvalue(%) GeneID GeneName Score(d) qvalue(%)
A_23_P212968 UGT2B11 2.7797 0 A_23_P31816 DEFA1 2.42 108.98
A_24_P521559 UGT2B10 2.7043 0 A_24_P945408 A_24_P945408 2.11 108.98
A_24_P180243 UGT2B28 2.492 0 A_23_P28485 GCA 2.09 108.98
A_24_P17691 UGT2B17 2.4912 0 A_23_P133606 SLC12A2 1.96 108.98
A_23_P7342 UGT2B11 2.4377 0 A_23_P155666 ASAHL 1.85 108.98
A_23_P136671 UGT2B7 2.3951 0 A_24_P521559 UGT2B10 1.85 108.98
A_24_P575267 835938 2.2204 16.580614 A_23_P57961 PLXNB1 1.85 108.98
A_23_P309739 ESR1 2.119 29.016075 A_23_P251002 A_23_P251002 1.76 108.98
A_24_P180243 UGT2B28 1.73 108.98
A_24_P682550 805257 1.73 108.98
Healthywomenage50+ A_24_P926053 EEF1D 1.73 108.98
n=43 A_24_P234732 MXD4 1.72 108.98
DownregulatedinhighMD A_23_P7342 UGT2B10 1.72 108.98
GeneID GeneName Score(d) qvalue(%) A_23_P218144 LTBP2 1.68 108.98
A_24_P932736 729641 2.85 0 A_23_P136671 UGT2B7 1.67 108.98
A_23_P102071 A_23_P102071 2.80 0 A_23_P55616 SLC14A1 1.67 108.98
A_24_P131589 CD86 2.73 0 A_24_P649357 LOC153561::SMA3 1.66 108.98
A_24_P18802 VPS18 2.68 0 A_24_P105913 660721 1.64 108.98
A_23_P144244 810781 2.64 0 A_23_P1833 B3GAT1 1.62 108.98
A_23_P427472 FLJ10404 2.58 0 A_23_P66481 RTN4RL1 1.62 108.98
A_23_P254212 DIAPH2::RPA4 2.55 0 A_24_P942694 C10orf118 1.62 108.98
A_32_P199824 LMOD1 2.54 0 A_23_P212968 UGT2B11 1.61 108.98
A_32_P107994 ATG7 2.52 0
A_24_P111096 PFKFB3 2.50 0
A_32_P35668 666399 2.47 0 HealthywomencurrentlyusingHT
A_23_P152570 580687 2.43 0 n=11
A_32_P133840 TMCC2 2.40 5.21 DownregulatedinhighMD
A_24_P375205 MKL2 2.40 5.21 GeneID GeneName Score(d) qvalue(%)
A_23_P69699 NPY1R 2.36 5.21 A_23_P150979 SBEM 2.02 0
A_24_P177236 CABP7 2.36 5.21 A_23_P8702 PIP 1.99 0
A_32_P80016 593535 2.35 5.21 A_23_P136671 UGT2B7 1.77 0
A_24_P693448 ZNF552 2.35 5.21 A_23_P393099 TFF3 1.73 0
A_23_P155463 LRRC2 2.31 5.21 A_24_P701582 755742 1.71 0
A_23_P366376 TDGF3 2.29 5.21 A_23_P212968 UGT2B11 1.70 0
A_23_P66543 PIK3R5 2.25 5.21 A_24_P180243 UGT2B28 1.61 14.86
A_24_P640617 Transcribed 2.25 5.21
A_24_P913847 797019 2.22 5.21
A_24_P46484 RBM22 2.21 5.21 Healthywomen50notcurrentlyusingHT
A_23_P204277 H2AFJ 2.16 7.22 n=32
A_32_P111996 MGC39584 2.16 7.22 DownregulatedinhighMD
A_23_P39095 CGB::CGB1 2.12 8.80 GeneID GeneName Score(d) qvalue(%)
A_23_P119448 SAPS1 2.11 8.80 A_23_P39095 CGB::CGB1 2.31 13.41
A_32_P20997 Transcribed 2.11 8.80 A_24_P131589 CD86 2.24 13.41
A_24_P287664 PLCB2 2.11 8.80 A_23_P102071 A_23_P102071 2.24 13.41
A_32_P77416 554489 2.11 8.80 A_32_P199824 LMOD1 2.16 13.41
A_24_P919640 CD44 2.10 8.80 A_24_P932736 729641 2.14 13.41
A_24_P125894 PPM1F 2.08 11.04 A_23_P144244 810781 2.12 13.41
A_24_P349633 FLJ32679::GOLGA8 2.07 11.04 A_24_P640617 Transcribed 2.10 13.41
A_23_P116694 RPS26 2.06 11.04 A_24_P18802 VPS18 2.09 13.41
A_23_P436284 OSTbeta 2.01 13.03 A_23_P366376 TDGF3 2.07 13.41
A_24_P315014 825337 2.01 13.03 A_23_P436284 OSTbeta 2.07 13.41
A_24_P36890 RAP1GAP 1.99 14.81 A_24_P111096 PFKFB3 2.06 13.41
A_23_P44663 SERPINA1 1.93 16.42 A_23_P254212 DIAPH2::RPA4 2.06 13.41
A_32_P149404 537146 1.93 16.42 A_32_P80016 593535 2.05 13.41
A_32_P79313 FLJ45244 1.92 18.31 A_23_P152570 580687 2.04 13.41
A_24_P110601 834483 1.90 18.31 A_23_P155463 LRRC2 2.03 13.41
A_23_P414793 CP 1.90 18.31 A_24_P913847 797019 2.02 13.41
A_23_P38732 CDH2 1.89 20.40 A_23_P66543 PIK3R5 2.00 13.41
A_24_P82880 TPM4 1.89 20.40 A_24_P919640 CD44 1.98 13.41
A_32_P147241 PKM2 1.88 20.40 A_32_P133840 TMCC2 1.97 13.41
A_32_P168431 RPS26 1.85 23.46 A_32_P107994 ATG7 1.97 13.41
A_23_P428184 HIST1H2AD 1.85 23.46 A_32_P149404 537146 1.89 20.43
A_24_P719081 786677 1.83 24.89
Additionalfile4eQTL
UGTtranscriptstheexpressionofwhichisassociatedtoSNPsintheirownorotherUGTgenesincis
Probe_ID Geneexp SNP_rs SNP_gene b1_p Probe_ID Geneexp SNP_rs SNP_gene b1_p
A_23_P41553 Ncaml rs1828705 UGT2B10 0.01 A_24_P521559 UGT2B10 rs1131878 UGT2B4 0.48
A_24_P575267 835938 rs1828705 UGT2B10 0.02 A_23_P136671 UGT2B7 rs1560605 UGT2A1 0.48
A_23_P136671 UGT2B7 rs1828705 UGT2B10 0.04 A_24_P521559 UGT2B10 rs903446 UGT2B4 0.49
A_23_P41553 Ncaml rs941389 UGT2B4 0.05 A_24_P575267 835938 rs10026603 UGT2A1 0.49
A_24_P180243 UGT2B28 rs1828705 UGT2B10 0.05 A_23_P41553 Ncaml rs13139888 UGT2B4 0.50
A_24_P180243 UGT2B28 rs2288741 UGT2A1 0.07 A_23_P212968 UGT2B11 rs4554145 UGT2B4 0.51
A_23_P7342 UGT2B11 rs2288741 UGT2A1 0.08 A_23_P212968 UGT2B11 rs2045100 UGT2B15 0.51
A_23_P58407 UGT2B15 rs1828705 UGT2B10 0.08 A_24_P575267 835938 rs4694211 UGT2B4 0.51
A_24_P180243 UGT2B28 rs4554145 UGT2B4 0.08 A_23_P58407 UGT2B15 rs1513559 UGT2B10 0.55
A_24_P575267 835938 rs4554145 UGT2B4 0.08 A_23_P212968 UGT2B11 rs4557343 UGT2B4 0.57
A_24_P575267 835938 rs13139888 UGT2B4 0.08 A_24_P521559 UGT2B10 rs7439366 UGT2B7 0.59
A_23_P41553 Ncaml rs4557343 UGT2B4 0.08 A_23_P58407 UGT2B15 rs7668258 UGT2B7 0.59
A_23_P7342 UGT2B11 rs1560605 UGT2A1 0.09 A_23_P58407 UGT2B15 rs4521414 UGT2B7 0.59
A_24_P180243 UGT2B28 rs1560605 UGT2A1 0.09 A_23_P136671 UGT2B7 rs13139888 UGT2B4 0.59
A_23_P212968 UGT2B11 rs1828705 UGT2B10 0.10 A_23_P136671 UGT2B7 rs4557343 UGT2B4 0.60
A_24_P575267 835938 rs3775782 UGT2A1 0.10 A_23_P7342 UGT2B11 rs7668258 UGT2B7 0.60
A_24_P180243 UGT2B28 rs10026603 UGT2A1 0.11 A_23_P7342 UGT2B11 rs4521414 UGT2B7 0.60
A_24_P575267 835938 rs2288741 UGT2A1 0.13 A_23_P136671 UGT2B7 rs2045100 UGT2B15 0.61
A_24_P180243 UGT2B28 rs1432329 UGT2A1 0.13 A_24_P180243 UGT2B28 rs7439366 UGT2B7 0.62
A_24_P575267 835938 rs1560605 UGT2A1 0.15 A_23_P136671 UGT2B7 rs941389 UGT2B4 0.62
A_24_P180243 UGT2B28 rs3775782 UGT2A1 0.15 A_24_P575267 835938 rs4148279 UGT2A1 0.63
A_23_P58407 UGT2B15 rs1454254 UGT2B15 0.16 A_24_P17691 UGT2B17 rs1513559 UGT2B10 0.63
A_24_P575267 835938 rs1131878 UGT2B4 0.16 A_24_P575267 835938 rs1513559 UGT2B10 0.64
A_24_P521559 UGT2B10 rs10026603 UGT2A1 0.16 A_23_P136671 UGT2B7 rs1432329 UGT2A1 0.64
A_23_P7342 UGT2B11 rs1432329 UGT2A1 0.19 A_24_P575267 835938 rs7668258 UGT2B7 0.65
A_24_P575267 835938 rs1432329 UGT2A1 0.20 A_24_P575267 835938 rs4521414 UGT2B7 0.65
A_23_P7342 UGT2B11 rs10026603 UGT2A1 0.21 A_24_P575267 835938 rs4235126 UGT2B28 0.65
A_24_P180243 UGT2B28 rs13139888 UGT2B4 0.21 A_23_P136671 UGT2B7 rs4694211 UGT2B4 0.66
A_24_P180243 UGT2B28 rs1131878 UGT2B4 0.21 A_23_P212968 UGT2B11 rs13139888 UGT2B4 0.67
A_23_P212968 UGT2B11 rs2288741 UGT2A1 0.23 A_23_P136671 UGT2B7 rs1131878 UGT2B4 0.67
A_23_P212968 UGT2B11 rs1560605 UGT2A1 0.23 A_24_P17691 UGT2B17 rs1454254 UGT2B15 0.68
A_23_P7342 UGT2B11 rs1828705 UGT2B10 0.23 A_23_P7342 UGT2B11 rs7439366 UGT2B7 0.68
A_24_P521559 UGT2B10 rs2288741 UGT2A1 0.24 A_24_P17691 UGT2B17 rs844342 UGT2B10 0.69
A_24_P180243 UGT2B28 rs4557343 UGT2B4 0.25 A_23_P7342 UGT2B11 rs4148279 UGT2A1 0.69
A_23_P7342 UGT2B11 rs4557343 UGT2B4 0.25 A_24_P521559 UGT2B10 rs4694211 UGT2B4 0.70
A_24_P521559 UGT2B10 rs1560605 UGT2A1 0.28 A_23_P7342 UGT2B11 rs844342 UGT2B10 0.70
A_23_P7342 UGT2B11 rs3775782 UGT2A1 0.29 A_24_P521559 UGT2B10 rs7668258 UGT2B7 0.71
A_24_P521559 UGT2B10 rs1828705 UGT2B10 0.29 A_24_P521559 UGT2B10 rs4521414 UGT2B7 0.71
A_24_P521559 UGT2B10 rs4554145 UGT2B4 0.29 A_24_P521559 UGT2B10 rs844342 UGT2B10 0.72
A_23_P7342 UGT2B11 rs4554145 UGT2B4 0.30 A_23_P212968 UGT2B11 rs1131878 UGT2B4 0.73
A_24_P17691 UGT2B17 rs1828705 UGT2B10 0.31 A_23_P41553 Ncaml rs4235126 UGT2B28 0.73
A_23_P41553 Ncaml rs3775782 UGT2A1 0.31 A_24_P180243 UGT2B28 rs4235126 UGT2B28 0.73
A_24_P521559 UGT2B10 rs4235126 UGT2B28 0.33 A_24_P180243 UGT2B28 rs844342 UGT2B10 0.74
A_23_P212968 UGT2B11 rs7668258 UGT2B7 0.34 A_23_P7342 UGT2B11 rs903446 UGT2B4 0.74
A_23_P212968 UGT2B11 rs4521414 UGT2B7 0.34 A_24_P521559 UGT2B10 rs941389 UGT2B4 0.75
A_23_P41553 Ncaml rs1513559 UGT2B10 0.35 A_23_P136671 UGT2B7 rs4235126 UGT2B28 0.75
A_23_P212968 UGT2B11 rs10026603 UGT2A1 0.35 A_24_P521559 UGT2B10 rs2045100 UGT2B15 0.76
A_24_P575267 835938 rs4557343 UGT2B4 0.36 A_24_P575267 835938 rs7439366 UGT2B7 0.77
A_23_P212968 UGT2B11 rs7439366 UGT2B7 0.36 A_23_P7342 UGT2B11 rs941389 UGT2B4 0.77
A_23_P41553 Ncaml rs844342 UGT2B10 0.37 A_24_P575267 835938 rs844342 UGT2B10 0.78
A_23_P136671 UGT2B7 rs4554145 UGT2B4 0.38 A_24_P180243 UGT2B28 rs7668258 UGT2B7 0.78
A_23_P212968 UGT2B11 rs3775782 UGT2A1 0.38 A_24_P180243 UGT2B28 rs4521414 UGT2B7 0.78
A_23_P136671 UGT2B7 rs10026603 UGT2A1 0.38 A_23_P136671 UGT2B7 rs4148279 UGT2A1 0.78
A_24_P180243 UGT2B28 rs4694211 UGT2B4 0.40 A_23_P7342 UGT2B11 rs4235126 UGT2B28 0.79
A_24_P521559 UGT2B10 rs3775782 UGT2A1 0.41 A_23_P212968 UGT2B11 rs4694211 UGT2B4 0.79
A_24_P521559 UGT2B10 rs1432329 UGT2A1 0.41 A_23_P41553 Ncaml rs1131878 UGT2B4 0.79
A_23_P7342 UGT2B11 rs13139888 UGT2B4 0.41 A_24_P575267 835938 rs1454254 UGT2B15 0.80
A_23_P136671 UGT2B7 rs3775782 UGT2A1 0.42 A_23_P7342 UGT2B11 rs1513559 UGT2B10 0.80
A_23_P136671 UGT2B7 rs2288741 UGT2A1 0.44 A_23_P58407 UGT2B15 rs7439366 UGT2B7 0.80
A_23_P41553 Ncaml rs1454254 UGT2B15 0.44 A_23_P41553 Ncaml rs7439366 UGT2B7 0.82
A_23_P41553 Ncaml rs4554145 UGT2B4 0.44 A_23_P41553 Ncaml rs7668258 UGT2B7 0.83
A_23_P7342 UGT2B11 rs1131878 UGT2B4 0.45 A_23_P41553 Ncaml rs4521414 UGT2B7 0.83
A_24_P575267 835938 rs2045100 UGT2B15 0.45 A_24_P521559 UGT2B10 rs4557343 UGT2B4 0.83
A_24_P180243 UGT2B28 rs2045100 UGT2B15 0.46 A_23_P58407 UGT2B15 rs844342 UGT2B10 0.83
A_23_P212968 UGT2B11 rs1432329 UGT2A1 0.46 A_23_P41553 Ncaml rs4694211 UGT2B4 0.83
A_24_P521559 UGT2B10 rs13139888 UGT2B4 0.47 A_23_P7342 UGT2B11 rs2045100 UGT2B15 0.84
A_23_P58407 UGT2B15 rs2045100 UGT2B15 0.47 A_23_P212968 UGT2B11 rs903446 UGT2B4 0.84
Probe_ID Geneexp SNP_rs SNP_gene b1_p Probe_ID Geneexp SNP_rs SNP_gene b1_p
A_23_P212968 UGT2B11 rs4235126 UGT2B28 0.84 A_23_P41365 SMR3A rs2288741 UGT2A1 0.90
A_23_P212968 UGT2B11 rs844342 UGT2B10 0.84 A_23_P41365 SMR3A rs10026603 UGT2A1 0.91
A_24_P180243 UGT2B28 rs1454254 UGT2B15 0.85 A_23_P362694 C4orf7 rs13139888 UGT2B4 0.92
A_24_P180243 UGT2B28 rs903446 UGT2B4 0.87 A_23_P110234 CSN1S1 rs903446 UGT2B4 0.92
A_23_P212968 UGT2B11 rs1513559 UGT2B10 0.87 A_23_P41365 SMR3A rs1560605 UGT2A1 0.94
A_23_P136671 UGT2B7 rs844342 UGT2B10 0.88 A_23_P41365 SMR3A rs4235126 UGT2B28 0.96
A_24_P180243 UGT2B28 rs4148279 UGT2A1 0.90 A_23_P110234 CSN1S1 rs4148279 UGT2A1 0.98
A_24_P521559 UGT2B10 rs4148279 UGT2A1 0.90
A_24_P521559 UGT2B10 rs1513559 UGT2B10 0.90
A_23_P41553 Ncaml rs903446 UGT2B4 0.90
A_23_P136671 UGT2B7 rs7668258 UGT2B7 0.90
A_23_P136671 UGT2B7 rs4521414 UGT2B7 0.90
A_23_P212968 UGT2B11 rs941389 UGT2B4 0.91
A_24_P521559 UGT2B10 rs1454254 UGT2B15 0.93
A_23_P7342 UGT2B11 rs1454254 UGT2B15 0.93
A_23_P212968 UGT2B11 rs1454254 UGT2B15 0.94
A_23_P41553 Ncaml rs2045100 UGT2B15 0.95
A_24_P17691 UGT2B17 rs2045100 UGT2B15 0.95
A_24_P180243 UGT2B28 rs1513559 UGT2B10 0.96
A_23_P136671 UGT2B7 rs903446 UGT2B4 0.96
A_24_P575267 835938 rs941389 UGT2B4 0.97
A_23_P136671 UGT2B7 rs1454254 UGT2B15 0.98
A_23_P7342 UGT2B11 rs4694211 UGT2B4 0.98
A_23_P212968 UGT2B11 rs4148279 UGT2A1 0.98
A_23_P41553 Ncaml rs2288741 UGT2A1 0.98
A_23_P136671 UGT2B7 rs1513559 UGT2B10 0.99
A_23_P136671 UGT2B7 rs7439366 UGT2B7 0.99
A_24_P180243 UGT2B28 rs941389 UGT2B4 1.00
A_23_P362694 C4orf7 rs903446 UGT2B4 0.01
A_23_P41365 SMR3A rs941389 UGT2B4 0.06
A_23_P362694 C4orf7 rs7439366 UGT2B7 0.10
A_23_P362694 C4orf7 rs4148279 UGT2A1 0.10
A_23_P362694 C4orf7 rs7668258 UGT2B7 0.14
A_23_P362694 C4orf7 rs4521414 UGT2B7 0.14
A_23_P110234 CSN1S1 rs3775782 UGT2A1 0.18
A_23_P110234 CSN1S1 rs13139888 UGT2B4 0.18
A_23_P110234 CSN1S1 rs1131878 UGT2B4 0.19
A_23_P362694 C4orf7 rs1131878 UGT2B4 0.22
A_23_P362694 C4orf7 rs4554145 UGT2B4 0.23
A_23_P110234 CSN1S1 rs4554145 UGT2B4 0.24
A_23_P41365 SMR3A rs3775782 UGT2A1 0.27
A_23_P362694 C4orf7 rs4235126 UGT2B28 0.33
A_23_P110234 CSN1S1 rs4694211 UGT2B4 0.34
A_23_P41365 SMR3A rs4557343 UGT2B4 0.40
A_23_P362694 C4orf7 rs4694211 UGT2B4 0.43
A_23_P110234 CSN1S1 rs1432329 UGT2A1 0.49
A_23_P362694 C4orf7 rs3775782 UGT2A1 0.52
A_23_P41365 SMR3A rs13139888 UGT2B4 0.52
A_23_P362694 C4orf7 rs2288741 UGT2A1 0.58
A_23_P110234 CSN1S1 rs4557343 UGT2B4 0.58
A_23_P41365 SMR3A rs903446 UGT2B4 0.61
A_23_P41365 SMR3A rs4554145 UGT2B4 0.64
A_23_P110234 CSN1S1 rs4235126 UGT2B28 0.68
A_23_P41365 SMR3A rs4148279 UGT2A1 0.70
A_23_P110234 CSN1S1 rs941389 UGT2B4 0.75
A_23_P362694 C4orf7 rs1432329 UGT2A1 0.75
A_23_P362694 C4orf7 rs941389 UGT2B4 0.78
A_23_P110234 CSN1S1 rs1560605 UGT2A1 0.78
A_23_P110234 CSN1S1 rs2288741 UGT2A1 0.79
A_23_P41365 SMR3A rs1131878 UGT2B4 0.81
A_23_P110234 CSN1S1 rs844342 UGT2B10 0.81
A_23_P362694 C4orf7 rs10026603 UGT2A1 0.81
A_23_P41365 SMR3A rs4694211 UGT2B4 0.84
A_23_P110234 CSN1S1 rs7439366 UGT2B7 0.85
A_23_P41365 SMR3A rs1432329 UGT2A1 0.85
A_23_P362694 C4orf7 rs1560605 UGT2A1 0.85
A_23_P110234 CSN1S1 rs7668258 UGT2B7 0.86
A_23_P110234 CSN1S1 rs4521414 UGT2B7 0.86
A_23_P110234 CSN1S1 rs10026603 UGT2A1 0.88
A_23_P362694 C4orf7 rs4557343 UGT2B4 0.89
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3Abstract
Introduction 
High serum levels of estradiol are associated with increased risk of breast cancer. Little is 
known about the gene expression in normal breast tissue in relation to levels of 
circulating serum estradiol.  
Methods 
We compared whole genome expression data of breast tissue samples with serum 
hormone levels using data from 79 healthy women and 64 breast cancer patients. 
Significance analysis of microarrays (SAM) was used to identify differentially expressed 
genes and multivariate linear regression was used to identify independent associations.  
Results
Six genes (SCGB3A1, RSPO1, TLN2, SLITRK4, DCLK1, PTGS1) were found 
differentially expressed according to serum estradiol levels (FDR=0). Three of these were 
independent predictors of estradiol levels in a multivariate model: SCGB3A1 (HIN1) and 
TLN2 were up-regulated and PTGS1 (COX1) was down-regulated in samples form 
women with high serum estradiol. SCGB3A1 is a suggested tumor suppressor gene that 
inhibits cell growth and invasion and is methylated and down-regulated in many 
epithelial cancers. PTGS1 induces prostaglandin E2 (PGE2) production which in turn 
stimulates aromatase expression and hence increases the local production of estradiol. 
Serum estradiol, but none of the differentially expressed genes were significantly 
associated with mammographic density, another strong breast cancer risk factor. In breast 
carcinomas, expression of GREB1 and AREG was associated with serum estradiol in all 
cancers and in the subgroup of estrogen receptor positive cases.  
Conclusion 
We have identified genes associated with serum estradiol levels in normal breast tissue 
and in breast carcinomas. This is the firs report studying such associations in normal 
breast tissue in humans. Serum estradiol, but none of the differentially expressed genes, 
was found to be an independent predictor of mammographic density.  
4Introduction 
Influence of estradiol on breast development [1], the menopausal transition [2] and on the 
breast epithelial cells [3] is widely studied. However, little is known about the effect of 
serum estradiol on gene expression in the normal breast tissue. For post-menopausal 
women, high serum estradiol levels are associated with increased risk of breast cancer [4-
6]. The results are less conclusive for premenopausal women, but epidemiologic evidence 
indicates an increased risk from higher exposure to female hormones [7].  
In estrogen receptor (ER) positive breast carcinomas, the proliferating tumor cells express 
ER while in normal breast tissue the proliferating epithelial cells are ER negative (ER-) 
[8,9]. Both normal and malignant breast epithelial cells are influenced by estradiol but 
through different mechanisms. In the lack of ER, normal breast epithelial cells receive 
proliferating paracrine signals from ER+ fibroblasts [3]. The importance of estrogen 
stimuli in the proliferation of ER+ breast cancer cells is evident from the effect of anti-
estrogen treatment. Previously, several studies have identified genes whose expression is 
regulated by estradiol in breast cancer cell lines. Recently, a study reported an association 
between serum levels of estradiol and gene expression of TFF1, GREB1, PDZK1 and 
PGR in ER+ breast carcinomas [10]. Functional studies on breast cancer cell lines have 
described that estradiol induces expression of c-fos [11] and that exposure to physiologic 
doses of estradiol is necessary for malignant transformation [12]. Intratumoral levels of 
estrogens have also been measured and were found correlated with tumor gene 
expression of estradiol-metabolizing enzymes and ESR1 [13] and of proliferation 
markers [14]. A recent study did, however, conclude that the intratumoral estradiol levels 
were mainly determined by its binding to ER (associated with ESR1-expression). The 
intratumoral estradiol levels were not found to be associated with local estradiol 
production [15]. Serum estradiol levels were found to be associated with local estradiol 
levels in normal breast tissue of breast cancer patients in a recent study [16]. This 
strengthens the hypothesis that serum estradiol levels influence the gene expression in 
breast tissue. 
Wilson and colleagues studied the effect of estradiol on normal human breast tissue 
transplanted into athymic nude mice. They identified a list of genes associated with 
estradiol treatment, including TFF1, AREG, SCGB2A2, GREB1 and GATA3. The 
normal tissues used in the xenografts were from breasts with benign breast disease and 
from mammoplasty reductions [17].  
Studies describing associations between serum estradiol levels and gene expression of 
normal human breast tissue in its natural milieu are lacking. Knowledge about gene 
expression changes associated with high serum estradiol may reveal biological 
mechanisms underlying the increased risk for both elevated mammographic density and 
for developing breast cancer as seen in women with high estradiol levels. We have 
identified genes differentially expressed between normal breast tissue samples according 
to serum estradiol levels. Several genes identified in previous studies using normal breast 
tissue or breast carcinomas are confirmed, but additional genes were identified making 
important contributions to our previous knowledge.
5Materials and methods 
Subjects
Two cohorts of women were recruited to the study from different breast diagnostic 
centers in Norway in the period 2002-2007 as described previously [18]. Exclusion 
criteria were pregnancy and use of anticoagulant therapy. The first cohort consisted of 
women referred to the breast diagnostic centers who were cancer-free after further 
evaluation. Breast biopsies were taken from an area with some mammographic density in 
the breast contralateral to any suspect lesion. The second cohort consisted of women who 
were diagnosed with breast cancer. For this cohort, study biopsies were taken from the 
breast carcinoma after the diagnostic biopsies were obtained. Fourteen gauge needles 
were used for the biopsies and sampling was guided by ultrasound. The biopsies were 
either soaked in RNAlater (Ambion, Austin, TX) and sent to the Oslo University 
Hospital, Radiumhospitalet, before storage at -20C or directly snap-frozen in liquid 
nitrogen and stored at -80C.
All women provided information about height, weight, parity, hormone therapy use and 
family history of breast cancer and provided a signed informed consent. The study was 
approved by the regional ethical committee (IRB approval no S-02036). In total, 120 
healthy women with no malignant disease were recruited in the first cohort. These are in 
the following referred to as ‘healthy women’. In the second cohort, 66 women with a 
newly diagnosed breast cancer were recruited.  
Three additional datasets were used to explore the regulation of identified genes in breast 
cancer. One unpublished dataset from the Akershus University Hospital (AHUS), 
Norway, included normal breast tissue from 42 reduction mammoplasties and both tumor 
and normal adjacent tissue from 48 breast cancer patients (referred to as the AHUS 
dataset). Another unpublished dataset from University of North Carolina (UNC), USA, 
included breast cancer and adjacent normal breast tissue from 55 breast cancer patients 
(referred to as the UNC dataset). The third dataset is previously published and consists of 
biopsies from 31 pure ductal carcinoma in situ (DCIS), 36 pure invasive breast cancers 
and 42 tumours with mixed histology, both DCIS and invasive [19].
Serum hormone analysis 
Serum hormone levels (LH, FSH, prolactin, estradiol, progesterone, SHBG and 
testosterone) were measured with electrochemiluminescence immunoassays (ECLIA) on 
a Roche Modular E instrument (Roche, Basel, Switzerland) by Department of Medical 
Biochemistry, Oslo University Hospital, Rikshospitalet. The menopausal status was 
determined based on serum levels of hormones, age and hormone use. The criteria used 
can be found in Supplementary Table S1. Biochemically perimenopausal women or 
women with uncertain menopausal status were excluded from analyses stratified on 
menopause. These hormone assays are tested through an external quality assessment 
scheme, Labquality, and the laboratory is accredited according to ISO–ES 17025. Serum 
estradiol values are given as picograms per milliliter (pg/ml).  
6Gene expression analysis 
RNA extraction and hybridization were performed as previously described [18]. Briefly, 
RNeasy Mini Protocol (Qiagen, Valencia, CA) was used for RNA extraction. Forty 
samples (38 from healthy women) were excluded from further analysis due to low RNA 
amount (<10ng) or poor RNA quality (measured by Agilent Bioanalyzer, Agilent 
Technologies, Palo Alto, CA). Agilent Low RNA input Fluorescent Linear Amplification 
Kit Protocol was used for amplification and labelling with Cy5 (Amersham Biosciences, 
Little Chalfont, England) for sample RNA and Cy3 (Amersham Biosciences, Little 
Chalfont, England) for the reference (Universal Human total RNA (Stratagene, La Jolla, 
CA)). Labelled RNA was hybridized onto Agilent Human Whole Genome Oligo 
Microarrays (G4110A) (Agilent Technologies, Santa Clara, CA). Three arrays were 
excluded due to poor quality leaving data from 79 healthy women and 64 breast cancer 
patients.
The scanned data was processed in Feature Extraction 9.1.3.1 (Agilent Technologies, 
Santa Clara, CA). Locally weighted scatterplot smoothing (lowess) was used to 
normalize the data. The normalized and log2-transformed data was stored in the Stanford 
Microarray Database (SMD)[20] and retrieved for further analysis. Gene filtering 
excluded probes with 20% missing values and probes with less than three arrays being 
at least 1.6 standard deviation away from the mean. This reduced the dataset from 40791 
probes to 9767 for the healthy women and to 10153 for the breast cancer patients. 
Missing values were imputed in R using the method impute.knn in the library impute 
[21].
Mammographic density
Mammographic density was estimated from digitized craniocaudal mammograms as 
previously described [18] using the University of Southern California Madena assessment 
method [22]. First, the total breast area was outlined using a computerized tool and the 
area was represented as number of pixels. One of the co-authors, GU, identified a region 
of interest that incorporated all dense areas of density excluding those representing the 
pectoralis muscle and scanning artifacts. All densities above a certain threshold were 
tinted yellow, and the tinted pixles converted to cm2 representing the absolute density and 
was available for 108 of 120 healthy women. Percent mammographic density is 
calculated as the absolute density divided by the total breast area and was available for 
114 of 120 healthy women. Test-retest reliability was 0.99 for absolute density.
Statistical Analysis 
Quantitative significance Analysis of Microarrays (SAM) [23,24] was used for analysis 
of differentially expressed genes, by the library samr in R 2.12.0. Serum estradiol 
(nmol/L) was used as dependent variable. The distribution of serum levels is skewed and 
therefore the non-parametric Wilcoxon test-statistic was used. Probes with an FDR<50% 
were included for gene ontology analyses.
DAVID Bioinformatics Resources 2008 from the National Institute of Allergy and 
Infectious Diseases, NIH [25] was used for gene ontology analysis. Functional annotation 
clustering was applied and the following annotation categories were selected: biological 
processes, molecular function, cellular compartment and KEGG pathways. We included 
7annotation terms with a p-value (FDR-corrected) of <0.01 containing between 5 and 500 
genes.
For multivariate analysis, linear regression was fitted in R 2.12.0 to identify independent 
associations. Stepwise selection was performed to determine which variables had an 
independent contribution to the response variable. In the first step, all variables were 
included in the model. The variable with the highest p-value was rejected from the model 
in each step, before the model was refitted. This was repeated until all variables in the 
model had a p-value smaller than 0.05.  
Linear regression was used to determine the independent association between serum 
estradiol and the differentially expressed genes in healthy women. Age, menopause and 
current hormone use were included in the model and forced to stay throughout the 
stepwise selection to correct for confounding by these factors. Linear regression was also 
fitted in two analyses with mammographic density in healthy women as a dependent 
variable. In one set of analyses serum hormone levels were included as the independent 
covariates, and in the other analysis, variables representing gene expression associated 
with serum estradiol were included as covariates. Epidemiologic covariates, such as age, 
BMI, parity and use of hormone therapy were included in the mammographic density 
analyses and forced to stay throughout the stepwise selection to control for potential 
confounding by these factors.
Tumor subtypes were calculated using the intrinsic subtypes published by Sørlie et al in 
2001 [26]. The total gene set was filtered for the intrinsic genes. The correlation between 
gene expression profiles for the intrinsic genes for each sample with each subtype was 
calculated. Each sample was assigned to the subtype with which it had the highest 
correlation. Samples with all correlations <0.1 were not assigned to any subtype. Two-
sided t-tests were used to check for difference in expression for single genes between two 
categories of variables (eg: pre- and postmenopausal).  
8Results
Gene expression in normal breast tissue according to serum estradiol levels 
Genes differentially expressed in normal breast tissue from healthy women according to 
serum estradiol levels with FDR=0 are listed in Table 1. The gene ontology terms 
extracellular region and skeletal system development were significantly enriched in the 
top 80 up-regulated genes (FDR<50%). There were no significant gene ontology terms 
enriched in the down-regulated genes with FDR<50 (n=8), although response to steroid 
hormone stimulus was the most enriched term with three observed genes (PTGS1, ESR1
and GATA3).
The genes differentially expressed in normal breast tissue according to serum estradiol 
with an FDR=0 (from Table 1) were tested for differential expression between breast 
cancer tissue and normal breast tissue from healthy women. All six genes were 
differentially expressed between carcinomas and normal tissue. Interestingly, the 
expression in breast carcinomas was similar to that in normal tissue from women with 
lower levels of circulating estradiol and opposite to that found in normal samples from 
women with higher levels of serum estradiol (Table 1). Comparing the expression of 
these genes in normal breast tissue with the expression in ER+ and ER- carcinomas 
respectively revealed similar results (Table 1).  
In tumors, SCGB3A1 tended to be expressed at a lower level in basal-like tumors 
compared with all other tumors or compared with luminal A tumors, but this did not 
reach statistical significance (both p-values=0.2). However in two other datasets (AHUS 
and UNC), SCGB3A1 was expressed at significantly lower levels in basal-like tumors 
compared with all other subtypes (p=0.04 and 0.003 respectively). There was no 
consistent significant difference in SCGB3A1 expression in ER+ and ER- tumors.  
Of the six genes differentially expressed according to serum estradiol in normal breast 
tissue, three were differentially expressed between DCIS and early invasive breast 
carcinomas based on a previously published dataset [19](Table 1). SCGB3A1 was down-
regulated in invasive compared with DCIS, whereas TLN2 and PTGS1 were up-regulated 
in invasive compared with DCIS.  
A linear regression was fitted with all differentially expressed genes as covariates and 
controlling for age, menopause and current hormone therapy use. After leave-one-out 
elimination of insignificant covariates, SCGB3A1, TLN2 and PTGS1 were still significant 
(Table 2). 
9Serum estradiol related to mammographic density in healthy women 
Regression analysis in postmenopausal women showed that serum estradiol was 
independently associated with both absolute and percent mammographic density when 
controlling for age, BMI and current use of hormone therapy (Table 3). None of the 
genes differentially expressed in normal breast tissue according to serum estradiol levels 
were independently associated with mammographic density (data not shown).
Gene expression in breast carcinomas according to serum estradiol levels 
In breast carcinomas, quantitative SAM revealed two genes, AREG and GREB1, as 
differentially expressed according to serum estradiol levels with FDR=0 (Table 4). Both 
genes were up-regulated in samples from women with high serum estradiol (estradiol was 
used as a continuous response variable in the analysis). Of 16 probes up-regulated in 
samples from women with high serum estradiol, there were three probes for TFF3 and 
one for TFF1, although these did not reach statistical significance (Table 4). No genes 
were significantly down-regulated. In ER+ samples (n=53), we also found AREG and 
GREB1 up-regulated in samples from women with high serum estradiol (FDR=0), but the 
TFF-genes were not up-regulated. Among the ER- samples (n=8) there was very little 
variation in serum estradiol levels and a search for genes differentially expressed 
according to serum estradiol is not feasible.  
Looking at normal breast tissue from healthy women, both AREG and GREB1 are up-
regulated in samples from women with high estradiol levels without reaching 
significance. Neither AREG nor GREB1 are differentially expressed between normal 
breast tissue and breast carcinomas. All the probes for TFF-genes are, however, 
significantly down-regulated in normal breast tissue compared with breast carcinomas 
(Supplementary Table 3). 
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Gene expression in normal breast tissue according to serum estradiol levels 
We have identified genes differentially expressed according to serum estradiol in normal 
breast tissue of healthy women.  
The genes up-regulated in normal breast tissue under influence of high serum estradiol 
are enriched for the gene ontology terms extracellular matrix and skeletal system 
development. Both ER isoforms  and  are expressed in the stromal cells [27]. The 
proliferating epithelial cells are not found to be ER+ [8] and most often negative to both 
ER isoforms [9]. In normal breast tissue, the estrogen-induced epithelial proliferation is, 
at least partly, caused by paracrine signals from ER+ fibroblasts [3]. The enrichment of 
gene ontology terms related to extracellular matrix may be linked to the effect of estradiol 
on the ER+ stromal cells.  
Three genes were independently associated with serum estradiol levels in normal breast 
tissue in a linear regression model after controlling for age, menopause and current 
hormone therapy. The two genes SCBG3A1 (HIN1) and TLN2 were positively associated 
with serum estradiol and PTGS1 (COX1) negatively.
SCBG3A1 is a secretoglobin transcribed in luminal, but not in myoepithelial breast cells 
and is secreted from the cell [28]. The protein is a tumor suppressor and inhibits cell 
growth, migration and invasion acting through the AKT-pathway. SCBG3A1 inhibits
Akt-phosphorylation, which reduces the Akt-funtion in promoting cell cycle progression 
(transition from the G1 to the S-phase) and preventing apoptosis (through inhibition of 
the TGF-pathway) [29] (Figure 1).
The SCBG3A1 promoter was found to be hypermethylated with down-regulated 
expression of the gene in breast carcinomas compared with normal breast tissue, where it 
is referred to as “high in normal 1” (HIN1)[30,31]. Interestingly, the gene is not 
methylated in BRCA-mutated and BRCA-like breast cancer [32]. Methylation of the gene 
is suggested to be an early event in non-BRCA-associated breast cancer [33].  
We found SCBG3A1 down-regulated in basal-like cancers compared to other subtypes. 
At first glance, this may seem contradictory to the observation that the gene is not 
methylated in BRCA-like breast cancers. However, Krop and colleagues found that the 
gene is expressed in luminal epithelial cell lines, but not in myoepithelial cell lines. The 
reduced expression seen in basal-like cancer could be due to a myoepithelial phenotype 
arising from a myoepithelial cell of origin or from phenotypic changes acquired during 
carcinogensis. This could also be linked to the lack of methylation in BRCA-associated 
breast cancers, which are often basal-like. An a priori low gene expression would make 
methylation unnecessary. The increased Akt-activity seen in basal-like cancers[34] is 
consistent with the low levels of SCBG3A1 expression observed in the basal-like cancers 
in this study leading to increased Akt-phosphorylation and thereby Akt-activity. 
PTGS1 (prostaglandin-endoperoxide synthase 1) is synonymous with cyclooxygenase 1 
(COX1) and codes for an enzyme important in prostaglandin production. Studies of 
normal human adiopocytes have shown that the enzyme induces production of 
prostaglandin E2 (PGE2) which in turn increases the expression of aromatase (CYP19A1)
[35]. Aromatase is the enzyme responsible for the last step in the conversion of 
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androgens to estrogens in adipose tissue. Hence, the expression of PTGS1 may lead to an 
increased production of estradiol locally (Figure 2). In normal breast tissue, we observed 
that the expression of PTGS1 was lower in samples from women with higher levels of 
serum estradiol. This may be due to negative feedback. High systemic levels of estradiol 
make local production unnecessary and PTGS1-induced aromatase production is 
abolished.
The up-regulation of PTGS1 in breast carcinomas compared to normal tissue is expected 
from current knowledge. Several studies have suggested that PTGS1 has a carcinogenic 
role in different epithelial cancers [36-40]. The gene has also previously been found over-
expressed in tumors compared with tumor adjacent normal tissue [41].  
Talin 2 (TLN2) is less known and less studied than Talin 1 (TLN1). Both talins are 
believed to connect integrins to the actin cytoskeleton and are involved in integrin-
associated cell adhesion [42,43]. TLN2 is located on chromosome 15q15-21, close to 
CYP19A1 coding for aromatase. A study on aromatase-excess syndrome found that 
certain minor chromosomal rearrangements may cause cryptic transcription of the 
CYP19A1 gene through the TLN2-promoter [44]. We found that TLN2 was up-regulated 
in breasts of healthy women with high levels of serum estradiol. This could indicate an 
activation of cell adhesion. This gene was the only gene significantly up-regulated 
according to serum estradiol in normal breast tissue of premenopausal women. The 
down-regulation observed in breast cancers compared with normal breast tissue indicates 
a loss of cell adhesion. The expression of the gene is lower in DCIS than in invasive 
carcinomas, which is contrary to expected, but the data set is small.   
A previous study report on the gene expression in normal human breast tissue 
transplanted into two groups of athymic mice treated with different levels of estradiol 
[17]. Neither SCGB3A1, TLN2 nor PTGS1 was significantly differentially expressed in 
their study. They did, however, identify many of the genes found to be significantly 
differentially expressed according to serum estradiol in breast carcinomas in the current 
study, such as AREG (amphiregulin), GREB1 (growth regulation by estrogen in breast 
cancer 1), TFF1 (Trefoil factor 1) and TFF3 (Trefoil factor 3). Going back to our normal 
samples, we see that several of their genes (including AREG, GREB1, TFF1 and TFF3,
GATA3 and two SERPIN-genes) are differentially expressed in our normal breast tissue, 
but did not reach statistical significance (Supplementary table S3).  
The differences observed between our study and that of Wilson and colleagues may be 
due to chance and due to the presence of different residual confounding in the two 
studies. Wilson and colleagues studied the effects of estradiol treatment, which may act 
differently upon the breast tissue than endogenous estradiol. Normal human breast tissue 
transplanted into mice may react differently to varying levels of estradiol than it does in 
its natural milieu in humans. The genes that were significant in the Wilson-study and 
differentially expressed but not significant in our study (eg: AREG, GREB1, TFF1, TFF3
and GATA3) may be associated with serum estradiol levels in normal tissues as well as in 
tumor tissues where we and others have observed significant associations. Our study is 
the first study to identify the expression of SCGB3A1, TLN2 and PTGS1 in normal breast 
tissue to be significantly associated with serum estradiol levels. These findings are 
biologically reasonable and may have been missed in previous studies due to lack of 
representative study material.  
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Serum estradiol associated with mammographic density in healthy women 
Serum estradiol levels were independently associated with mammographic density 
controlling for age, BMI and current use of hormone therapy, and the magnitude of the 
association was substantial (Table 3). The high beta-value in the regression equation 
implies a large magnitude of impact which supports the hypothesis that high serum 
estradiol levels increases mammographic density with both statistical and biological 
significance.  
Gene expression in breast carcinomas according to serum estradiol levels 
The expression of genes found to be differentially expressed in normal breast tissue 
according to serum estradiol levels was examined in breast carcinomas. We found that 
the expression was all opposite of that in normal breast tissue from women with high 
serum estrogen (Table 1). This may be due to lack of negative feedback of growth 
regulation in breast tumors. In breast cancer cell lines, estrogen induced up-regulation of 
positive proliferation regulators and down-regulation of anti-proliferative and pro-
apoptotic genes, resulting in a net positive proliferative drive [45]. This is in line with our 
findings. In normal breast tissue from women with high serum estradiol, SCGB3A1,
which regulate proliferation negatively, and TLN2, which prevents invasion, are up-
regulated. PTGS1, which induce local production of estradiol-stimulated proliferation, is 
down-regulated. All three genes are expressed to maintain control and regulation of the 
epithelial cells. In breast cancers the expression of these genes favors growth, migration 
and proliferation. This supports the hypothesis that high serum estradiol increases the 
proliferative pressure in normal breasts, which leads to an activation of mechanisms 
counter-acting this proliferative pressure. In carcinomas, growth regulation is lost, and 
these hormone-related growth-promoting mechanisms are turned on simultaneously.  
Interestingly, both AREG and GREB1 were up-regulated in ER+ breast carcinomas of 
younger (<45 years) compared with older (>70 years) women in a previous publication. 
The increased expression of these genes was proposed as a mechanism responsible for 
the observed increase in proliferation seen in the tumors of younger compared with older 
women [46]  
The genes differentially expressed according to serum estradiol levels in tumors 
confirmed many of the findings from the Dunbier-study of ER+ tumors [10]. The 
previously published list of genes positively correlated with serum estradiol included 
three TFF-genes and GREB1. These genes were  also found significant in the analysis of 
all tumors in this study, although TFF1 and TFF3 did not reach statistical significance 
(Table 4). In addition to the previously published genes, we identified the gene AREG, an 
EGFR-ligand essential for breast development, as up-regulated in tumors from patients 
with high serum estradiol. 
GREB1 is previously found to be an important estrogen-induced stimulator of growth in 
ER+ breast cancer cell lines[47]. AREG binds to and stimulates EGFR and hence 
epithelial cell growth. The up-regulation of these two genes in breast carcinomas of 
women with high estradiol levels may indicate a loss of regulation of growth associated 
with cancer development. This corresponds well with the interpretation our findings in 
normal breast tissue referred above and confirms the results indicated by the cell line 
studies by Frasor and colleagues [45]. These two genes are not differentially expressed 
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between normal breast tissue and breast cancers. Both are, however, higher expressed in 
ER+ than ER- breast carcinomas.  
Overall strengths and limitations of the study 
The currently used method for detection of serum estradiol has a limited sensitivity in the 
lower serum levels often seen in postmenopausal women. Despite the limited sample size 
we found several biologically plausible associations. However, due to limited power, 
there may be other associations that we could not reveal. We have included women with 
and without hormone therapy in the study. There may be differences in action between 
endogenous and exogenous estradiol that will not be revealed in this study.
One important strength of this study is the unique material with normal human tissue in 
its natural mileu, not influenced by an adjacent tumor[48-50] or by an adipose-dominated 
biology that may bias the study of reduction mammoplasties.  
Conclusion
In conclusion we report a list of genes whose gene expression is associated with serum 
estradiol levels. This list includes genes with known relation to estradiol-signaling, 
mammary proliferation and breast carcinogenesis. All these genes were expressed 
differently in tumor and normal breast tissue. The gene expression in tumors resembled 
that in normal breast tissue from women with low serum estradiol. Associations between 
serum estradiol and the expression in breast carcinomas confirmed previous findings and 
revealed new associations. The comparison of results between normal breast tissue from 
healthy women and breast carcinomas indicate the difference in biological impact of 
estradiol in normal and cancerous breast tissue.  
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Table 1 Genes significantly differentially expressed in normal breast tissue of healthy 
women according to serum estradiol. A) Q-values and regulation of gene expression from 
quantitative SAM analysis of gene expression according to serum estradiol. B) 
Significance testing of difference in gene expression of the genes identified in A) in 
different sample cohorts.
 GeneName SCGB3A1 SLITRK4 TLN2 DCLK1 RSPO1 PTGS1
Chromosomallocationofthegene 5q35.3 Xq27.3 15q15q21 13q13 1p34.3 9q32q33.3
qvalue(%)SAM1) 0 0 0 0 0 0
Geneexpressioninhighsest2)
A
(comparedwithlowsest) up up up up up down
B BC3)vsnormalbreasttissue(pvalue)4) 5.00E15 1.50E03 2.60E04 6.00E04 4.90E12 0.02
 GeneexpressionnBC3)
 (comparedwithnormaltissue) down down down down down up
 NormaltissuevsER+BC5)4) 2.20E13 0.01 1.30E03 4.20E03 3.30E12 0.05
 GeneexpressioninER+BC
 (comparedwithnormaltissue) down down down down down up
 NormaltissuevsERBC6)4) 1.10E04 0.03 0.01 0.01 0.02 0.05
 GeneexpressioninERBC
 (comparedwithnormaltissue) down down down down down up
 DCISvsinvasiveBC3)4) 0.04 0.12 0.01 0.66 0.24 0.001
 Geneexpressionininvasive
 (comparedwithDCIS) down  up   up
1) QvaluefromSAMofgeneexpressioninnormalbreasttissueaccordingtoserumestradiol
2) sest=serumestradiol
3) BC=breastcancer
4) P-value from two-sided t-test 
5) ER+BC=estrogenreceporpositivebreastcancer(n=53)
6) ERBC=estrogenrecepornegativebreastcancer(n=8)
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Table 2 Genes independently associated with serum estradiol in a linear regression 
modell. All genes differentially expressed according to serum estradiol (Table 1) were 
included. Values shown are corrected for age, menopause and current hormone therapy. 
After leave-one-out stepwise selection the following covariates remained:  
Covariate Estimate1) Stderror pvalue
SCGB3A1 0.068 0.025 0.009
TLN2 0.142 0.061 0.024
PTGS1 0.145 0.066 0.030
SLITRK4 0.086 0.075 0.252)
RSPO1 0.045 0.045 0.322)
DCLK1 0.023 0.063 0.712)
1) Estimate denotes the beta-value corresponding to each covariate in the regression 
equation.
2) Values for the non-significant genes are from the last model before they were 
excluded.
Table 3 Serum hormones independently associated with mammographic density in linear 
regression models. Values shown are corrected for age, HT and BMI. Through leave-one-
out stepwise elimination of covariates, prolactin, SHBG and testosterone were excluded 
and the following variables remained.  
 Absolutedensity Percentdensity
Covariate Estimate1) pvalue Estimate pvalue
Parity 8.18 0.01  
Serumestradiol 95.55 7.1E05 51.31 9.3E03
1) Estimate denotes the beta-value corresponding to each covariate in the regression 
equation.
22
Table 4 Genes significantly differentially expressed according to serum estradiol levels 
in breast carcinomas. A) Quantitativ SAM analysis for differential expression according 
to serum estradiol with q-values and direction of regulation indicated. B) Significance 
testing of difference in gene expression of the genes identified in A) in different sample 
cohorts.
 GeneName AREG GREB1 TFF3 TFF3 TFF1
A Chromosomallocation 4q1321 2p25.1 21q22.3 21q22.3 21q22.3
 qvalue(%)SAMalltumors1) 0 0 20.5 20.5 20.5
 Geneexpressioninhighsest
 (comparedwithlowsest)2) up up up up up
 qvalue(%)SAMER+BC1)3) 0 0   
 Geneexpressioninhighsest
 (comparedwithlowsest)2) up up   
B BC4)vsnormalbreasttissue5 0.38 0.18 4.80E05 2.60E04 1.20E07
 GeneexpressioninBC4)
 (comparedwithnormal)   up up up
 ER+vsERBC4)5 0.08 4.80E08 2.00E06 2.40E07 0.002
 GeneexpressioninER+BC
 (comparedwithERBC6)) up up up up up
1) QvaluefromSAMofgeneexpressionaccordingtoserumestradiol
2) Geneexpressioninsamplesfrompatientswithhighcomparedwithlowserumestradiol
3) ER+BC=Estrogenreceptorpositivebreastcancer(n=53)
4) BC=breastcancer
5) P-value from two-sided t-test 
6) ERBC=Estrogenreceptornegativebreastcancer(n=8)
Figure 1 Simplified illustration of the cellular mechanisms of SCGB3A1. SCGB3A1 
inhibits the phosphorylation of Akt leading to reduced cell cycle division and increased 
apoptosis. Molecules in red are increased/stimulated as result of SCGB3A1-action, 
whereas molecules in blue are decreased/inhibited.
Figure 2 Schematic illustration of mechanism of PTGS1. PTGS1 induces PGE2-
production. PGE2 increases the expression of aromatase (CYP19A1) which in turn 
converts androgens to estrogens in adipose tissue. 17HSD1= 17bhydroxysteroid 
dehydrogenase.
Supplementary tables and figures 
Table S1: Criteria for estimation of menopausal status.  
FSH>20 LH>15 FSH>LH
s-est1)
<0.1
menopausal 
status criteria
1 1 1 1 post
1 1 1 0 post s-est<0.3
1 1 1 0 peri s-est>0.3
1 0 1 1 post
1 1 0 0 peri s-est>0.3 without HT2)
1 1 0 0 post s-est <0.3 or HT 
1 0 1 0 post s-est >0.3 without HT 
1 0 1 0 peri s-est <0.3 or HT 
0 0 1 1 peri FSH>15  
0 0 1 1 pre FSH<15
0 1 0 0 pre Age>50=peri
0 0 1 0 peri s-est <0.3 
0 0 1 0 pre s-est >0.3 
0 0 0 0 pre
Any Any Any Any post/peri HT-use
1) serum estradiol 
2) HT: hormone therapy 
Table S2: Genes differentially expressed according to serum estradiol in breast 
carciomas and their expression in normal breast tissue
 AREG GREB1 TFF3 TFF3 TFF1
AgilentID A_23_P259071 A_23_P329768 A_23_P257296 A_23_P393099 A_24_P322771
pvalue(normalvstumor)1) 0.38 0.18 4.8E05 2.6E04 1.2E07
Meannormal 0.35 1.29 1.45 1.44 2.76
Meantumor 0.61 1.02 2.74 2.65 1.13
pvalue(ER+vsER)1) 0.08 4.8E08 2.0E06 2.4E07 2.3E03
MeanER+tumors(n=53) 0.44 0.60 3.21 3.19 0.81
MeanERtumors(n=8) 1.54 3.17 0.17 0.51 3.32
qvalue(%)SAM2) 52.9 28.4 52.9 39.5 75.3
1) Two-sided t-test 
2) Q-value for genes up-regulated in samples from women with high serum estradiol (SAM 
on samples from normal breast tissue according to serum estradiol).  
Table S3: Genes differentially expressed according to estradiol treatment in Wilson et al 
and according to serum estradiol in the current study 
Genesdifferentiallyexpressedbetween
micetreatedandnottreatedwith
estradiolinWilsonetal,2006
QuantitativSAMaccordingtoserum
estradiollevelsinthecurrentstudy.Gene
expressioninhighserumestradiol.
Symbol
geneexperession
inestradiol
treatedmice
Normal
breast
tisssue
Breast
carcinomas
ER+breast
carcinomas
TFF1 up up up 
MYBPC1 up up  
AREG up up up up
SCGB2D2 up   
TFF3 up up up 
SCGB2A2 up   
GREB1 up up up up
SERPINA1 up up  
C1orf34 up up  
PIP up  down down
AGR2 up   down
SERPINA3 up up  
PRR4 up   
HBE1 up   
EEF1A2 up   
DSU up   
MYB up   
AZGP1 up   down
TACSTD1 up   down
KRT19 up  down down
CELSR2 up   
FXYD3 up   
XBP1 up   down
PRG4 up  down down
MMP up   
MMP12 down  down down
ME1 down up down down
CXCL11 down   
COL6A down   
CXCL11 down   
GATA3 down down  
HSPG2 down   
CCl2 down  down down
EMILIN down   
CXCL10 down   
TablsS3cont

Genesdifferentiallyexpressedbetween
micetreatedandnottreatedwith
estradiolinWilsonetal,2006

QuantitativSAMaccordingtoserum
estradiollevels.Geneexpressioninhigh
serumestradiol
Symbol
geneexpression
intreatedmice
Normal
breast
tisssue
Breast
cancers
ER+breast
cancers
RARRES1 down up down 
S100A8 down  down down
IGJ down up  
CXCL9 down  down down
FN1 down   
DPT down  down 
RGS5 down  down down
CCL19 down  down down
DPT down  down 
TPSAB1 down   
CSPG2 down up  
ENPEP down   
SERPINH1 down up  
RGS5 down  down down
IL8 down   
IGHA1 down  down 
BGN down   
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